

Exome sequencing reveals heterogeneous clonal dynamics in donor cell myeloid neoplasms after stem cell transplantation

Julia Suárez-González,^{1,2} Juan Carlos Triviño,³ Guiomar Bautista,⁴ José Antonio García-Marco,⁴ Ángela Figuera,⁵ Antonio Balas,⁶ José Luis Vicario,⁶ Francisco José Ortúñoz,⁷ Raúl Teruel,⁷ José María Álamo,⁸ Diego Carbonell,^{2,9} Cristina Andrés-Zayas,^{1,2} Nieves Dorado,^{2,9} Gabriela Rodríguez-Macías,⁹ Mi Kwon,^{2,9} José Luis Díez-Martín,^{2,9,10} Carolina Martínez-Laperche^{2,9*} and Ismael Buño^{1,2,9,11*} on behalf of the Spanish Group for Hematopoietic Transplantation (GETH)

¹Genomics Unit, Gregorio Marañón General University Hospital, Gregorio Marañón Health Research Institute (IISGM), Madrid; ²Gregorio Marañón Health Research Institute (IISGM), Madrid; ³Sistemas Genómicos, Valencia; ⁴Department of Hematology, Puerta de Hierro General University Hospital, Madrid; ⁵Department of Hematology, La Princesa University Hospital, Madrid; ⁶Department of Histocompatibility, Madrid Blood Centre, Madrid; ⁷Department of Hematology and Medical Oncology Unit, IMIB-Arrizaca, Morales Meseguer General University Hospital, Murcia; ⁸Centro Inmunológico de Alicante - CIALAB, Alicante; ⁹Department of Hematology, Gregorio Marañón General University Hospital, Madrid; ¹⁰Department of Medicine, School of Medicine, Complutense University of Madrid, Madrid and ¹¹Department of Cell Biology, School of Medicine, Complutense University of Madrid, Madrid, Spain

*CM-L and IB contributed equally as co-senior authors.

Correspondence: ISMAEL BUÑO - ismaelbuno@iisgm.es

doi:10.3324/haematol.2019.234609

Supplementary Material

This appendix has been provided by the authors to give readers additional information about their work.

Supplement to Julia Suárez-González^{1,2}, Juan Carlos Triviño³, Guiomar Bautista⁴, Jose Antonio García Marco⁴, Ángela Figuera⁵, Antonio Balas⁶, José Luis Vicario⁶, Francisco José Ortúñoz⁷, Raúl Teruel⁷, José María Álamo⁸, Diego Carbonell^{2,9}, Cristina Andrés-Zayas^{1,2}, Nieves Dorado^{2,9}, Gabriela Rodríguez-Macías⁹, Mi Kwon^{2,9}, José Luis Díez-Martín^{2,9,10}, Carolina Martínez-Laperche^{2,9#*}, Ismael Buño^{1,2,9#*}. **Whole exome sequencing reveals clonal dynamics in seven donor cell myeloid neoplasms after hematopoietic transplantation.**

Supplementary Methods

WES and variant analysis.

DNA was extracted directly from PB and BM samples and donor origin of the DCMN was confirmed in a centralized laboratory by short tandem repeat chimerism analysis in samples along post-transplant period (AmpFISTR SGM plus; Applied Biosystems, Foster City, CA, USA; Supplemental Figure S2). Genomic DNA samples were prepared according to Agilent SureSelect-XT Human exon 50Mb enrichment kit (Agilent Technologies, Santa Clara, CA, USA) preparation guide. Libraries were sequenced on an Illumina HiSeq platform (Illumina, San Diego, CA, USA).

WES was generated from 40 samples to an average sequencing depth of 57 fold (range 30-110), a median of 155,949 singleton SNPs (range 150,477-194,363) was identified for each sample.

Variant calling and annotations strategies

Exome sequencing data were aligned against the last version of the Human Reference Genome (GRCh38/hg38) using the Burrows Wheeler Alignment tool (BWA) v0.7.15-r1140.¹ From the BAM formatted file obtained after read mapping, low quality reads (<= 20 Phred Scale) and sequences flagged as PCR duplicates were removed using Samtools v1.2² and Picard Tools v2.12.1 methods (Table S2). Variant calling was performed using a combination of two different algorithms: VarScan³ and GATK.⁴ The copy number variant (CNV) analysis was performed using CNVkit algorithms, v0.7.7.dev0.⁵

All predicted variants were filtered to remove false positives related to potential homopolymer artifacts (variants found in homopolymers having a sequence length ≥ 10 were removed), with a mapping quality of 20 and with a minimum of 5 variants reads. Variant transcript annotation was based on all human transcripts obtained from Ensembl Release v81.6 All variants that occurred in coding exons and splice sites of canonical transcripts were annotated in multiple databases such as Database of single nucleotide polymorphisms (dbSNP),⁷ the 1000 genomes project⁸ and the Catalogue of somatic mutations in cancer⁹ (COSMIC). Splice site mutations were restricted to substitutions, deletions or insertions overlapping the 2bp intronic sequence defined as the canonical splice donor or splice acceptor. Variants affecting, 3'UTR, 5'UTR, intronic sequences, non-canonical transcripts, RNA genes and all those that did no change the amino acid sequence, were discarded for the purpose of downstream analysis. In addition, all variants from genes suspected to have pseudogenes were discarded. Variants selected were visually examined with the IGV and any data that appeared to be supported by potential sequencing, amplification, or alignment artifacts were discarded.

Identification of mutations in post-transplant samples

In the case of DCHN, samples obtained along the post-transplant period as a result of routine follow-up analysis, prior to the diagnosis of leukemia are available for study.

To identify the acquisition of mutations along the post-allo-HSCT period, DNA sequencing data from recipient post-transplant BM samples, were matched against their donor PB sample and previous BM samples (Supplemental Figure S2). Those variants detected with minor allelic frequency >0.01 in the general population were excluded. Remaining variants were further filtered to retain variants reported in the literature as associated with cancer development,

variants reported in COSMIC or variants identified as deleterious by three *in silico* analysis platforms (SIFT,¹⁰ Polyphen-2¹¹ and condel).

Donor analysis

To perform the donor analysis a cancer-associated gene list was compiled. The list comprised of a total of 2197 genes (Table S2) that included genes grouped by functional cancer related pathways such as phosphatidylinositol 3-kinase pathway-Akt (PI3K-Akt) signaling, mammalian target of rapamycin (mTOR) signaling, Janus tyrosine Kinase-Signal Transducer and Activator of Transcription (JAK-STAT) signaling, cytokine-cytokine receptor interaction, mitogen-activated protein kinase (MAPK) cascade, Peroxisome proliferator-activated receptors (PPARs) signaling, cell cycle, p53 signaling, vascular endothelial growth factor (VEGF) signaling, apoptosis, adherents junctions, Wnt signaling, cyclic AMP (cAMP) signaling, focal adhesion, extracellular matrix receptor (ECM-receptor) interaction and transforming growth factor beta (TGFB) signaling, spliceosome components; genes involved in the development of hematopoietic cell lineage, transcriptional miss-regulation in cancer, signaling pathways regulating pluripotency of stem cells, development of myeloid neoplasm, cancer predisposition, immunodeficiency and evasion of the immune response. Variants detected in these genes were further filtered to retain only those reported to the database Human Gene Mutation Database¹² (HGMD) or reported in the literature as responsible or predisposing to cancer, with a minor allelic frequency <0.01 in the general population.

Gene panel resequencing

Potential mutations identified by WES were validated by targeted (IDT, Coralville, Iowa, USA) next generation sequencing (>1000x depth, sensitivity 1%; Illumina MiSeq) of a custom panel which included all such genes plus 17 genes frequently

mutated in MN (*NRAS*, *WT1*, *KRAS*, *FLT3*, *IDH2*, *SRSF2*, *TP53*, *CEBPA*, *SF3B1*, *IDH1*, *DNMT3A*, *ASXL1*, *RUNX1*, *U2AF1*, *TET2*, *NPM1*, *JAK2*). All patient post-HSCT samples as well as donor samples were reanalyzed using this gene panel.

CNV analysis

CNVs alterations detected by WES had been previously detected by cytogenetics analysis, FISH or CGH/SNP arrays.

Clonal architecture

To reconstruct and visualize clonal architecture in order to understand inter- and intra-tumor heterogeneity and evolution, R v.3.2.2 (The R Foundation) Fishplot package was applied, for adjusting the spatial and temporal patterns, and for visualizing clonal evolution.¹³

Patient #1

A 56-year-old man presented in 2005 a mantle cell lymphoma stage IV-A with supra and infradiaphragmatic affection and BM involvement. The patient achieved complete remission (CR) after treatment with cyclophosphamide, vincristine, doxorubicin, dexamethasone and rituximab (hyper CVAD-R). Three years later a disease relapse was diagnosed and chemotherapy with etoposide, methylprednisolone, high-dose of cytarabine, cisplatin and rituximab (ESHAP-R) induced a second remission.

When the patient was 60 years old, allogeneic peripheral blood SCT from an identical HLA, 72-year-old brother was performed for mantle cell lymphoma during the second remission. The conditioning regimen consisted of ibritumomab tiuxetan, fludarabine and melphalan. His post-transplant course was complicated by neurotoxicity and severe mucositis grade IV, that needed a tracheotomy.

4 years and 9 months after transplantation, follow-up PB examination showed bicytopenia and the BM showed dysplastic changes without blasts. Cytogenetic studies showed a karyotype //45,XY,-7,del(12)(p12) karyotype in 95% of metaphases. Short tandem repeat (STR) analysis of the BM cells showed complete donor chimera. Within this scenario, diagnosis of myelodysplastic syndrome (MDS) type refractory cytopenia with multilineage dysplasia (RCMD) with origin in donor-derived cells was made. The hypomethylating agent azacitidine (AZA) was administered, the patient received a total of 8 cycles of AZA with initial partial response but with posterior progression to refractory anemia with excess blast-1 (RAEB-1). Fourteen months after the diagnosis of MDS in donor cells, the patient underwent allogeneic transplantation from his haploidentical 33-year-old son after a conditioning regimen with busulfan and flurabine, cyclophosphamide in days +3, +4 and cyclosporine in day +5. He developed febrile neutropenia, renal complications, severe exudative skin reaction, pneumonia and polyneuropathy that eventually led to his death.

The donor remained healthy after transplantation, but a BM aspirated showed 5% of blastic cells and dysplastic features.

Genomic DNA was isolated and subjected to whole-exome sequencing from BM specimens of the recipient at day +25, +428, +866, +1081, +1477, +1704, +1727, +1755, +2098 after first allo-HSCT, as well as PB specimen from donor at the time of transplant.

Patient #2

A 26-year old woman was diagnosed as having pre-B acute lymphoblastic leukemia (ALL) on the basis of a BM with 50% blasts. After treatment with prednisone, daunorubicin, L-asparaginase, intratecal methotrexate followed by radiotherapy (24 Gy) and consolidation therapy with citarabine and tenoposide to complete treatment, she achieved a new complete remission. 6 years after diagnosis, the patient relapsed, and the patient achieved complete remission after treatment with conventional chemotherapy (PETHEMA ALL-AR-03).¹⁴ One year after relapse, an allo-HSCT from her father, 1-

antigen HLA-antigen mismatched, was planned in second complete remission. Conditioning regimen consisted in cytarabine, total body irradiation (TBI) and timoglobulin. The patient developed cytomegalovirus viremia (VEB) resolved with Rituximab and skin rash resolved with cyclosporine. She also developed bronchiolitis accordant with chronic pulmonary graft *versus* host disease (GVHD).

Two years after the allo-HSCT the patient showed a history of anemia, without response to erythropoietin, and 34 months after allo-HSCT, a BM aspirated showed dysplastic changes without blasts, FISH studies showed del(5q) and monosomy of chromosome 7. Chimerism studies by STR of the BM cells showed 100% donor origin. The patient was diagnosed of MDS with origin in donor-derived cells. The donor remained healthy after transplantation.

Genomic DNA was isolated from BM specimens of the recipient at day +364, +609, +858 and +1012 after allo-HSCT and subjected to whole-exome sequencing, as well as PB specimen from donor at the time of transplant.

Patient #3

A 39-years-old male patient was diagnosed with chronic myeloid leukemia in chronic phase (CML-CP) with leukocytosis, cytogenetic studies performed in BM specimen showed a karyotype 46,XY,t(9;22) in all metaphases analyzed. Six months after treatment with hydroxyurea and interferon, the patient did not achieve hematologic response, neither cytogenetic response. Fourteen months after diagnosis, an allo-HSCT from his HLA-identical brother was performed following conditioning regimen with busulfan and cytarabine. His post-transplant period was complicated by neutropenic fever, oral mucositis grade II-IV, bilateral conjunctival hemorrhage, candidemia and cholestasis.

Twenty years after allo-HSCT the patient was noted to be neutropenic and thrombocytopenic. A BM aspirate was performed, which revealed dysplastic changes with 3% blasts and plasmacytosis (20% plasmatic cells). Cytogenetic studies showed a

karyotype //46,XY karyotype. FISH was negative for t(9;22) and STR analysis of the BM cells revealed full donor chimera. The patient was diagnosed of MDS with origin in donor-derived cells and plasmacytosis.

Due to progression of cytopenias a new BM aspirated was performed 6 months after the diagnosis of donor-cell derived MDS, that confirmed the diagnosis and associated FISH studies demonstrated the presence of a monosomy of chromosome 7 in 30% of the cells analyzed. Fifteen months after the diagnosis of MDS in donor cells and after 6 cycles of subcutaneous AZA, the pancytopenia was progressed and at this time the BM revealed hypercellular marrow with trilineal dysplasia, 23% blasts and significant plasmacytosis. Cytogenetic studies showed a karyotype //45,XY,-7 karyotype, confirmed by FISH in 40% of the cells. The patient was diagnosed of secondary AML in donor cells and myeloma quiescent IgA kappa (IgAk), and underwent a haploidentical-HSCT from his son.

The donor remained healthy at the moment of the diagnosis of MDS in donor derived-cells. He was evaluated and his tests were significant for an elevated serum protein electrophoresis demonstrated an abnormal band in the beta region revealing the existence of the same paraprotein (IgAk).

Genomic DNA was isolated and subjected to whole-exome sequencing from BM specimens of the recipient at days +1589, +6087, +7469 and +7675 after allo-HSCT, as well as PB specimen from donor at the time of transplant.

Patient #4

A 60-year-old male with a history of asthenia was diagnosed with AML. Cytogenetic studies in BM showed a karyotype 46,XY,t(3;17)(q21;q21),del(5q) karyotype. After treatment with fludarabine and cytarabine he achieved CR and 4 months after diagnosis an allo-HSCT from his HLA-id sister was performed. SCs mobilized from PB were infused following non-myeloablative conditioning regimen with fludarabine, busulfan and thymoglobulin. GVHD prophylaxis consisted of tacrolimus and methotrexate (MTX).

Post-transplant period was complicated by sickness, metabolic acidosis, fever, hypotension, acute cutaneous GVHD grade II and digestive GVHD grade III-IV treated with budesonide, metilprednisolone and etanercept. He also presented recurring cytomegalovirus viremias and positive EBV, resolved with ganciclovir and valganciclovir. Nineteen months after allo-HSCT, the patient presented with fever and interstitial pneumonia secondary to an upper respiratory infection. BM analysis revealed 21% myeloid blasts. Immunophenotype was CD38+, CD34+, CD64+d, CD13+, CD33+, CD117+, CD1a+d, CD123+d, CD4+d (24% of leucocytes). Moreover, cytogenetic analysis showed a complex karyotype: //45,XX,t(3;16)(q21;q22),-7[16]/90-130,XXXX,t(3;16)(q21;q22),t(3;16)(q21;q22),-7,-7,+2-5 mar[2]/46,XX[2]. Molecular STR analysis showed complete donor chimerism. Within this scenario, diagnosis of AML with origin in donor-derived cells was made. The patient received a total of 6 cycles of AZA, resulting in severe thrombopenia and disease progression. The donor remained healthy at the moment of the diagnosis of DCMN.

Genomic DNA was isolated and subjected to whole-exome sequencing from BM specimens of the recipient at day +95, +388 and +570 after allo-HSCT, as well as PB specimen from donor at the time of transplant.

Patient #5

A 55-years-old male presented a mantle cell lymphoma stage IV-A. The patient achieved complete remission (CR) after treatment with cyclophosphamide, vincristine, doxorubicin, dexamethasone, rituximab (hyper CVAD-R) and MTX-AraC, he underwent an allo-HSCT from his HLA-id brother 10 months after diagnosis. His post-transplant course was complicated by a moderate chronic cutaneous GVHD.

Routine blood analysis performed 5,5 years after transplantation showed severe pancytopenia (leucocytes 1540 u/L, Hb 10,8 g/dL and platelets 31000 u/l). A BM aspirate revealed a hypocellular BM with 27% of myeloid blast cells. Cytogenetics studies showed an abnormal karyotype: //46,XY,del(7)(q31q36) [4]// 47,XY,+1,der(1;7)(q10;p10) [18].

Immunophenotype was DR+, CD34+, CD38+, CD13+, CD33+, CD64+, CD15+, CD117+, CD123+, CD4+, CD14+d (24% of leucocytes). Molecular STR determinations showed complete donor chimerism and diagnosis of AML with origin in donor-derived cells was made. Thereafter, the patient received a new transplant and AZA were administrated as maintenance therapy after transplant. Relapse occurred and a third allo-HSCT was planned from his HLA-id brother, 7 cycles of AZA were administrated after transplant, however, the patient relapsed again and finally he death.

Genomic DNA was isolated and subjected to whole-exome sequencing from BM specimens of the recipient at day +128, +368 and +2011 after allo-HSCT, as well as PB specimen from donor at the time of transplant.

Patient #6

A 46-year-old woman presented a pro-B ALL, cytogenetic studies in the diagnostic BM showed a karyotype 46,XY,t(4;11) karyotype confirmed by FISH. The patient achieved complete remission after treatment with chemotherapy (PETHEMA LAL-AR 2011). She underwent Haplo-cord allo-HSCT from a matched unrelated umbilical cord blood (with her brother as third party donor) 4 months after diagnosis. Conditioning regimen consisted in fludarabine, ciclofosfamide, timoglobuline and TBI (10Gy). GVHD prophylaxis consisted of tacrolimus and metilprednisone. Her post-transplant course was complicated by diarrhea associated with *Clostridium difficile* and urinary tract infection by *Escherichia coli* and *Enterococo faecium*, she also developed bronchiolitis obliterans and fever. A complete blood test obtained the following results 24 months after allo-HSCT: leucocytes 3790 u/L, Hb 6.1 g/dL and platelets 57000 u/l, the patient reported a history of asthenia and cutaneous lesions. A BM smear demonstrated a hypercelular BM, multilineage dysplasia and myeloblasts accounted for 66%. Immunophenotype was DR+, CD38+, CD64+, CD56+, CD15+, CD14+, CD13+d, CD33+ and CD4+. STR analysis of the BM cells revealed full donor chimera and the patient was diagnosed of monocytic AML with origin in donor-derived cells. Fludarabine, cytarabine and idarubicine

were administrated to the patient for induction chemotherapy and AZA as maintenance chemotherapy. she underwent a second haplo-cord allo-SCT from an unrelated matched donor in CR, but finally the patient died.

Genomic DNA was isolated and subjected to whole-exome sequencing from BM specimens of the recipient at day +99, +229, +358 and +722 after allo-HSCT, as well as PB specimen from donor at the time of transplant and from CB unit.

Patient #7

A 46-year-old male presented with a 1-week history of epistaxis, hemoptysis and fever and was diagnosed as having ALL on the basis of a blood test including 95% blasts, together with a BM aspirate with massive infiltration by mid-sized, high n/c ratio, PAS+ blast cells, with a immunophenotype CD19+, CD22+, CD10+, TdT+ and CD34+ immunophenotype. Cytogenetic studies showed a 46,XY,t(9;22)(q34;q11) karyotype. The patient achieved CR after treatment with chemotherapy (PETHEMA AL-Ph-2008)¹⁵ and 5 months after diagnosis he underwent an allo-HSCT from his 1-antigen HLA-mismatched sister. Conditioning regimen consisted in cytarabine and TBI (12Gy).

At day +150 after allo-HSCT, bycytopenia with progressive dysgranulopiesis were observed in PB, while the BM aspirate showed dyserythropoiesis, dysgranulopoiesis, dysmegakaryopoiesis and 4% blast cells. Cytogenetic studies showed a //46,XX,t(10;11)(q24;p15) karyotype, finding that was confirmed by M-FISH. At day +500 after allo-SCT, the percentage of blast cells raised up to 14% and a complex karyotype was observed: //46,XX,t(10;11)(q24;p15)[13]//45,sl,-13,-16,+mar[2]//46,sl,del(7)(q22)[5]. CGH/SNP array analysis showed: a 54.55 Mb deletion in 7q22.2-q36.3 (25%) and a 17.32 Mb duplication in 11q23.3-q25 (60%). Molecular studies for *BCR-ABL* detection were negative. STR analysis of the BM cells revealed full donor chimera and the patient was diagnosed of MDS with origin in donor-derived cells. The donor remained healthy at the moment of the diagnosis of MDS in donor derived-cells.

Genomic DNA was isolated and subjected to whole-exome sequencing from BM specimens of the recipient at day +71, +113, +162, +419 and +728 after allo-HSCT, as well as PB specimen from donor at the time of diagnosis of MDS in donor derived-cells.

| Gene | Ch | Gene description | HGVSc_name | HGVSp_name | Effect | Months post allo-TPH (VAF) | | | | | | | | |
|------------------|----|---|------------------|---------------------|-------------|----------------------------|------|------|-----|-----|------|------|------|------|
| | | | | | | 2 | 15 | 30 | 37 | 50 | 58 | 58.5 | 59 | 60 |
| Patient 1 | | | | | | | | | | | | | | |
| 45,XY-7 | 7 | - | - | - | CNV | 0.1 | 0.1 | 0.1 | 0.2 | 0.1 | 0.3 | 0.4 | 0.4 | 0.4 |
| LUC7L2 | 7 | LUC7 like 2, pre-mRNA splicing factor | c.568TG>CT | p.Cys190Leu | missense | - | - | - | - | - | 0.28 | 0.4 | 0.22 | 0.38 |
| del(12p) | 12 | - | - | - | CNV | - | - | - | - | - | - | 0.4 | 0.2 | 0.4 |
| SETBP1 | 18 | SET binding protein | c.2612T>C | p.Ile871Thr | missense | - | - | - | - | - | - | 0.4 | - | - |
| Patient 2 | | | | | | 12 | 20 | 29 | | | | 34 | | |
| DNMT3A | 2 | DNA methyltransferase 3 alpha 5 | c.893G>A | p.Gly298Glu | missense | - | 0.32 | 0.51 | | | | 0.44 | | |
| TP53* | 17 | Tumor protein p53 | - | p.Gly302AlafsTer42 | frameshift | - | 0.49 | 0.53 | | | | 0.64 | | |
| LAMA5 | 20 | Laminin subunit alpha 5 | c.3407delA | p.Gln1136ArgfsTer38 | frameshift | - | 0.32 | 0.40 | | | | 0.54 | | |
| del(5q) | 5 | - | - | - | CNV | - | 0.2 | 0.4 | | | | 0.4 | | |
| del(7q) | 7 | - | - | - | CNV | - | 0.2 | 0.4 | | | | 0.4 | | |
| Patient 3 | | | | | | 53 | 203 | 248 | | | | 256 | | |
| CSF3R* | 1 | Colony stimulating factor 3 receptor | c.2296C>T | p.Gln766Ter | stop gained | - | - | - | | | 0.15 | | 0.08 | |
| TET2 | 4 | Tet methylcytosine dioxygenase | c.4594C>T | p.Gln1532Ter | stop gained | - | - | - | | | 0.27 | | 0.13 | |
| TET2 | 4 | Tet methylcytosine dioxygenase | c.5230_5246del | p.Leu1744GlyfsTer3 | frameshift | - | - | - | | | 0.21 | | 0.14 | |
| SNX13 | 7 | Sorting nexin 13 | c.2366G>C | p.Arg789Thr | missense | - | - | - | | | 0.28 | | 0.15 | |
| MEFV | 16 | MEFV, pyrin innate immunity regulator | c.1937C>T | p.Pro646Leu | missense | - | - | - | | | 0.11 | | 0.18 | |
| SKOR2 | 18 | SKI family transcriptional corepressor 2 | c.194C>T | p.Ala65Val | missense | - | - | - | | | 0.18 | | 0.20 | |
| ASXL1* | 20 | Additional Sex Combs-like 1 | c.1888_1910del | p.Glu635ArgfsTer15 | frameshift | - | - | - | | | 0.08 | | 0.10 | |
| RUNX1 | 21 | Runt related transcriptional factor 1 | c.876dupC | p.Ser293LeufsTer307 | frameshift | - | - | - | | | 0.18 | | 0.05 | |
| 45,XY-7 | 7 | - | - | - | CNV | - | - | - | | | 0.15 | | 0.1 | |
| Patient 4 | | | | | | 3 | 13 | | | | | 19 | | |
| GSE1 | 16 | Gse1 coiled-coil protein | c.366dupC | p.Val123ArgfsTer17 | frameshift | - | - | - | | | - | 0.16 | | |
| CK | - | - | - | - | CNV | - | - | - | | | - | 0.15 | | |
| Patient 5 | | | | | | 4 | 12 | | | | | 67 | | |
| CSF3R | 1 | Colony stimulating factor 3 receptor | c.2433dupC | p.Lys812GlnfsTer4 | frameshift | - | - | - | | | - | 0.2 | | |
| EML1 | 14 | echinoderm microtubule associated protein like 1 | c.632G>A | p.Arg211His | missense | - | - | - | | | - | 0.12 | | |
| del(7q) | 7 | - | - | - | CNV | - | - | - | | | - | 0.1 | | |
| Patient 6 | | | | | | 3 | 8 | 12 | | | | 24 | | |
| IRS1 | 2 | Insulin receptor substrate 1 | c.32C>A | p.Ser11Ter | stop gained | - | - | - | | | - | 0.20 | | |
| SENP7 | 3 | SUMO1sentrin specific peptidase 7 | c.478G>T | p.Glu160Ter | stop gained | - | - | - | | | - | 0.19 | | |
| NPM1* | 5 | Nucleophosmin | c.860_863dupCTCG | - | frameshift | - | - | - | | | - | 0.10 | | |
| NOTCH4 | 6 | notch 4 | c.1040G>T | p.Trp347Leu | missense | - | - | - | | | - | 0.24 | | |
| TAF1L | 9 | TATA-box binding protein associated factor 1 like | c.3313G>T | p.Asp1105Tyr | missense | - | - | - | | | - | 0.17 | | |
| DTX1 | 12 | deltex E3 ubiquitin ligase 1 | c.1245G>T | p.Met415Ile | missense | - | - | - | | | - | 0.16 | | |
| TP53* | 17 | Tumor protein p53 | C.824G>T | P.Cys275Phe | missense | - | - | - | | | - | 0.13 | | |
| GRB7 | 17 | growth factor receptor bound protein 7 | c.748G>T | p.Gly250Cys | missense | - | - | - | | | - | 0.15 | | |
| EP300 | 22 | E1A binding protein p300 | c.3728+1G>T | - | splicing | - | - | - | | | - | 0.19 | | |
| Patient 7 | | | | | | 2 | 3 | 5 | | | 14 | 24 | | |
| CK | - | - | - | - | CNV | - | - | - | | | 0.1 | 0.2 | 0.3 | |

| | | | | | | | | | | |
|----------------|----|--|-----------|-------------|----------|---|---|---|------|------|
| <i>ZKSCAN2</i> | 16 | Zinc finger with KRAB and SCAN domains 2 | c.2461C>A | p.His821Asn | missense | - | - | - | 0.09 | 0.3 |
| <i>PNKP</i> | 19 | Polynucleotide kinase 3-phosphatase | c.298C>A | p.His100Asn | missense | - | - | - | 0.13 | 0.38 |
| <i>del(7q)</i> | 7 | - | - | - | CNV | - | - | - | 0.1 | 0.3 |
| <i>NOP14</i> | 4 | NOP14 nucleolar protein | c.2382C>A | p.His794Gln | missense | - | - | - | - | 0.2 |
| <i>MEGF10</i> | 5 | Multiple EGF like domains 10 | c.1418G>T | p.Cys473Phe | missense | - | - | - | - | 0.26 |
| <i>TENM2</i> | 5 | Teneurin transmembrane protein 2 | c.1381G>T | p.Gly461Cys | missense | - | - | - | - | 0.35 |
| <i>IDH2</i> | 15 | Isocitrate dehydrogenase (NADP(+)) 2 | c.418C>T | p.Arg140Trp | missense | - | - | - | - | 0.14 |
| <i>ZNF461</i> | 19 | Zinc finger protein 461 | c.1021G>T | p.Gly341Cys | missense | - | - | - | - | 0.3 |

Supplemental Table S1. Deleterious somatic variants acquired in post allo-HSCT period. VAF detected in the moment of DCMN diagnosis are marked in light grey. The frequency population of the detected variants is 0, except for the variant detected in *SKOR2* which is equal to 0.0002. (*) Variants detected by target resequencing custom gene panel. (Abbreviations: VAF: Variant allele frequency, CK: Complex Karyotype, Ch: chromosome, allo-HSCT: allogeneic hematopoietic stem cell transplantation).

| Pathway | Gene | Gene description |
|-----------------------|----------------|---|
| Adherens junctions | <i>NECTIN1</i> | nectin cell adhesion molecule 1 |
| | <i>NECTIN2</i> | nectin cell adhesion molecule 2 |
| | <i>NECTIN3</i> | nectin cell adhesion molecule 3 |
| | <i>NECTIN4</i> | nectin cell adhesion molecule 4 |
| | <i>PARD3</i> | par-3 family cell polarity regulator |
| | <i>SRC</i> | SRC proto-oncogene, non-receptor tyrosine kinase |
| | <i>FARP2</i> | FERM, ARH/RhoGEF and pleckstrin domain protein 2 |
| | <i>CDC42</i> | cell division cycle 42 |
| | <i>RAC1</i> | Rac family small GTPase 1 |
| | <i>RAC2</i> | Rac family small GTPase 2 |
| | <i>RAC3</i> | Rac family small GTPase 3 |
| | <i>WAS</i> | Wiskott-Aldrich syndrome |
| | <i>WASL</i> | Wiskott-Aldrich syndrome like |
| | <i>IQGAP1</i> | IQ motif containing GTPase activating protein 1 |
| | <i>BA1AP2</i> | BA1 associated protein 2 |
| | <i>WASF1</i> | WAS protein family member 1 |
| | <i>WASF2</i> | WAS protein family member 2 |
| | <i>WASF3</i> | WAS protein family member 3 |
| | <i>AFDN</i> | afadin, adherens junction formation factor |
| | <i>LMO7</i> | LIM domain 7 |
| | <i>SSX2IP</i> | SSX family member 2 interacting protein |
| | <i>SORBS1</i> | sorbin and SH3 domain containing 1 |
| | <i>ACTN1</i> | actinin alpha 1 |
| | <i>ACTN4</i> | actinin alpha 4 |
| | <i>VCL</i> | vinculin |
| | <i>TJP1</i> | tight junction protein 1 |
| | <i>CDH1</i> | cadherin 1 |
| | <i>CTNND1</i> | catenin delta 1 |
| | <i>CTNNB1</i> | catenin beta 1 |
| | <i>CTNNA3</i> | catenin alpha 3 |
| | <i>CTNNA1</i> | catenin alpha 1 |
| | <i>CTNNA2</i> | catenin alpha 2 |
| | <i>ACTB</i> | Actin beta |
| | <i>ACTG1</i> | actin gamma 1 |
| | <i>RHOA</i> | ras homolog family member A |
| | <i>PTPRM</i> | protein tyrosine phosphatase, receptor type M |
| | <i>PTPRB</i> | protein tyrosine phosphatase, receptor type B |
| | <i>PTPRF</i> | protein tyrosine phosphatase, receptor type F |
| | <i>PTPN1</i> | protein tyrosine phosphatase, non-receptor type 1 |
| | <i>PTPN6</i> | protein tyrosine phosphatase, non-receptor type 6 |
| | <i>PTPRJ</i> | protein tyrosine phosphatase, receptor type J |
| | <i>CSNK2A1</i> | casein kinase 2 alpha 1 |
| | <i>CSNK2A2</i> | casein kinase 2 alpha 2 |
| | <i>CSNK2A3</i> | casein kinase 2 alpha 3 |
| | <i>CSNK2B</i> | casein kinase 2 beta |
| | <i>TCF7</i> | transcription factor 7 |
| | <i>TCF7L1</i> | transcription factor 7 like 1 |
| | <i>TCF7L2</i> | transcription factor 7 like 2 |
| | <i>LEF1</i> | lymphoid enhancer binding factor 1 |
| | <i>IGF1R</i> | insulin like growth factor 1 receptor |
| | <i>INSR</i> | insulin receptor |
| | <i>MET</i> | MET proto-oncogene, receptor tyrosine kinase |
| | <i>EGFR</i> | epidermal growth factor receptor |
| | <i>ERBB2</i> | erb-b2 receptor tyrosine kinase 2 |
| | <i>FGFR1</i> | fibroblast growth factor receptor 1 |
| | <i>FYN</i> | FYN proto-oncogene, Src family tyrosine kinase |
| | <i>YES1</i> | YES proto-oncogene 1, Src family tyrosine kinase |
| | <i>MAPK1</i> | mitogen-activated protein kinase 1 |
| | <i>MAPK3</i> | mitogen-activated protein kinase 3 |
| | <i>SNAI2</i> | snail family transcriptional repressor 2 |
| | <i>SNAI1</i> | snail family transcriptional repressor 1 |
| | <i>TGFBR1</i> | transforming growth factor beta receptor 1 |
| | <i>TGFBR2</i> | transforming growth factor beta receptor 2 |
| | <i>SMAD2</i> | SMAD family member 2 |
| | <i>SMAD3</i> | SMAD family member 3 |
| | <i>SMAD4</i> | SMAD family member 4 |
| | <i>CREBBP</i> | CREB binding protein |
| | <i>EP300</i> | E1A binding protein p300 |
| | <i>MAP3K7</i> | mitogen-activated protein kinase kinase kinase 7 |
| | <i>NLK</i> | nemo like kinase |
| | <i>FER</i> | FER tyrosine kinase |
| | <i>ACP1</i> | acid phosphatase 1, soluble |
| Wnt signaling pathway | <i>PORCN</i> | porcupine O-acyltransferase |
| | <i>WNT1</i> | Wnt family member 1 |
| | <i>WNT2</i> | Wnt family member 2 |
| | <i>WNT2B</i> | Wnt family member 2B |
| | <i>WNT3</i> | Wnt family member 3 |
| | <i>WNT3A</i> | Wnt family member 3A |
| | <i>WNT4</i> | Wnt family member 4 |
| | <i>WNT5A</i> | Wnt family member 5A |
| | <i>WNT5B</i> | Wnt family member 5B |
| | <i>WNT6</i> | Wnt family member 6 |
| | <i>WNT7A</i> | Wnt family member 7A |
| | <i>WNT7B</i> | Wnt family member 7B |
| | <i>WNT8A</i> | Wnt family member 8A |
| | <i>WNT8B</i> | Wnt family member 8B |
| | <i>WNT9A</i> | Wnt family member 9A |
| | <i>WNT9B</i> | Wnt family member 9B |

| | |
|-----------------|---|
| <i>WNT10B</i> | Wnt family member 10B |
| <i>WNT10A</i> | Wnt family member 10A |
| <i>WNT11</i> | Wnt family member 11 |
| <i>WNT16</i> | Wnt family member 16 |
| <i>CER1</i> | cerberus 1, DAN family BMP antagonist |
| <i>NOTUM</i> | NOTUM, palmitoleoyl-protein carboxylesterase |
| <i>WIF1</i> | WNT inhibitory factor 1 |
| <i>SERPINF1</i> | serpin family F member 1 |
| <i>SOST</i> | sclerostin |
| <i>DKK1</i> | dickkopf WNT signaling pathway inhibitor 1 |
| <i>DKK2</i> | dickkopf WNT signaling pathway inhibitor 2 |
| <i>DKK4</i> | dickkopf WNT signaling pathway inhibitor 4 |
| <i>SFRP1</i> | secreted frizzled related protein 1 |
| <i>SFRP2</i> | secreted frizzled related protein 2 |
| <i>SFRP4</i> | secreted frizzled related protein 4 |
| <i>SFRP5</i> | secreted frizzled related protein 5 |
| <i>FZD1</i> | frizzled class receptor 1 |
| <i>FZD7</i> | frizzled class receptor 7 |
| <i>FZD2</i> | frizzled class receptor 2 |
| <i>FZD3</i> | frizzled class receptor 3 |
| <i>FZD4</i> | frizzled class receptor 4 |
| <i>FZD5</i> | frizzled class receptor 5 |
| <i>FZD8</i> | frizzled class receptor 8 |
| <i>FZD6</i> | frizzled class receptor 6 |
| <i>FZD10</i> | frizzled class receptor 10 |
| <i>FZD9</i> | frizzled class receptor 9 |
| <i>LRP5</i> | LDL receptor related protein 5 |
| <i>LRP6</i> | LDL receptor related protein 6 |
| <i>BAMBI</i> | BMP and activin membrane bound inhibitor |
| <i>CSNK1E</i> | casein kinase 1 epsilon |
| <i>DVL3</i> | dishevelled segment polarity protein 3 |
| <i>DVL2</i> | dishevelled segment polarity protein 2 |
| <i>DVL1</i> | dishevelled segment polarity protein 1 |
| <i>FRAT1</i> | FRAT1, WNT signaling pathway regulator |
| <i>FRAT2</i> | FRAT2, WNT signaling pathway regulator |
| <i>CSNK2A1</i> | casein kinase 2 alpha 1 |
| <i>CSNK2A2</i> | casein kinase 2 alpha 2 |
| <i>CSNK2A3</i> | casein kinase 2 alpha 3 |
| <i>CSNK2B</i> | casein kinase 2 beta |
| <i>NKD1</i> | naked cuticle homolog 1 |
| <i>NKD2</i> | naked cuticle homolog 2 |
| <i>CXXC4</i> | CXXC finger protein 4 |
| <i>SENP2</i> | SUMO1/sentrin/SMT3 specific peptidase 2 |
| <i>GSK3B</i> | glycogen synthase kinase 3 beta |
| <i>CTNNB1</i> | catenin beta 1 |
| <i>AXIN1</i> | axin 1 |
| <i>AXIN2</i> | axin 2 |
| <i>APC</i> | APC, WNT signaling pathway regulator |
| <i>APC2</i> | APC2, WNT signaling pathway regulator |
| <i>CSNK1A1L</i> | casein kinase 1 alpha 1 like |
| <i>CSNK1A1</i> | casein kinase 1 alpha 1 |
| <i>TCF7</i> | transcription factor 7 |
| <i>TCF7L1</i> | transcription factor 7 like 1 |
| <i>TCF7L2</i> | transcription factor 7 like 2 |
| <i>LEF1</i> | lymphoid enhancer binding factor 1 |
| <i>CTNNBIP1</i> | catenin beta interacting protein 1 |
| <i>CHD8</i> | chromodomain helicase DNA binding protein 8 |
| <i>SOX17</i> | SRY-box 17 |
| <i>CTBP1</i> | C-terminal binding protein 1 |
| <i>CTBP2</i> | C-terminal binding protein 2 |
| <i>CREBBP</i> | CREB binding protein |
| <i>EP300</i> | E1A binding protein p300 |
| <i>RUVBL1</i> | RuvB like AAA ATPase 1 |
| <i>SMAD4</i> | SMAD family member 4 |
| <i>MAP3K7</i> | mitogen-activated protein kinase kinase kinase 7 |
| <i>NLK</i> | nemo like kinase |
| <i>MYC</i> | MYC proto-oncogene, bHLH transcription factor |
| <i>JUN</i> | Jun proto-oncogene, AP-1 transcription factor subunit |
| <i>FOSL1</i> | FOS like 1, AP-1 transcription factor subunit |
| <i>CCND1</i> | cyclin D1 |
| <i>CCND2</i> | cyclin D2 |
| <i>CCND3</i> | cyclin D3 |
| <i>PPARD</i> | peroxisome proliferator activated receptor delta |
| <i>MMP7</i> | matrix metallopeptidase 7 |
| <i>PSEN1</i> | presenilin 1 |
| <i>PRKACA</i> | protein kinase cAMP-activated catalytic subunit alpha |
| <i>PRKACB</i> | protein kinase cAMP-activated catalytic subunit beta |
| <i>PRKACG</i> | protein kinase cAMP-activated catalytic subunit gamma |
| <i>TP53</i> | tumor protein p53 |
| <i>SIAH1</i> | siah E3 ubiquitin protein ligase 1 |
| <i>CACYBP</i> | calcyclin binding protein |
| <i>SKP1</i> | S-phase kinase associated protein 1 |
| <i>TBL1X</i> | transducin beta like 1X-linked |
| <i>TBL1Y</i> | transducin beta like 1, Y-linked |
| <i>TBL1XR1</i> | transducin beta like 1 X-linked receptor 1 |
| <i>BTRC</i> | beta-transducin repeat containing E3 ubiquitin protein ligase |
| <i>FBXW11</i> | F-box and WD repeat domain containing 11 |
| <i>CUL1</i> | cullin 1 |
| <i>RBX1</i> | ring-box 1 |

| | | |
|------------------------|------------------|--|
| | <i>GPC4</i> | glycan 4 |
| | <i>VANGL2</i> | VANGL planar cell polarity protein 2 |
| | <i>VANGL1</i> | VANGL planar cell polarity protein 1 |
| | <i>PRICKLE1</i> | prickle planar cell polarity protein 1 |
| | <i>PRICKLE2</i> | prickle planar cell polarity protein 2 |
| | <i>INVS</i> | inversin |
| | <i>DAAM1</i> | dishevelled associated activator of morphogenesis 1 |
| | <i>DAAM2</i> | dishevelled associated activator of morphogenesis 2 |
| | <i>RHOA</i> | ras homolog family member A |
| | <i>ROCK2</i> | Rho associated coiled-coil containing protein kinase 2 |
| | <i>RAC1</i> | Rac family small GTPase 1 |
| | <i>RAC2</i> | Rac family small GTPase 2 |
| | <i>RAC3</i> | Rac family small GTPase 3 |
| | <i>MAPK8</i> | mitogen-activated protein kinase 8 |
| | <i>MAPK10</i> | mitogen-activated protein kinase 10 |
| | <i>MAPK9</i> | mitogen-activated protein kinase 9 |
| | <i>PLCB1</i> | phospholipase C beta 1 |
| | <i>PLCB2</i> | phospholipase C beta 2 |
| | <i>PLCB3</i> | phospholipase C beta 3 |
| | <i>PLCB4</i> | phospholipase C beta 4 |
| | <i>CAMK2A</i> | calcium/calmodulin dependent protein kinase II alpha |
| | <i>CAMK2D</i> | calcium/calmodulin dependent protein kinase II delta |
| | <i>CAMK2B</i> | calcium/calmodulin dependent protein kinase II beta |
| | <i>CAMK2G</i> | calcium/calmodulin dependent protein kinase II gamma |
| | <i>PPP3CA</i> | protein phosphatase 3 catalytic subunit alpha |
| | <i>PPP3CB</i> | protein phosphatase 3 catalytic subunit beta |
| | <i>PPP3CC</i> | protein phosphatase 3 catalytic subunit gamma |
| | <i>PPP3R1</i> | protein phosphatase 3 regulatory subunit B, alpha |
| | <i>PPP3R2</i> | protein phosphatase 3 regulatory subunit B, beta |
| | <i>PRKCA</i> | protein kinase C alpha |
| | <i>PRKCB</i> | protein kinase C beta |
| | <i>PRKG</i> | protein kinase C gamma |
| | <i>NFATC1</i> | nuclear factor of activated T-cells 1 |
| | <i>NFATC2</i> | nuclear factor of activated T-cells 2 |
| | <i>NFATC3</i> | nuclear factor of activated T-cells 3 |
| | <i>NFATC4</i> | nuclear factor of activated T-cells 4 |
| | <i>SMAD3</i> | SMAD family member 3 |
| cAMP signaling pathway | <i>FSHB</i> | follicle stimulating hormone beta subunit |
| | <i>ADRB1</i> | adrenoceptor beta 1 |
| | <i>DRD1</i> | dopamine receptor D1 |
| | <i>DRD5</i> | dopamine receptor D5 |
| | <i>ADORA2A</i> | adenosine A2a receptor |
| | <i>HTR4</i> | 5-hydroxytryptamine receptor 4 |
| | <i>HTR6</i> | 5-hydroxytryptamine receptor 6 |
| | <i>PTGER2</i> | prostaglandin E receptor 2 |
| | <i>ADCYAP1R1</i> | ADCYAP receptor type I |
| | <i>VIPR2</i> | vasoactive intestinal peptide receptor 2 |
| | <i>TSHR</i> | thyroid stimulating hormone receptor |
| | <i>MC2R</i> | melanocortin 2 receptor |
| | <i>GLP1R</i> | glucagon like peptide 1 receptor |
| | <i>GIPR</i> | gastric inhibitory polypeptide receptor |
| | <i>GPR119</i> | G protein-coupled receptor 119 |
| | <i>FSHR</i> | follicle stimulating hormone receptor |
| | <i>NPR1</i> | natriuretic peptide receptor 1 |
| | <i>GNAS</i> | GNAS complex locus |
| | <i>NPY</i> | neuropeptide Y |
| | <i>GHRL</i> | ghrelin and obestatin prepropeptide |
| | <i>ADRB2</i> | adrenoceptor beta 2 |
| | <i>HTR1A</i> | 5-hydroxytryptamine receptor 1A |
| | <i>HTR1B</i> | 5-hydroxytryptamine receptor 1B |
| | <i>HTR1D</i> | 5-hydroxytryptamine receptor 1D |
| | <i>HTR1E</i> | 5-hydroxytryptamine receptor 1E |
| | <i>HTR1F</i> | 5-hydroxytryptamine receptor 1F |
| | <i>CHRM1</i> | cholinergic receptor muscarinic 1 |
| | <i>CHRM2</i> | cholinergic receptor muscarinic 2 |
| | <i>DRD2</i> | dopamine receptor D2 |
| | <i>GABBR1</i> | gamma-aminobutyric acid type B receptor subunit 1 |
| | <i>GABBR2</i> | gamma-aminobutyric acid type B receptor subunit 2 |
| | <i>ADORA1</i> | adenosine A1 receptor |
| | <i>EDNRA</i> | endothelin receptor type A |
| | <i>NPY1R</i> | neuropeptide Y receptor Y1 |
| | <i>SSTR1</i> | somatostatin receptor 1 |
| | <i>SSTR2</i> | somatostatin receptor 2 |
| | <i>SSTR5</i> | somatostatin receptor 5 |
| | <i>HCAR1</i> | hydroxycarboxylic acid receptor 1 |
| | <i>HCAR2</i> | hydroxycarboxylic acid receptor 2 |
| | <i>HCAR3</i> | hydroxycarboxylic acid receptor 3 |
| | <i>FFAR2</i> | free fatty acid receptor 2 |
| | <i>SUCNR1</i> | succinate receptor 1 |
| | <i>PTGER3</i> | prostaglandin E receptor 3 |
| | <i>OXTR</i> | oxytocin receptor |
| | <i>GHSR</i> | growth hormone secretagogue receptor |
| | <i>GNAI1</i> | G protein subunit alpha i1 |
| | <i>GNAI3</i> | G protein subunit alpha i3 |
| | <i>GNAI2</i> | G protein subunit alpha i2 |
| | <i>ADCY1</i> | adenylate cyclase 1 |
| | <i>ADCY2</i> | adenylate cyclase 2 |
| | <i>ADCY3</i> | adenylate cyclase 3 |
| | <i>ADCY4</i> | adenylate cyclase 4 |

| | |
|----------------|--|
| <i>ADCY5</i> | adenylate cyclase 5 |
| <i>ADCY6</i> | adenylate cyclase 6 |
| <i>ADCY7</i> | adenylate cyclase 7 |
| <i>ADCY8</i> | adenylate cyclase 8 |
| <i>ADCY9</i> | adenylate cyclase 9 |
| <i>ADCY10</i> | adenylate cyclase 10, soluble |
| <i>HCN2</i> | hyperpolarization activated cyclic nucleotide gated potassium and sodium channel 2 |
| <i>HCN4</i> | hyperpolarization activated cyclic nucleotide gated potassium channel 4 |
| <i>CNGA1</i> | cyclic nucleotide gated channel alpha 1 |
| <i>CNGA2</i> | cyclic nucleotide gated channel alpha 2 |
| <i>CNGA3</i> | cyclic nucleotide gated channel alpha 3 |
| <i>CNGA4</i> | cyclic nucleotide gated channel alpha 4 |
| <i>CNGB1</i> | cyclic nucleotide gated channel beta 1 |
| <i>CNGB3</i> | cyclic nucleotide gated channel beta 3 |
| <i>CALML3</i> | calmodulin like 3 |
| <i>CALM2</i> | calmodulin 2 |
| <i>CALM3</i> | calmodulin 3 |
| <i>CALM1</i> | calmodulin 1 |
| <i>CALML6</i> | calmodulin like 6 |
| <i>CALMLS</i> | calmodulin like 5 |
| <i>CALML4</i> | calmodulin like 4 |
| <i>CAMK2A</i> | calcium/calmodulin dependent protein kinase II alpha |
| <i>CAMK2D</i> | calcium/calmodulin dependent protein kinase II delta |
| <i>CAMK2B</i> | calcium/calmodulin dependent protein kinase II beta |
| <i>CAMK2G</i> | calcium/calmodulin dependent protein kinase II gamma |
| <i>CAMK4</i> | calcium/calmodulin dependent protein kinase IV |
| <i>ABCC4</i> | ATP binding cassette subfamily C member 4 |
| <i>RAPGEF3</i> | Rap guanine nucleotide exchange factor 3 |
| <i>RAPGEF4</i> | Rap guanine nucleotide exchange factor 4 |
| <i>RRAS</i> | RAS related |
| <i>RRAS2</i> | RAS related 2 |
| <i>PLD1</i> | phospholipase D1 |
| <i>PLD2</i> | phospholipase D2 |
| <i>PLCE1</i> | phospholipase C epsilon 1 |
| <i>MAPK8</i> | mitogen-activated protein kinase 8 |
| <i>MAPK10</i> | mitogen-activated protein kinase 10 |
| <i>MAPK9</i> | mitogen-activated protein kinase 9 |
| <i>RAP1A</i> | RAP1A, member of RAS oncogene family |
| <i>RAP1B</i> | RAP1B, member of RAS oncogene family |
| <i>PIAM1</i> | T-cell lymphoma invasion and metastasis 1 |
| <i>VAV3</i> | vav guanine nucleotide exchange factor 3 |
| <i>VAV1</i> | vav guanine nucleotide exchange factor 1 |
| <i>VAV2</i> | vav guanine nucleotide exchange factor 2 |
| <i>RAC1</i> | Rac family small GTPase 1 |
| <i>RAC2</i> | Rac family small GTPase 2 |
| <i>RAC3</i> | Rac family small GTPase 3 |
| <i>PAK1</i> | p21 (RAC1) activated kinase 1 |
| <i>ARAP3</i> | ArfGAP with RhoGAP domain, ankyrin repeat and PH domain 3 |
| <i>RHOA</i> | ras homolog family member A |
| <i>AFDN</i> | afadin, adherens junction formation factor |
| <i>PIK3CA</i> | phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha |
| <i>PIK3CD</i> | phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta |
| <i>PIK3CB</i> | phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta |
| <i>PIK3R1</i> | phosphoinositide-3-kinase regulatory subunit 1 |
| <i>PIK3R2</i> | phosphoinositide-3-kinase regulatory subunit 2 |
| <i>PIK3R3</i> | phosphoinositide-3-kinase regulatory subunit 3 |
| <i>AKT1</i> | AKT serine/threonine kinase 1 |
| <i>AKT2</i> | AKT serine/threonine kinase 2 |
| <i>AKT3</i> | AKT serine/threonine kinase 3 |
| <i>BRAF</i> | B-Raf proto-oncogene, serine/threonine kinase |
| <i>RAF1</i> | Raf-1 proto-oncogene, serine/threonine kinase |
| <i>MAP2K1</i> | mitogen-activated protein kinase kinase 1 |
| <i>MAP2K2</i> | mitogen-activated protein kinase kinase 2 |
| <i>MAPK1</i> | mitogen-activated protein kinase 1 |
| <i>MAPK3</i> | mitogen-activated protein kinase 3 |
| <i>PRKACA</i> | protein kinase cAMP-activated catalytic subunit alpha |
| <i>PRKACB</i> | protein kinase cAMP-activated catalytic subunit beta |
| <i>PRKACG</i> | protein kinase cAMP-activated catalytic subunit gamma |
| <i>PPP1R1B</i> | protein phosphatase 1 regulatory inhibitor subunit 1B |
| <i>PPP1CA</i> | protein phosphatase 1 catalytic subunit alpha |
| <i>PPP1CB</i> | protein phosphatase 1 catalytic subunit beta |
| <i>PPP1CC</i> | protein phosphatase 1 catalytic subunit gamma |
| <i>CREB1</i> | cAMP responsive element binding protein 1 |
| <i>CREB3</i> | cAMP responsive element binding protein 3 |
| <i>CREB3L1</i> | cAMP responsive element binding protein 3 like 1 |
| <i>CREB3L2</i> | cAMP responsive element binding protein 3 like 2 |
| <i>CREB3L3</i> | cAMP responsive element binding protein 3 like 3 |
| <i>CREB3L4</i> | cAMP responsive element binding protein 3 like 4 |
| <i>CREB5</i> | cAMP responsive element binding protein 5 |
| <i>CREBBP</i> | CREB binding protein |
| <i>EP300</i> | E1A binding protein p300 |
| <i>BDNF</i> | brain derived neurotrophic factor |
| <i>FOS</i> | Fos proto-oncogene, AP-1 transcription factor subunit |
| <i>JUN</i> | Jun proto-oncogene, AP-1 transcription factor subunit |
| <i>GLI3</i> | GLI family zinc finger 3 |
| <i>GLI1</i> | GLI family zinc finger 1 |
| <i>PTCH1</i> | patched 1 |
| <i>HHIP</i> | hedgehog interacting protein |
| <i>NFKBIA</i> | NFKB inhibitor alpha |

| | | |
|----------------|-----------------|---|
| | <i>NFKB1</i> | nuclear factor kappa B subunit 1 |
| | <i>RELA</i> | RELA proto-oncogene, NF- κ B subunit |
| | <i>SOX9</i> | SRY-box 9 |
| | <i>AMH</i> | anti-Mullerian hormone |
| | <i>PPARA</i> | peroxisome proliferator activated receptor alpha |
| | <i>ACOX3</i> | acyl-CoA oxidase 3, pristanoyl |
| | <i>ACOX1</i> | acyl-CoA oxidase 1 |
| | <i>NFATC1</i> | nuclear factor of activated T-cells 1 |
| | <i>F2R</i> | coagulation factor II thrombin receptor |
| | <i>BAD</i> | BCL2 associated agonist of cell death |
| | <i>LIPE</i> | lipase E, hormone sensitive type |
| | <i>ROCK1</i> | Rho associated coiled-coil containing protein kinase 1 |
| | <i>ROCK2</i> | Rho associated coiled-coil containing protein kinase 2 |
| | <i>PPP1R12A</i> | protein phosphatase 1 regulatory subunit 12A |
| | <i>MYL9</i> | myosin light chain 9 |
| | <i>TNNI3</i> | troponin I3, cardiac type |
| | <i>PLN</i> | phospholamban |
| | <i>RYR2</i> | ryanodine receptor 2 |
| | <i>GRIN1</i> | glutamate ionotropic receptor NMDA type subunit 1 |
| | <i>GRIN2A</i> | glutamate ionotropic receptor NMDA type subunit 2A |
| | <i>GRIN2B</i> | glutamate ionotropic receptor NMDA type subunit 2B |
| | <i>GRIN2C</i> | glutamate ionotropic receptor NMDA type subunit 2C |
| | <i>GRIN2D</i> | glutamate ionotropic receptor NMDA type subunit 2D |
| | <i>GRIN3A</i> | glutamate ionotropic receptor NMDA type subunit 3A |
| | <i>GRIN3B</i> | glutamate ionotropic receptor NMDA type subunit 3B |
| | <i>GRIA1</i> | glutamate ionotropic receptor AMPA type subunit 1 |
| | <i>GRIA2</i> | glutamate ionotropic receptor AMPA type subunit 2 |
| | <i>GRIA3</i> | glutamate ionotropic receptor AMPA type subunit 3 |
| | <i>GRIA4</i> | glutamate ionotropic receptor AMPA type subunit 4 |
| | <i>CFTR</i> | cystic fibrosis transmembrane conductance regulator |
| | <i>ATP1A1</i> | ATPase Na ⁺ /K ⁺ transporting subunit alpha 1 |
| | <i>ATP1A2</i> | ATPase Na ⁺ /K ⁺ transporting subunit alpha 2 |
| | <i>ATP1A3</i> | ATPase Na ⁺ /K ⁺ transporting subunit alpha 3 |
| | <i>ATP1A4</i> | ATPase Na ⁺ /K ⁺ transporting subunit alpha 4 |
| | <i>ATP1B4</i> | ATPase Na ⁺ /K ⁺ transporting family member beta 4 |
| | <i>ATP1B1</i> | ATPase Na ⁺ /K ⁺ transporting subunit beta 1 |
| | <i>ATP1B2</i> | ATPase Na ⁺ /K ⁺ transporting subunit beta 2 |
| | <i>ATP1B3</i> | ATPase Na ⁺ /K ⁺ transporting subunit beta 3 |
| | <i>FXYD2</i> | FXYD domain containing ion transport regulator 2 |
| | <i>FXYD1</i> | FXYD domain containing ion transport regulator 1 |
| | <i>SLC9A1</i> | solute carrier family 9 member A1 |
| | <i>ORAI1</i> | ORAI calcium release-activated calcium modulator 1 |
| | <i>ATP2B1</i> | ATPase plasma membrane Ca ²⁺ transporting 1 |
| | <i>ATP2B3</i> | ATPase plasma membrane Ca ²⁺ transporting 3 |
| | <i>ATP2B4</i> | ATPase plasma membrane Ca ²⁺ transporting 4 |
| | <i>ATP2B2</i> | ATPase plasma membrane Ca ²⁺ transporting 2 |
| | <i>CACNA1C</i> | calcium voltage-gated channel subunit alpha1 C |
| | <i>CACNA1D</i> | calcium voltage-gated channel subunit alpha1 D |
| | <i>CACNA1F</i> | calcium voltage-gated channel subunit alpha1 F |
| | <i>CACNA1S</i> | calcium voltage-gated channel subunit alpha1 S |
| | <i>PDE3A</i> | phosphodiesterase 3A |
| | <i>PDE3B</i> | phosphodiesterase 3B |
| | <i>PDE4A</i> | phosphodiesterase 4A |
| | <i>PDE4B</i> | phosphodiesterase 4B |
| | <i>PDE4C</i> | phosphodiesterase 4C |
| | <i>PDE4D</i> | phosphodiesterase 4D |
| | <i>ATP2A2</i> | ATPase sarcoplasmic/endoplasmic reticulum Ca ²⁺ transporting 2 |
| Focal adhesion | <i>COL1A1</i> | collagen type I alpha 1 chain |
| | <i>COL1A2</i> | collagen type I alpha 2 chain |
| | <i>COL2A1</i> | collagen type II alpha 1 chain |
| | <i>COL4A2</i> | collagen type IV alpha 2 chain |
| | <i>COL4A4</i> | collagen type IV alpha 4 chain |
| | <i>COL4A6</i> | collagen type IV alpha 6 chain |
| | <i>COL4A1</i> | collagen type IV alpha 1 chain |
| | <i>COL4A5</i> | collagen type IV alpha 5 chain |
| | <i>COL4A3</i> | collagen type IV alpha 3 chain |
| | <i>COL6A1</i> | collagen type VI alpha 1 chain |
| | <i>COL6A2</i> | collagen type VI alpha 2 chain |
| | <i>COL6A3</i> | collagen type VI alpha 3 chain |
| | <i>COL6A6</i> | collagen type VI alpha 6 chain |
| | <i>COL6A5</i> | collagen type VI alpha 5 chain |
| | <i>COL9A1</i> | collagen type IX alpha 1 chain |
| | <i>COL9A2</i> | collagen type IX alpha 2 chain |
| | <i>COL9A3</i> | collagen type IX alpha 3 chain |
| | <i>LAMA1</i> | laminin subunit alpha 1 |
| | <i>LAMA2</i> | laminin subunit alpha 2 |
| | <i>LAMA3</i> | laminin subunit alpha 3 |
| | <i>LAMAS5</i> | laminin subunit alpha 5 |
| | <i>LAMA4</i> | laminin subunit alpha 4 |
| | <i>LAMB1</i> | laminin subunit beta 1 |
| | <i>LAMB2</i> | laminin subunit beta 2 |
| | <i>LAMB3</i> | laminin subunit beta 3 |
| | <i>LAMB4</i> | laminin subunit beta 4 |
| | <i>LAMC1</i> | laminin subunit gamma 1 |
| | <i>LAMC2</i> | laminin subunit gamma 2 |
| | <i>LAMC3</i> | laminin subunit gamma 3 |
| | <i>CHAD</i> | chondroadherin |
| | <i>REIN</i> | reelin |
| | <i>THBS1</i> | thrombospondin 1 |

| | |
|-----------------|--|
| <i>COMP</i> | cartilage oligomeric matrix protein |
| <i>THBS2</i> | thrombospondin 2 |
| <i>THBS3</i> | thrombospondin 3 |
| <i>THBS4</i> | thrombospondin 4 |
| <i>FN1</i> | fibronectin 1 |
| <i>SPP1</i> | secreted phosphoprotein 1 |
| <i>VTN</i> | vitronectin |
| <i>TNC</i> | tenascin C |
| <i>TNN</i> | tenascin N |
| <i>TNR</i> | tenascin R |
| <i>TNXB</i> | tenascin XB |
| <i>VWF</i> | von Willebrand factor |
| <i>IBSP</i> | integrin binding sialoprotein |
| <i>ITGA1</i> | integrin subunit alpha 1 |
| <i>ITGA2</i> | integrin subunit alpha 2 |
| <i>ITGA2B</i> | integrin subunit alpha 2b |
| <i>ITGA3</i> | integrin subunit alpha 3 |
| <i>ITGA4</i> | integrin subunit alpha 4 |
| <i>ITGA5</i> | integrin subunit alpha 5 |
| <i>ITGA6</i> | integrin subunit alpha 6 |
| <i>ITGA7</i> | integrin subunit alpha 7 |
| <i>ITGA8</i> | integrin subunit alpha 8 |
| <i>ITGA9</i> | integrin subunit alpha 9 |
| <i>ITGA10</i> | integrin subunit alpha 10 |
| <i>ITGA11</i> | integrin subunit alpha 11 |
| <i>ITGAV</i> | integrin subunit alpha V |
| <i>ITGB1</i> | integrin subunit beta 1 |
| <i>ITGB3</i> | integrin subunit beta 3 |
| <i>ITGB4</i> | integrin subunit beta 4 |
| <i>ITGB5</i> | integrin subunit beta 5 |
| <i>ITGB6</i> | integrin subunit beta 6 |
| <i>ITGB7</i> | integrin subunit beta 7 |
| <i>ITGB8</i> | integrin subunit beta 8 |
| <i>PDGFA</i> | platelet derived growth factor subunit A |
| <i>PDGFB</i> | platelet derived growth factor subunit B |
| <i>PDGFC</i> | platelet derived growth factor C |
| <i>PDGFD</i> | platelet derived growth factor D |
| <i>EGF</i> | epidermal growth factor |
| <i>IGF1</i> | insulin like growth factor 1 |
| <i>VEGFA</i> | vascular endothelial growth factor A |
| <i>VEGFB</i> | vascular endothelial growth factor B |
| <i>PGF</i> | placental growth factor |
| <i>VEGFC</i> | vascular endothelial growth factor C |
| <i>VEGFD</i> | vascular endothelial growth factor D |
| <i>HGF</i> | hepatocyte growth factor |
| <i>PDGFRα</i> | platelet derived growth factor receptor alpha |
| <i>PDGFRβ</i> | platelet derived growth factor receptor beta |
| <i>IGF1R</i> | insulin like growth factor 1 receptor |
| <i>KDR</i> | kinase insert domain receptor |
| <i>EGFR</i> | epidermal growth factor receptor |
| <i>FLT1</i> | fms related tyrosine kinase 1 |
| <i>FLT4</i> | fms related tyrosine kinase 4 |
| <i>MET</i> | MET proto-oncogene, receptor tyrosine kinase |
| <i>ERBB2</i> | erb-B2 receptor tyrosine kinase 2 |
| <i>SRC</i> | SRC proto-oncogene, non-receptor tyrosine kinase |
| <i>ARHGAP35</i> | Rho GTPase activating protein 35 |
| <i>ARHGAP5</i> | Rho GTPase activating protein 5 |
| <i>RHOA</i> | ras homolog family member A |
| <i>DIAPH1</i> | diaphanous related formin 1 |
| <i>ROCK1</i> | Rho associated coiled-coil containing protein kinase 1 |
| <i>ROCK2</i> | Rho associated coiled-coil containing protein kinase 2 |
| <i>MYL2</i> | myosin light chain 2 |
| <i>MYL5</i> | myosin light chain 5 |
| <i>MYL7</i> | myosin light chain 7 |
| <i>MYL9</i> | myosin light chain 9 |
| <i>MYL10</i> | myosin light chain 10 |
| <i>MYL12B</i> | myosin light chain 12B |
| <i>MYL12A</i> | myosin light chain 12A |
| <i>MYLPF</i> | myosin light chain, phosphorylatable, fast skeletal muscle |
| <i>PPP1CA</i> | protein phosphatase 1 catalytic subunit alpha |
| <i>PPP1CB</i> | protein phosphatase 1 catalytic subunit beta |
| <i>PPP1CC</i> | protein phosphatase 1 catalytic subunit gamma |
| <i>PPP1R12A</i> | protein phosphatase 1 regulatory subunit 12A |
| <i>PPP1R12B</i> | protein phosphatase 1 regulatory subunit 12B |
| <i>PPP1R12C</i> | protein phosphatase 1 regulatory subunit 12C |
| <i>MYLK</i> | myosin light chain kinase |
| <i>MYLK2</i> | myosin light chain kinase 2 |
| <i>MYLK3</i> | myosin light chain kinase 3 |
| <i>MYLK4</i> | myosin light chain kinase family member 4 |
| <i>ACTB</i> | actin beta |
| <i>ACTG1</i> | actin gamma 1 |
| <i>RASGRF1</i> | Ras protein specific guanine nucleotide releasing factor 1 |
| <i>CAPN2</i> | calpain 2 |
| <i>ACTN1</i> | actinin alpha 1 |
| <i>ACTN4</i> | actinin alpha 4 |
| <i>TLN1</i> | talin 1 |
| <i>TLN2</i> | talin 2 |
| <i>FLNA</i> | filamin A |
| <i>FLNC</i> | filamin C |

| | | |
|--------------------------|-------------------|--|
| | <i>FLNB</i> | filamin B |
| | <i>PXN</i> | paxillin |
| | <i>ILK</i> | integrin linked kinase |
| | <i>ZYX</i> | zyxin |
| | <i>VASP</i> | vasodilator stimulated phosphoprotein |
| | <i>VCL</i> | vinculin |
| | <i>PARVB</i> | parvin beta |
| | <i>PARVA</i> | parvin alpha |
| | <i>PARVG</i> | parvin gamma |
| | <i>PDPK1</i> | 3-phosphoinositide dependent protein kinase 1 |
| | <i>AKT1</i> | AKT serine/threonine kinase 1 |
| | <i>AKT2</i> | AKT serine/threonine kinase 2 |
| | <i>AKT3</i> | AKT serine/threonine kinase 3 |
| | <i>GSK3B</i> | glycogen synthase kinase 3 beta |
| | <i>CTNNB1</i> | catenin beta 1 |
| | <i>PRKCA</i> | protein kinase C alpha |
| | <i>PRKCB</i> | protein kinase C beta |
| | <i>PRKG</i> | protein kinase C gamma |
| | <i>PTK2</i> | protein tyrosine kinase 2 |
| | <i>PIK3CA</i> | phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha |
| | <i>PIK3CD</i> | phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta |
| | <i>PIK3CB</i> | phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta |
| | <i>PIK3R1</i> | phosphoinositide-3-kinase regulatory subunit 1 |
| | <i>PIK3R2</i> | phosphoinositide-3-kinase regulatory subunit 2 |
| | <i>PIK3R3</i> | phosphoinositide-3-kinase regulatory subunit 3 |
| | <i>PTEN</i> | phosphatase and tensin homolog |
| | <i>VAV3</i> | vav guanine nucleotide exchange factor 3 |
| | <i>VAV1</i> | vav guanine nucleotide exchange factor 1 |
| | <i>VAV2</i> | vav guanine nucleotide exchange factor 2 |
| | <i>RAC1</i> | Rac family small GTPase 1 |
| | <i>RAC2</i> | Rac family small GTPase 2 |
| | <i>RAC3</i> | Rac family small GTPase 3 |
| | <i>PAK1</i> | p21 (RAC1) activated kinase 1 |
| | <i>PAK2</i> | p21 (RAC1) activated kinase 2 |
| | <i>PAK3</i> | p21 (RAC1) activated kinase 3 |
| | <i>PAK4</i> | p21 (RAC1) activated kinase 4 |
| | <i>PAK6</i> | p21 (RAC1) activated kinase 6 |
| | <i>BUB1B-PAK6</i> | BUB1B-PAK6 readthrough |
| | <i>PAK5</i> | p21 (RAC1) activated kinase 5 |
| | <i>CDC42</i> | cell division cycle 42 |
| | <i>BCAR1</i> | BCAR1, Cas family scaffolding protein |
| | <i>CRK</i> | CRK proto-oncogene, adaptor protein |
| | <i>CRKL</i> | CRK like proto-oncogene, adaptor protein |
| | <i>DOCK1</i> | dedicator of cytokinesis 1 |
| | <i>RAPGEF1</i> | Rap guanine nucleotide exchange factor 1 |
| | <i>RAP1A</i> | RAP1A, member of RAS oncogene family |
| | <i>RAP1B</i> | RAP1B, member of RAS oncogene family |
| | <i>MAPK8</i> | mitogen-activated protein kinase 8 |
| | <i>MAPK10</i> | mitogen-activated protein kinase 10 |
| | <i>MAPK9</i> | mitogen-activated protein kinase 9 |
| | <i>JUN</i> | Jun proto-oncogene, AP-1 transcription factor subunit |
| | <i>BRAF</i> | B-Raf proto-oncogene, serine/threonine kinase |
| | <i>CAV1</i> | caveolin 1 |
| | <i>CAV2</i> | caveolin 2 |
| | <i>CAV3</i> | caveolin 3 |
| | <i>FYN</i> | FYN proto-oncogene, Src family tyrosine kinase |
| | <i>SHC1</i> | SHC adaptor protein 1 |
| | <i>SHC2</i> | SHC adaptor protein 2 |
| | <i>SHC3</i> | SHC adaptor protein 3 |
| | <i>SHC4</i> | SHC adaptor protein 4 |
| | <i>GRB2</i> | growth factor receptor bound protein 2 |
| | <i>SOS1</i> | SOS Ras/Rac guanine nucleotide exchange factor 1 |
| | <i>SOS2</i> | SOS Ras/Rho guanine nucleotide exchange factor 2 |
| | <i>HRAS</i> | HRas proto-oncogene, GTPase |
| | <i>RAF1</i> | Raf-1 proto-oncogene, serine/threonine kinase |
| | <i>MAP2K1</i> | mitogen-activated protein kinase kinase 1 |
| | <i>MAPK1</i> | mitogen-activated protein kinase 1 |
| | <i>MAPK3</i> | mitogen-activated protein kinase 3 |
| | <i>ELK1</i> | ELK1, ETS transcription factor |
| | <i>CCND1</i> | cyclin D1 |
| | <i>CCND2</i> | cyclin D2 |
| | <i>CCND3</i> | cyclin D3 |
| | <i>BIRC2</i> | baculoviral IAP repeat containing 2 |
| | <i>BIRC3</i> | baculoviral IAP repeat containing 3 |
| | <i>XIAP</i> | X-linked inhibitor of apoptosis |
| | <i>BAD</i> | BCL2 associated agonist of cell death |
| | <i>BCL2</i> | BCL2, apoptosis regulator |
| | <i>PIP5K1C</i> | phosphatidylinositol-4-phosphate 5-kinase type 1 gamma |
| ECM-receptor interaction | <i>COL1A1</i> | collagen type I alpha 1 chain |
| | <i>COL1A2</i> | collagen type I alpha 2 chain |
| | <i>COL2A1</i> | collagen type II alpha 1 chain |
| | <i>COL4A2</i> | collagen type IV alpha 2 chain |
| | <i>COL4A4</i> | collagen type IV alpha 4 chain |
| | <i>COL4A6</i> | collagen type IV alpha 6 chain |
| | <i>COL4A1</i> | collagen type IV alpha 1 chain |
| | <i>COL4A5</i> | collagen type IV alpha 5 chain |
| | <i>COL4A3</i> | collagen type IV alpha 3 chain |
| | <i>COL6A1</i> | collagen type VI alpha 1 chain |
| | <i>COL6A2</i> | collagen type VI alpha 2 chain |

| | | |
|----------------------------|---------------|--|
| | <i>COL6A3</i> | collagen type VI alpha 3 chain |
| | <i>COL6A6</i> | collagen type VI alpha 6 chain |
| | <i>COL6A5</i> | collagen type VI alpha 5 chain |
| | <i>COL9A1</i> | collagen type IX alpha 1 chain |
| | <i>COL9A2</i> | collagen type IX alpha 2 chain |
| | <i>COL9A3</i> | collagen type IX alpha 3 chain |
| | <i>LAMA1</i> | laminin subunit alpha 1 |
| | <i>LAMA2</i> | laminin subunit alpha 2 |
| | <i>LAMA3</i> | laminin subunit alpha 3 |
| | <i>LAMAS</i> | laminin subunit alpha 5 |
| | <i>LAMA4</i> | laminin subunit alpha 4 |
| | <i>LAMB1</i> | laminin subunit beta 1 |
| | <i>LAMB2</i> | laminin subunit beta 2 |
| | <i>LAMB3</i> | laminin subunit beta 3 |
| | <i>LAMB4</i> | laminin subunit beta 4 |
| | <i>LAMC1</i> | laminin subunit gamma 1 |
| | <i>LAMC2</i> | laminin subunit gamma 2 |
| | <i>LAMC3</i> | laminin subunit gamma 3 |
| | <i>CHAD</i> | chondroadherin |
| | <i>RELN</i> | reelin |
| | <i>THBS1</i> | thrombospondin 1 |
| | <i>COMP</i> | cartilage oligomeric matrix protein |
| | <i>THBS2</i> | thrombospondin 2 |
| | <i>THBS3</i> | thrombospondin 3 |
| | <i>THBS4</i> | thrombospondin 4 |
| | <i>FN1</i> | fibronectin 1 |
| | <i>SPP1</i> | secreted phosphoprotein 1 |
| | <i>VTN</i> | vitronectin |
| | <i>TNC</i> | tenascin C |
| | <i>TNN</i> | tenascin N |
| | <i>TNR</i> | tenascin R |
| | <i>TNXB</i> | tenascin XB |
| | <i>VWF</i> | von Willebrand factor |
| | <i>IBSP</i> | integrin binding sialoprotein |
| | <i>AGRN</i> | agrin |
| | <i>HSPG2</i> | heparan sulfate proteoglycan 2 |
| | <i>ITGA1</i> | integrin subunit alpha 1 |
| | <i>ITGA2</i> | integrin subunit alpha 2 |
| | <i>ITGA2B</i> | integrin subunit alpha 2b |
| | <i>ITGA3</i> | integrin subunit alpha 3 |
| | <i>ITGA4</i> | integrin subunit alpha 4 |
| | <i>ITGA5</i> | integrin subunit alpha 5 |
| | <i>ITGA6</i> | integrin subunit alpha 6 |
| | <i>ITGA7</i> | integrin subunit alpha 7 |
| | <i>ITGA8</i> | integrin subunit alpha 8 |
| | <i>ITGA9</i> | integrin subunit alpha 9 |
| | <i>ITGA10</i> | integrin subunit alpha 10 |
| | <i>ITGA11</i> | integrin subunit alpha 11 |
| | <i>ITGAV</i> | integrin subunit alpha V |
| | <i>ITGB1</i> | integrin subunit beta 1 |
| | <i>ITGB3</i> | integrin subunit beta 3 |
| | <i>ITGB4</i> | integrin subunit beta 4 |
| | <i>ITGB5</i> | integrin subunit beta 5 |
| | <i>ITGB6</i> | integrin subunit beta 6 |
| | <i>ITGB7</i> | integrin subunit beta 7 |
| | <i>ITGB8</i> | integrin subunit beta 8 |
| | <i>CD44</i> | CD44 molecule (Indian blood group) |
| | <i>SDC1</i> | syndecan 1 |
| | <i>SDC4</i> | syndecan 4 |
| | <i>SV2C</i> | synaptic vesicle glycoprotein 2C |
| | <i>SV2B</i> | synaptic vesicle glycoprotein 2B |
| | <i>SV2A</i> | synaptic vesicle glycoprotein 2A |
| | <i>CD36</i> | CD36 molecule |
| | <i>GP5</i> | glycoprotein V platelet |
| | <i>GP1BA</i> | glycoprotein Ib platelet alpha subunit |
| | <i>GP1BB</i> | glycoprotein Ib platelet beta subunit |
| | <i>GP9</i> | glycoprotein IX platelet |
| | <i>GP6</i> | glycoprotein VI platelet |
| | <i>DAG1</i> | dystroglycan 1 |
| | <i>CD47</i> | CD47 molecule |
| | <i>HMMR</i> | hyaluronan mediated motility receptor |
| PI3K-Akt signaling pathway | <i>EGF</i> | epidermal growth factor |
| | <i>FGF1</i> | fibroblast growth factor 1 |
| | <i>FGF2</i> | fibroblast growth factor 2 |
| | <i>FGF3</i> | fibroblast growth factor 3 |
| | <i>FGF4</i> | fibroblast growth factor 4 |
| | <i>FGF17</i> | fibroblast growth factor 17 |
| | <i>FGF6</i> | fibroblast growth factor 6 |
| | <i>FGF7</i> | fibroblast growth factor 7 |
| | <i>FGF8</i> | fibroblast growth factor 8 |
| | <i>FGF9</i> | fibroblast growth factor 9 |
| | <i>FGF10</i> | fibroblast growth factor 10 |
| | <i>FGF11</i> | fibroblast growth factor 11 |
| | <i>FGF12</i> | fibroblast growth factor 12 |
| | <i>FGF13</i> | fibroblast growth factor 13 |
| | <i>FGF14</i> | fibroblast growth factor 14 |
| | <i>FGF16</i> | fibroblast growth factor 16 |
| | <i>FGF5</i> | fibroblast growth factor 5 |
| | <i>FGF18</i> | fibroblast growth factor 18 |

| | |
|----------------|--|
| <i>FGF19</i> | fibroblast growth factor 19 |
| <i>FGF20</i> | fibroblast growth factor 20 |
| <i>FGF21</i> | fibroblast growth factor 21 |
| <i>FGF22</i> | fibroblast growth factor 22 |
| <i>FGF23</i> | fibroblast growth factor 23 |
| <i>NGF</i> | nerve growth factor |
| <i>INS</i> | insulin |
| <i>IGF1</i> | insulin like growth factor 1 |
| <i>PDGFA</i> | platelet derived growth factor subunit A |
| <i>PDGF8</i> | platelet derived growth factor subunit B |
| <i>PDGFC</i> | platelet derived growth factor C |
| <i>PDGFD</i> | platelet derived growth factor D |
| <i>CSF1</i> | colony stimulating factor 1 |
| <i>KITLG</i> | KIT ligand |
| <i>VEGFA</i> | vascular endothelial growth factor A |
| <i>VEGFB</i> | vascular endothelial growth factor B |
| <i>PGF</i> | placental growth factor |
| <i>VEGFC</i> | vascular endothelial growth factor C |
| <i>VEGFD</i> | vascular endothelial growth factor D |
| <i>HGF</i> | hepatocyte growth factor |
| <i>ANGPT1</i> | angiopoietin 1 |
| <i>ANGPT2</i> | angiopoietin 2 |
| <i>ANGPT4</i> | angiopoietin 4 |
| <i>EFNA1</i> | ephrin A1 |
| <i>EFNA2</i> | ephrin A2 |
| <i>EFNA3</i> | ephrin A3 |
| <i>EFNA4</i> | ephrin A4 |
| <i>EFNA5</i> | ephrin A5 |
| <i>EGFR</i> | epidermal growth factor receptor |
| <i>FGFR1</i> | fibroblast growth factor receptor 1 |
| <i>FGFR2</i> | fibroblast growth factor receptor 2 |
| <i>FGFR3</i> | fibroblast growth factor receptor 3 |
| <i>FGFR4</i> | fibroblast growth factor receptor 4 |
| <i>NGFR</i> | nerve growth factor receptor |
| <i>INSR</i> | insulin receptor |
| <i>IGF1R</i> | insulin like growth factor 1 receptor |
| <i>PDGFRA</i> | platelet derived growth factor receptor alpha |
| <i>PDGFRB</i> | platelet derived growth factor receptor beta |
| <i>CSF1R</i> | colony stimulating factor 1 receptor |
| <i>KIT</i> | KIT proto-oncogene tyrosine kinase |
| <i>FLT1</i> | fms related tyrosine kinase 1 |
| <i>FLT4</i> | fms related tyrosine kinase 4 |
| <i>KDR</i> | kinase insert domain receptor |
| <i>MET</i> | MET proto-oncogene, receptor tyrosine kinase |
| <i>TEK</i> | TEK receptor tyrosine kinase |
| <i>EPHA2</i> | EPH receptor A2 |
| <i>GRB2</i> | growth factor receptor bound protein 2 |
| <i>SOS1</i> | SOS Ras/Rac guanine nucleotide exchange factor 1 |
| <i>SOS2</i> | SOS Ras/Rho guanine nucleotide exchange factor 2 |
| <i>HRAS</i> | HRas proto-oncogene, GTPase |
| <i>KRAS</i> | KRas proto-oncogene, GTPase |
| <i>NRAS</i> | NRas proto-oncogene, GTPase |
| <i>RAF1</i> | Raf-1 proto-oncogene, serine/threonine kinase |
| <i>MAP2K1</i> | mitogen-activated protein kinase kinase 1 |
| <i>MAP2K2</i> | mitogen-activated protein kinase kinase 2 |
| <i>MAPK1</i> | mitogen-activated protein kinase 1 |
| <i>MAPK3</i> | mitogen-activated protein kinase 3 |
| <i>IRS1</i> | insulin receptor substrate 1 |
| <i>TLR2</i> | toll like receptor 2 |
| <i>TLR4</i> | toll like receptor 4 |
| <i>RAC1</i> | Rac family small GTPase 1 |
| <i>IGH</i> | putative V-set and immunoglobulin domain-containing-like protein IGHV4OR15-8 |
| <i>SYK</i> | spleen associated tyrosine kinase |
| <i>CD19</i> | CD19 molecule |
| <i>PIK3AP1</i> | phosphoinositide-3-kinase adaptor protein 1 |
| <i>GH1</i> | growth hormone 1 |
| <i>GH2</i> | growth hormone 2 |
| <i>CSH1</i> | chorionic somatomammotropin hormone 1 |
| <i>CSH2</i> | chorionic somatomammotropin hormone 2 |
| <i>PRL</i> | prolactin |
| <i>OSM</i> | oncostatin M |
| <i>IL2</i> | interleukin 2 |
| <i>IL3</i> | interleukin 3 |
| <i>IL6</i> | interleukin 6 |
| <i>IL4</i> | interleukin 4 |
| <i>IL7</i> | interleukin 7 |
| <i>IFNA1</i> | interferon alpha 1 |
| <i>IFNA2</i> | interferon alpha 2 |
| <i>IFNA4</i> | interferon alpha 4 |
| <i>IFNA5</i> | interferon alpha 5 |
| <i>IFNA6</i> | interferon alpha 6 |
| <i>IFNA7</i> | interferon alpha 7 |
| <i>IFNA8</i> | interferon alpha 8 |
| <i>IFNA10</i> | interferon alpha 10 |
| <i>IFNA13</i> | interferon alpha 13 |
| <i>IFNA14</i> | interferon alpha 14 |
| <i>IFNA16</i> | interferon alpha 16 |
| <i>IFNA17</i> | interferon alpha 17 |
| <i>IFNA21</i> | interferon alpha 21 |

| | |
|---------------|--|
| <i>IFNB1</i> | interferon beta 1 |
| <i>EPO</i> | erythropoietin |
| <i>CSF3</i> | colony stimulating factor 3 |
| <i>GHR</i> | growth hormone receptor |
| <i>PRLR</i> | prolactin receptor |
| <i>OSMR</i> | oncostatin M receptor |
| <i>IL2RA</i> | interleukin 2 receptor subunit alpha |
| <i>IL2RB</i> | interleukin 2 receptor subunit beta |
| <i>IL2RG</i> | interleukin 2 receptor subunit gamma |
| <i>IL3RA</i> | interleukin 3 receptor subunit alpha |
| <i>IL6R</i> | interleukin 6 receptor |
| <i>IL4R</i> | interleukin 4 receptor |
| <i>IL7R</i> | interleukin 7 receptor |
| <i>IFNAR1</i> | interferon alpha and beta receptor subunit 1 |
| <i>IFNAR2</i> | interferon alpha and beta receptor subunit 2 |
| <i>EPOR</i> | erythropoietin receptor |
| <i>CSF3R</i> | colony stimulating factor 3 receptor |
| <i>JAK1</i> | Janus kinase 1 |
| <i>JAK2</i> | Janus kinase 2 |
| <i>JAK3</i> | Janus kinase 3 |
| <i>COL1A1</i> | collagen type I alpha 1 chain |
| <i>COL1A2</i> | collagen type I alpha 2 chain |
| <i>COL2A1</i> | collagen type II alpha 1 chain |
| <i>COL4A2</i> | collagen type IV alpha 2 chain |
| <i>COL4A4</i> | collagen type IV alpha 4 chain |
| <i>COL4A6</i> | collagen type IV alpha 6 chain |
| <i>COL4A1</i> | collagen type IV alpha 1 chain |
| <i>COL4A5</i> | collagen type IV alpha 5 chain |
| <i>COL4A3</i> | collagen type IV alpha 3 chain |
| <i>COL6A1</i> | collagen type VI alpha 1 chain |
| <i>COL6A2</i> | collagen type VI alpha 2 chain |
| <i>COL6A3</i> | collagen type VI alpha 3 chain |
| <i>COL6A6</i> | collagen type VI alpha 6 chain |
| <i>COL6A5</i> | collagen type VI alpha 5 chain |
| <i>COL9A1</i> | collagen type IX alpha 1 chain |
| <i>COL9A2</i> | collagen type IX alpha 2 chain |
| <i>COL9A3</i> | collagen type IX alpha 3 chain |
| <i>LAMA1</i> | laminin subunit alpha 1 |
| <i>LAMA2</i> | laminin subunit alpha 2 |
| <i>LAMA3</i> | laminin subunit alpha 3 |
| <i>LAMA5</i> | laminin subunit alpha 5 |
| <i>LAMA4</i> | laminin subunit alpha 4 |
| <i>LAMB1</i> | laminin subunit beta 1 |
| <i>LAMB2</i> | laminin subunit beta 2 |
| <i>LAMB3</i> | laminin subunit beta 3 |
| <i>LAMB4</i> | laminin subunit beta 4 |
| <i>LAMC1</i> | laminin subunit gamma 1 |
| <i>LAMC2</i> | laminin subunit gamma 2 |
| <i>LAMC3</i> | laminin subunit gamma 3 |
| <i>CHAD</i> | chondroadherin |
| <i>RELN</i> | reelin |
| <i>THBS1</i> | thrombospondin 1 |
| <i>COMP</i> | cartilage oligomeric matrix protein |
| <i>THBS2</i> | thrombospondin 2 |
| <i>THBS3</i> | thrombospondin 3 |
| <i>THBS4</i> | thrombospondin 4 |
| <i>FN1</i> | fibronectin 1 |
| <i>SPP1</i> | secreted phosphoprotein 1 |
| <i>VTN</i> | vitronectin |
| <i>TNC</i> | tenascin C |
| <i>TNN</i> | tenascin N |
| <i>TNR</i> | tenascin R |
| <i>TNXB</i> | tenascin XB |
| <i>VWF</i> | von Willebrand factor |
| <i>IBSP</i> | integrin binding sialoprotein |
| <i>ITGA1</i> | integrin subunit alpha 1 |
| <i>ITGA2</i> | integrin subunit alpha 2 |
| <i>ITGA2B</i> | integrin subunit alpha 2b |
| <i>ITGA3</i> | integrin subunit alpha 3 |
| <i>ITGA4</i> | integrin subunit alpha 4 |
| <i>ITGA5</i> | integrin subunit alpha 5 |
| <i>ITGA6</i> | integrin subunit alpha 6 |
| <i>ITGA7</i> | integrin subunit alpha 7 |
| <i>ITGA8</i> | integrin subunit alpha 8 |
| <i>ITGA9</i> | integrin subunit alpha 9 |
| <i>ITGA10</i> | integrin subunit alpha 10 |
| <i>ITGA11</i> | integrin subunit alpha 11 |
| <i>ITGAV</i> | integrin subunit alpha V |
| <i>ITGB1</i> | integrin subunit beta 1 |
| <i>ITGB3</i> | integrin subunit beta 3 |
| <i>ITGB4</i> | integrin subunit beta 4 |
| <i>ITGB5</i> | integrin subunit beta 5 |
| <i>ITGB6</i> | integrin subunit beta 6 |
| <i>ITGB7</i> | integrin subunit beta 7 |
| <i>ITGB8</i> | integrin subunit beta 8 |
| <i>PTK2</i> | protein tyrosine kinase 2 |
| <i>PIK3CA</i> | phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha |
| <i>PIK3CD</i> | phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta |
| <i>PIK3CB</i> | phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta |

| | |
|---------------------|--|
| <i>PIK3R1</i> | phosphoinositide-3-kinase regulatory subunit 1 |
| <i>PIK3R2</i> | phosphoinositide-3-kinase regulatory subunit 2 |
| <i>PIK3R3</i> | phosphoinositide-3-kinase regulatory subunit 3 |
| <i>F2R</i> | coagulation factor II thrombin receptor |
| <i>CHRM1</i> | cholinergic receptor muscarinic 1 |
| <i>CHRM2</i> | cholinergic receptor muscarinic 2 |
| <i>LPAR1</i> | lysophosphatidic acid receptor 1 |
| <i>LPAR2</i> | lysophosphatidic acid receptor 2 |
| <i>LPAR3</i> | lysophosphatidic acid receptor 3 |
| <i>LPAR4</i> | lysophosphatidic acid receptor 4 |
| <i>LPAR5</i> | lysophosphatidic acid receptor 5 |
| <i>LPAR6</i> | lysophosphatidic acid receptor 6 |
| <i>GNB1</i> | G protein subunit beta 1 |
| <i>GNB2</i> | G protein subunit beta 2 |
| <i>GNB3</i> | G protein subunit beta 3 |
| <i>GNB4</i> | G protein subunit beta 4 |
| <i>GNB5</i> | G protein subunit beta 5 |
| <i>GNG2</i> | G protein subunit gamma 2 |
| <i>GNG3</i> | G protein subunit gamma 3 |
| <i>GNG4</i> | G protein subunit gamma 4 |
| <i>GNG5</i> | G protein subunit gamma 5 |
| <i>GNG7</i> | G protein subunit gamma 7 |
| <i>GNG8</i> | G protein subunit gamma 8 |
| <i>GNG10</i> | G protein subunit gamma 10 |
| <i>GNG11</i> | G protein subunit gamma 11 |
| <i>GNG12</i> | G protein subunit gamma 12 |
| <i>GNG13</i> | G protein subunit gamma 13 |
| <i>GNGT1</i> | G protein subunit gamma transducin 1 |
| <i>GNGT2</i> | G protein subunit gamma transducin 2 |
| <i>PIK3CG</i> | phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma |
| <i>PIK3R5</i> | phosphoinositide-3-kinase regulatory subunit 5 |
| <i>PIK3R6</i> | phosphoinositide-3-kinase regulatory subunit 6 |
| <i>PDPK1</i> | 3-phosphoinositide dependent protein kinase 1 |
| <i>STK11</i> | serine/threonine kinase 11 |
| <i>PRKAA1</i> | protein kinase AMP-activated catalytic subunit alpha 1 |
| <i>PRKAA2</i> | protein kinase AMP-activated catalytic subunit alpha 2 |
| <i>DDIT4</i> | DNA damage inducible transcript 4 |
| <i>TSC1</i> | TSC complex subunit 1 |
| <i>TSC2</i> | TSC complex subunit 2 |
| <i>RHEB</i> | Ras homolog, mTORC1 binding |
| <i>MLST8</i> | MTOR associated protein, LST8 homolog |
| <i>MTOR</i> | mechanistic target of rapamycin kinase |
| <i>RPTOR</i> | regulatory associated protein of MTOR complex 1 |
| <i>EIF4EBP1</i> | eukaryotic translation initiation factor 4E binding protein 1 |
| <i>EIF4E</i> | eukaryotic translation initiation factor 4E |
| <i>EIF4E2</i> | eukaryotic translation initiation factor 4E family member 2 |
| <i>EIF4E1B</i> | eukaryotic translation initiation factor 4E family member 1B |
| <i>RPS6KB1</i> | ribosomal protein S6 kinase B1 |
| <i>RPS6KB2</i> | ribosomal protein S6 kinase B2 |
| <i>EIF4B</i> | eukaryotic translation initiation factor 4B |
| <i>RPS6</i> | ribosomal protein S6 |
| <i>PRKCA</i> | protein kinase C alpha |
| <i>PKN1</i> | protein kinase N1 |
| <i>PKN3</i> | protein kinase N3 |
| <i>PKN2</i> | protein kinase N2 |
| <i>SGK1</i> | serum/glucocorticoid regulated kinase 1 |
| <i>SGK2</i> | SGK2, serine/threonine kinase 2 |
| <i>SGK3</i> | serum/glucocorticoid regulated kinase family member 3 |
| <i>C8orf44-SGK3</i> | C8orf44-SGK3 readthrough |
| <i>AKT1</i> | AKT serine/threonine kinase 1 |
| <i>AKT2</i> | AKT serine/threonine kinase 2 |
| <i>AKT3</i> | AKT serine/threonine kinase 3 |
| <i>PTEN</i> | phosphatase and tensin homolog |
| <i>THEM4</i> | thioesterase superfamily member 4 |
| <i>PPP2CA</i> | protein phosphatase 2 catalytic subunit alpha |
| <i>PPP2CB</i> | protein phosphatase 2 catalytic subunit beta |
| <i>PPP2R1B</i> | protein phosphatase 2 scaffold subunit Abeta |
| <i>PPP2R1A</i> | protein phosphatase 2 scaffold subunit Aalpha |
| <i>PPP2R2A</i> | protein phosphatase 2 regulatory subunit Balpha |
| <i>PPP2R2B</i> | protein phosphatase 2 regulatory subunit Bbeta |
| <i>PPP2R2C</i> | protein phosphatase 2 regulatory subunit Bgamma |
| <i>PPP2R2D</i> | protein phosphatase 2 regulatory subunit Bdelta |
| <i>PPP2R3B</i> | protein phosphatase 2 regulatory subunit B'beta |
| <i>PPP2R3C</i> | protein phosphatase 2 regulatory subunit B'gamma |
| <i>PPP2R3A</i> | protein phosphatase 2 regulatory subunit B'alpha |
| <i>PPP2R5B</i> | protein phosphatase 2 regulatory subunit B'beta |
| <i>PPP2R5C</i> | protein phosphatase 2 regulatory subunit B gamma |
| <i>PPP2R5D</i> | protein phosphatase 2 regulatory subunit B'delta |
| <i>PPP2R5E</i> | protein phosphatase 2 regulatory subunit B'epsilon |
| <i>PPP2R5A</i> | protein phosphatase 2 regulatory subunit B'alpha |
| <i>HSP90AA1</i> | heat shock protein 90 alpha family class A member 1 |
| <i>HSP90AB1</i> | heat shock protein 90 alpha family class B member 1 |
| <i>HSP90B1</i> | heat shock protein 90 beta family member 1 |
| <i>CDC37</i> | cell division cycle 37 |
| <i>CRTC2</i> | CREB regulated transcription coactivator 2 |
| <i>PHLP1</i> | PH domain and leucine rich repeat protein phosphatase 1 |
| <i>PHLP2</i> | PH domain and leucine rich repeat protein phosphatase 2 |
| <i>TCL1A</i> | T-cell leukemia/lymphoma 1A |
| <i>TCL1B</i> | T-cell leukemia/lymphoma 1B |

| | | |
|--|-----------------|--|
| | <i>MTCP1</i> | mature T-cell proliferation 1 |
| | <i>NOS3</i> | nitric oxide synthase 3 |
| | <i>BRCA1</i> | BRCA1, DNA repair associated |
| | <i>GSK3B</i> | glycogen synthase kinase 3 beta |
| | <i>GYS2</i> | glycogen synthase 2 |
| | <i>GYS1</i> | glycogen synthase 1 |
| | <i>PCK1</i> | phosphoenolpyruvate carboxykinase 1 |
| | <i>PCK2</i> | phosphoenolpyruvate carboxykinase 2, mitochondrial |
| | <i>G6PC</i> | glucose-6-phosphatase catalytic subunit |
| | <i>G6PC2</i> | glucose-6-phosphatase catalytic subunit 2 |
| | <i>G6PC3</i> | glucose-6-phosphatase catalytic subunit 3 |
| | <i>MYC</i> | MYC proto-oncogene, bHLH transcription factor |
| | <i>CCND1</i> | cyclin D1 |
| | <i>CDKN1A</i> | cyclin dependent kinase inhibitor 1A |
| | <i>CDKN1B</i> | cyclin dependent kinase inhibitor 1B |
| | <i>CDK2</i> | cyclin dependent kinase 2 |
| | <i>CDK4</i> | cyclin dependent kinase 4 |
| | <i>CDK6</i> | cyclin dependent kinase 6 |
| | <i>CCND2</i> | cyclin D2 |
| | <i>CCND3</i> | cyclin D3 |
| | <i>CCNE1</i> | cyclin E1 |
| | <i>CCNE2</i> | cyclin E2 |
| | <i>FOXO3</i> | forkhead box O3 |
| | <i>RBL2</i> | RB transcriptional corepressor like 2 |
| | <i>FASLG</i> | Fas ligand |
| | <i>BCL2L11</i> | BCL2 like 11 |
| | <i>YWHAZ</i> | tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein zeta |
| | <i>YWHAB</i> | tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein beta |
| | <i>YWHAQ</i> | tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein theta |
| | <i>YWHAE</i> | tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein epsilon |
| | <i>YWAH</i> | tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein eta |
| | <i>YWHAG</i> | tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein gamma |
| | <i>BAD</i> | BCL2 associated agonist of cell death |
| | <i>BCL2L1</i> | BCL2 like 1 |
| | <i>BCL2</i> | BCL2, apoptosis regulator |
| | <i>CASP9</i> | caspase 9 |
| | <i>CREB1</i> | cAMP responsive element binding protein 1 |
| | <i>ATF2</i> | activating transcription factor 2 |
| | <i>ATF4</i> | activating transcription factor 4 |
| | <i>CREB3</i> | cAMP responsive element binding protein 3 |
| | <i>CREB3L1</i> | cAMP responsive element binding protein 3 like 1 |
| | <i>CREB3L2</i> | cAMP responsive element binding protein 3 like 2 |
| | <i>CREB3L3</i> | cAMP responsive element binding protein 3 like 3 |
| | <i>CREB3L4</i> | cAMP responsive element binding protein 3 like 4 |
| | <i>CREB5</i> | cAMP responsive element binding protein 5 |
| | <i>ATF6B</i> | activating transcription factor 6 beta |
| | <i>MCL1</i> | MCL1, BCL2 family apoptosis regulator |
| | <i>RXRA</i> | retinoid X receptor alpha |
| | <i>NR4A1</i> | nuclear receptor subfamily 4 group A member 1 |
| | <i>IKBKG</i> | inhibitor of nuclear factor kappa B kinase subunit gamma |
| | <i>CHUK</i> | conserved helix-loop-helix ubiquitous kinase |
| | <i>IKBKB</i> | inhibitor of nuclear factor kappa B kinase subunit beta |
| | <i>RELA</i> | RELA proto-oncogene, NF- κ B subunit |
| | <i>NFKB1</i> | nuclear factor kappa B subunit 1 |
| | <i>MYB</i> | MYB proto-oncogene, transcription factor |
| | <i>MDM2</i> | MDM2 proto-oncogene |
| | <i>TP53</i> | tumor protein p53 |
| | <i>SLC7A5</i> | solute carrier family 7 member 5 |
| | <i>SLC3A2</i> | solute carrier family 3 member 2 |
| | <i>SLC38A9</i> | solute carrier family 38 member 9 |
| | <i>ATP6V1A</i> | ATPase H ⁺ transporting V1 subunit A |
| | <i>ATP6V1B1</i> | ATPase H ⁺ transporting V1 subunit B1 |
| | <i>ATP6V1B2</i> | ATPase H ⁺ transporting V1 subunit B2 |
| | <i>ATP6V1C2</i> | ATPase H ⁺ transporting V1 subunit C2 |
| | <i>ATP6V1C1</i> | ATPase H ⁺ transporting V1 subunit C1 |
| | <i>ATP6V1D</i> | ATPase H ⁺ transporting V1 subunit D |
| | <i>ATP6V1E2</i> | ATPase H ⁺ transporting V1 subunit E2 |
| | <i>ATP6V1E1</i> | ATPase H ⁺ transporting V1 subunit E1 |
| | <i>ATP6V1F</i> | ATPase H ⁺ transporting V1 subunit F |
| | <i>ATP6V1G1</i> | ATPase H ⁺ transporting V1 subunit G1 |
| | <i>ATP6V1G3</i> | ATPase H ⁺ transporting V1 subunit G3 |
| | <i>ATP6V1G2</i> | ATPase H ⁺ transporting V1 subunit G2 |
| | <i>ATP6V1H</i> | ATPase H ⁺ transporting V1 subunit H |
| | <i>LAMTOR1</i> | late endosomal/lysosomal adaptor, MAPK and MTOR activator 1 |
| | <i>LAMTOR2</i> | late endosomal/lysosomal adaptor, MAPK and MTOR activator 2 |
| | <i>LAMTOR3</i> | late endosomal/lysosomal adaptor, MAPK and MTOR activator 3 |
| | <i>LAMTOR4</i> | late endosomal/lysosomal adaptor, MAPK and MTOR activator 4 |
| | <i>LAMTOR5</i> | late endosomal/lysosomal adaptor, MAPK and MTOR activator 5 |
| | <i>FLCN</i> | folliculin |
| | <i>FNIP1</i> | folliculin interacting protein 1 |
| | <i>FNIP2</i> | folliculin interacting protein 2 |
| | <i>RRAGA</i> | Ras related GTP binding A |
| | <i>RRAGB</i> | Ras related GTP binding B |
| | <i>RRAGC</i> | Ras related GTP binding C |
| | <i>RRAGD</i> | Ras related GTP binding D |
| | <i>RPTOR</i> | regulatory associated protein of MTOR complex 1 |
| | <i>AKT1S1</i> | AKT1 substrate 1 |
| | <i>MTOR</i> | mechanistic target of rapamycin kinase |
| | <i>DEPTOR</i> | DEP domain containing MTOR interacting protein |

| | |
|-----------------|---|
| <i>MLST8</i> | MTOR associated protein, LST8 homolog |
| <i>TEL02</i> | telomere maintenance 2 |
| <i>TTI1</i> | TELO2 interacting protein 1 |
| <i>CIP1</i> | CAP-Gly domain containing linker protein |
| <i>GRB10</i> | growth factor receptor bound protein 10 |
| <i>ULK1</i> | unc-51 like autophagy activating kinase 1 |
| <i>ULK2</i> | unc-51 like autophagy activating kinase 2 |
| <i>EIF4EBP1</i> | eukaryotic translation initiation factor 4E binding protein 1 |
| <i>EIF4E</i> | eukaryotic translation initiation factor 4E |
| <i>EIF4E2</i> | eukaryotic translation initiation factor 4E family member 2 |
| <i>EIF4E1B</i> | eukaryotic translation initiation factor 4E family member 1B |
| <i>RPS6KB1</i> | ribosomal protein S6 kinase B1 |
| <i>RPS6KB2</i> | ribosomal protein S6 kinase B2 |
| <i>EIF4B</i> | eukaryotic translation initiation factor 4B |
| <i>RPS6</i> | ribosomal protein S6 |
| <i>RNF152</i> | ring finger protein 152 |
| <i>SKP2</i> | S-phase kinase associated protein 2 |
| <i>DEPD5</i> | DEP domain containing 5 |
| <i>NPRL2</i> | NPR2 like, GATOR1 complex subunit |
| <i>NPRL3</i> | NPR3 like, GATOR1 complex subunit |
| <i>MIOS</i> | meiosis regulator for oocyte development |
| <i>SEH1L</i> | SEH1 like nucleoporin |
| <i>WDR24</i> | WD repeat domain 24 |
| <i>WDR59</i> | WD repeat domain 59 |
| <i>SEC13</i> | SEC13 homolog, nuclear pore and COPII coat complex component |
| <i>SESN2</i> | sestrin 2 |
| <i>STRADA</i> | STE20-related kinase adaptor alpha |
| <i>STRADB</i> | STE20-related kinase adaptor beta |
| <i>STK11</i> | serine/threonine kinase 11 |
| <i>CAB39</i> | calcium binding protein 39 |
| <i>CAB39L</i> | calcium binding protein 39 like |
| <i>PRKAA1</i> | protein kinase AMP-activated catalytic subunit alpha 1 |
| <i>PRKAA2</i> | protein kinase AMP-activated catalytic subunit alpha 2 |
| <i>TSC1</i> | TSC complex subunit 1 |
| <i>TSC2</i> | TSC complex subunit 2 |
| <i>TBC1D7</i> | TBC1 domain family member 7 |
| <i>RHEB</i> | Ras homolog, mTORC1 binding |
| <i>DDIT4</i> | DNA damage inducible transcript 4 |
| <i>WNT1</i> | Wnt family member 1 |
| <i>WNT2</i> | Wnt family member 2 |
| <i>WNT2B</i> | Wnt family member 2B |
| <i>WNT3</i> | Wnt family member 3 |
| <i>WNT3A</i> | Wnt family member 3A |
| <i>WNT4</i> | Wnt family member 4 |
| <i>WNT5A</i> | Wnt family member 5A |
| <i>WNT5B</i> | Wnt family member 5B |
| <i>WNT6</i> | Wnt family member 6 |
| <i>WNT7A</i> | Wnt family member 7A |
| <i>WNT7B</i> | Wnt family member 7B |
| <i>WNT8A</i> | Wnt family member 8A |
| <i>WNT8B</i> | Wnt family member 8B |
| <i>WNT9A</i> | Wnt family member 9A |
| <i>WNT9B</i> | Wnt family member 9B |
| <i>WNT10B</i> | Wnt family member 10B |
| <i>WNT10A</i> | Wnt family member 10A |
| <i>WNT11</i> | Wnt family member 11 |
| <i>WNT16</i> | Wnt family member 16 |
| <i>FZD1</i> | frizzled class receptor 1 |
| <i>FZD7</i> | frizzled class receptor 7 |
| <i>FZD2</i> | frizzled class receptor 2 |
| <i>FZD3</i> | frizzled class receptor 3 |
| <i>FZD4</i> | frizzled class receptor 4 |
| <i>FZD5</i> | frizzled class receptor 5 |
| <i>FZD8</i> | frizzled class receptor 8 |
| <i>FZD6</i> | frizzled class receptor 6 |
| <i>FZD10</i> | frizzled class receptor 10 |
| <i>FZD9</i> | frizzled class receptor 9 |
| <i>LRP5</i> | LDL receptor related protein 5 |
| <i>LRP6</i> | LDL receptor related protein 6 |
| <i>DVL3</i> | dishevelled segment polarity protein 3 |
| <i>DVL2</i> | dishevelled segment polarity protein 2 |
| <i>DVL1</i> | dishevelled segment polarity protein 1 |
| <i>GSK3B</i> | glycogen synthase kinase 3 beta |
| <i>TNF</i> | tumor necrosis factor |
| <i>TNFRSF1A</i> | TNF receptor superfamily member 1A |
| <i>IKBKB</i> | inhibitor of nuclear factor kappa B kinase subunit beta |
| <i>INS</i> | insulin |
| <i>IGF1</i> | insulin like growth factor 1 |
| <i>INSR</i> | insulin receptor |
| <i>IGF1R</i> | insulin like growth factor 1 receptor |
| <i>GRB2</i> | growth factor receptor bound protein 2 |
| <i>SOS1</i> | SOS Ras/Rac guanine nucleotide exchange factor 1 |
| <i>SOS2</i> | SOS Ras/Rho guanine nucleotide exchange factor 2 |
| <i>HRAS</i> | HRas proto-oncogene, GTPase |
| <i>KRAS</i> | KRas proto-oncogene, GTPase |
| <i>NRAS</i> | NRas proto-oncogene, GTPase |
| <i>BRAF</i> | B-Raf proto-oncogene, serine/threonine kinase |
| <i>RAF1</i> | Raf-1 proto-oncogene, serine/threonine kinase |
| <i>MAP2K1</i> | mitogen-activated protein kinase kinase 1 |

| | | |
|----------------------------|----------------|--|
| | <i>MAP2K2</i> | mitogen-activated protein kinase kinase 2 |
| | <i>MAPK1</i> | mitogen-activated protein kinase 1 |
| | <i>MAPK3</i> | mitogen-activated protein kinase 3 |
| | <i>RPS6KA3</i> | ribosomal protein S6 kinase A3 |
| | <i>RPS6KA1</i> | ribosomal protein S6 kinase A1 |
| | <i>RPS6KA2</i> | ribosomal protein S6 kinase A2 |
| | <i>RPS6KA6</i> | ribosomal protein S6 kinase A6 |
| | <i>IRS1</i> | insulin receptor substrate 1 |
| | <i>PIK3R1</i> | phosphoinositide-3-kinase regulatory subunit 1 |
| | <i>PIK3R2</i> | phosphoinositide-3-kinase regulatory subunit 2 |
| | <i>PIK3R3</i> | phosphoinositide-3-kinase regulatory subunit 3 |
| | <i>PIK3CA</i> | phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha |
| | <i>PIK3CD</i> | phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta |
| | <i>PIK3CB</i> | phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta |
| | <i>PTEN</i> | phosphatase and tensin homolog |
| | <i>PDPK1</i> | 3-phosphoinositide dependent protein kinase 1 |
| | <i>AKT1</i> | AKT serine/threonine kinase 1 |
| | <i>AKT2</i> | AKT serine/threonine kinase 2 |
| | <i>AKT3</i> | AKT serine/threonine kinase 3 |
| | <i>CHUK</i> | conserved helix-loop-helix ubiquitous kinase |
| | <i>MAPKAP1</i> | mitogen-activated protein kinase associated protein 1 |
| | <i>RICTOR</i> | RPTOR independent companion of MTOR complex 2 |
| | <i>PRRS</i> | proline rich 5 |
| | <i>RHOA</i> | ras homolog family member A |
| | <i>PRKCA</i> | protein kinase C alpha |
| | <i>PRKCB</i> | protein kinase C beta |
| | <i>PRKCG</i> | protein kinase C gamma |
| | <i>SGK1</i> | serum/glucocorticoid regulated kinase 1 |
| | <i>LIPIN1</i> | lipin 1 |
| Jak-STAT signaling pathway | <i>IL2</i> | interleukin 2 |
| | <i>IL3</i> | interleukin 3 |
| | <i>IL4</i> | interleukin 4 |
| | <i>IL5</i> | interleukin 5 |
| | <i>IL6</i> | interleukin 6 |
| | <i>IL7</i> | interleukin 7 |
| | <i>IL9</i> | interleukin 9 |
| | <i>IL10</i> | interleukin 10 |
| | <i>IL11</i> | interleukin 11 |
| | <i>IL12A</i> | interleukin 12A |
| | <i>IL12B</i> | interleukin 12B |
| | <i>IL13</i> | interleukin 13 |
| | <i>IL15</i> | interleukin 15 |
| | <i>IL19</i> | interleukin 19 |
| | <i>IL20</i> | interleukin 20 |
| | <i>IL24</i> | interleukin 24 |
| | <i>IL21</i> | interleukin 21 |
| | <i>IL22</i> | interleukin 22 |
| | <i>IL23A</i> | interleukin 23 subunit alpha |
| | <i>IL17D</i> | interleukin 17D |
| | <i>IFNA1</i> | interferon alpha 1 |
| | <i>IFNA2</i> | interferon alpha 2 |
| | <i>IFNA4</i> | interferon alpha 4 |
| | <i>IFNA5</i> | interferon alpha 5 |
| | <i>IFNA6</i> | interferon alpha 6 |
| | <i>IFNA7</i> | interferon alpha 7 |
| | <i>IFNA8</i> | interferon alpha 8 |
| | <i>IFNA10</i> | interferon alpha 10 |
| | <i>IFNA13</i> | interferon alpha 13 |
| | <i>IFNA14</i> | interferon alpha 14 |
| | <i>IFNA16</i> | interferon alpha 16 |
| | <i>IFNA17</i> | interferon alpha 17 |
| | <i>IFNA21</i> | interferon alpha 21 |
| | <i>IFNB1</i> | interferon beta 1 |
| | <i>IFNG</i> | interferon gamma |
| | <i>IFNE</i> | interferon epsilon |
| | <i>IFNK</i> | interferon kappa |
| | <i>IFNL2</i> | interferon lambda 2 |
| | <i>IFNL3</i> | interferon lambda 3 |
| | <i>IFNL1</i> | interferon lambda 1 |
| | <i>IFNW1</i> | interferon omega 1 |
| | <i>OSM</i> | oncostatin M |
| | <i>LIF</i> | LIF, interleukin 6 family cytokine |
| | <i>TSLP</i> | thymic stromal lymphopoietin |
| | <i>CTF1</i> | cardiotrophin 1 |
| | <i>CSF2</i> | colony stimulating factor 2 |
| | <i>CNTF</i> | ciliary neurotrophic factor |
| | <i>CSF3</i> | colony stimulating factor 3 |
| | <i>EPO</i> | erythropoietin |
| | <i>GH1</i> | growth hormone 1 |
| | <i>GH2</i> | growth hormone 2 |
| | <i>CSH1</i> | chorionic somatomammotropin hormone 1 |
| | <i>CSH2</i> | chorionic somatomammotropin hormone 2 |
| | <i>LEP</i> | leptin |
| | <i>THPO</i> | thrombopoietin |
| | <i>PRL</i> | prolactin |
| | <i>IL2RA</i> | interleukin 2 receptor subunit alpha |
| | <i>IL2RB</i> | interleukin 2 receptor subunit beta |
| | <i>IL2RG</i> | interleukin 2 receptor subunit gamma |
| | <i>IL3RA</i> | interleukin 3 receptor subunit alpha |

| | |
|----------------|--|
| <i>IL4R</i> | interleukin 4 receptor |
| <i>IL5RA</i> | interleukin 5 receptor subunit alpha |
| <i>IL6R</i> | interleukin 6 receptor |
| <i>IL7R</i> | interleukin 7 receptor |
| <i>IL9R</i> | interleukin 9 receptor |
| <i>IL10RA</i> | interleukin 10 receptor subunit alpha |
| <i>IL10RB</i> | interleukin 10 receptor subunit beta |
| <i>IL11RA</i> | interleukin 11 receptor subunit alpha |
| <i>IL12RB1</i> | interleukin 12 receptor subunit beta 1 |
| <i>IL12RB2</i> | interleukin 12 receptor subunit beta 2 |
| <i>IL13RA1</i> | interleukin 13 receptor subunit alpha 1 |
| <i>IL13RA2</i> | interleukin 13 receptor subunit alpha 2 |
| <i>IL15RA</i> | interleukin 15 receptor subunit alpha |
| <i>IL20RA</i> | interleukin 20 receptor subunit alpha |
| <i>IL20RB</i> | interleukin 20 receptor subunit beta |
| <i>IL21R</i> | interleukin 21 receptor |
| <i>IL22RA1</i> | interleukin 22 receptor subunit alpha 1 |
| <i>IL22RA2</i> | interleukin 22 receptor subunit alpha 2 |
| <i>IL23R</i> | interleukin 23 receptor |
| <i>IL27RA</i> | interleukin 27 receptor subunit alpha |
| <i>IL6ST</i> | interleukin 6 signal transducer |
| <i>IFNAR1</i> | interferon alpha and beta receptor subunit 1 |
| <i>IFNAR2</i> | interferon alpha and beta receptor subunit 2 |
| <i>IFNGR1</i> | interferon gamma receptor 1 |
| <i>IFNGR2</i> | interferon gamma receptor 2 |
| <i>IFNL1</i> | interferon lambda receptor 1 |
| <i>OSMR</i> | oncostatin M receptor |
| <i>LIFR</i> | LIF receptor alpha |
| <i>CRLF2</i> | cytokine receptor like factor 2 |
| <i>CNTFR</i> | ciliary neurotrophic factor receptor |
| <i>CSF2RA</i> | colony stimulating factor 2 receptor alpha subunit |
| <i>CSF2RB</i> | colony stimulating factor 2 receptor beta common subunit |
| <i>CSF3R</i> | colony stimulating factor 3 receptor |
| <i>EPOR</i> | erythropoietin receptor |
| <i>GHR</i> | growth hormone receptor |
| <i>LEPR</i> | leptin receptor |
| <i>MPL</i> | MPL proto-oncogene, thrombopoietin receptor |
| <i>PRLR</i> | prolactin receptor |
| <i>JAK1</i> | Janus kinase 1 |
| <i>JAK2</i> | Janus kinase 2 |
| <i>JAK3</i> | Janus kinase 3 |
| <i>TYK2</i> | tyrosine kinase 2 |
| <i>STAT1</i> | signal transducer and activator of transcription 1 |
| <i>STAT2</i> | signal transducer and activator of transcription 2 |
| <i>STAT3</i> | signal transducer and activator of transcription 3 |
| <i>STAT4</i> | signal transducer and activator of transcription 4 |
| <i>STAT5A</i> | signal transducer and activator of transcription 5A |
| <i>STAT5B</i> | signal transducer and activator of transcription 5B |
| <i>STAT6</i> | signal transducer and activator of transcription 6 |
| <i>CISH</i> | cytokine inducible SH2 containing protein |
| <i>SOCs1</i> | suppressor of cytokine signaling 1 |
| <i>SOCs2</i> | suppressor of cytokine signaling 2 |
| <i>SOCs3</i> | suppressor of cytokine signaling 3 |
| <i>SOCs4</i> | suppressor of cytokine signaling 4 |
| <i>SOCs5</i> | suppressor of cytokine signaling 5 |
| <i>SOCs7</i> | suppressor of cytokine signaling 7 |
| <i>SOCs6</i> | suppressor of cytokine signaling 6 |
| <i>BCL2</i> | BCL2, apoptosis regulator |
| <i>MCL1</i> | MCL1, BCL2 family apoptosis regulator |
| <i>BCL2L1</i> | BCL2 like 1 |
| <i>PIM1</i> | Pim-1 proto-oncogene, serine/threonine kinase |
| <i>MYC</i> | MYC proto-oncogene, bHLH transcription factor |
| <i>CCND1</i> | cyclin D1 |
| <i>CCND2</i> | cyclin D2 |
| <i>CCND3</i> | cyclin D3 |
| <i>CDKN1A</i> | cyclin dependent kinase inhibitor 1A |
| <i>AOX1</i> | aldehyde oxidase 1 |
| <i>GFAP</i> | glial fibrillary acidic protein |
| <i>STAM2</i> | signal transducing adaptor molecule 2 |
| <i>STAM</i> | signal transducing adaptor molecule |
| <i>PTPN2</i> | protein tyrosine phosphatase, non-receptor type 2 |
| <i>PTPN6</i> | protein tyrosine phosphatase, non-receptor type 6 |
| <i>IRF9</i> | interferon regulatory factor 9 |
| <i>CREBBP</i> | CREB binding protein |
| <i>EP300</i> | E1A binding protein p300 |
| <i>PIAS1</i> | protein inhibitor of activated STAT 1 |
| <i>PIAS2</i> | protein inhibitor of activated STAT 2 |
| <i>PIAS3</i> | protein inhibitor of activated STAT 3 |
| <i>PIAS4</i> | protein inhibitor of activated STAT 4 |
| <i>FHL1</i> | four and a half LIM domains 1 |
| <i>PTPN11</i> | protein tyrosine phosphatase, non-receptor type 11 |
| <i>GRB2</i> | growth factor receptor bound protein 2 |
| <i>SOS1</i> | SOS Ras/Rac guanine nucleotide exchange factor 1 |
| <i>SOS2</i> | SOS Ras/Rho guanine nucleotide exchange factor 2 |
| <i>HRAS</i> | HRas proto-oncogene, GTPase |
| <i>RAF1</i> | Raf-1 proto-oncogene, serine/threonine kinase |
| <i>PIK3CA</i> | phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha |
| <i>PIK3CD</i> | phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta |
| <i>PIK3CB</i> | phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta |

| | | |
|--|---------------|--|
| | <i>PIK3R1</i> | phosphoinositide-3-kinase regulatory subunit 1 |
| | <i>PIK3R2</i> | phosphoinositide-3-kinase regulatory subunit 2 |
| | <i>PIK3R3</i> | phosphoinositide-3-kinase regulatory subunit 3 |
| | <i>AKT1</i> | AKT serine/threonine kinase 1 |
| | <i>AKT2</i> | AKT serine/threonine kinase 2 |
| | <i>AKT3</i> | AKT serine/threonine kinase 3 |
| | <i>MTOR</i> | mechanistic target of rapamycin kinase |
| Citokine-cytokine receptor interaction | <i>CXCL1</i> | C-X-C motif chemokine ligand 1 |
| | <i>CXCL2</i> | C-X-C motif chemokine ligand 2 |
| | <i>CXCL3</i> | C-X-C motif chemokine ligand 3 |
| | <i>CXCL5</i> | C-X-C motif chemokine ligand 5 |
| | <i>CXCL6</i> | C-X-C motif chemokine ligand 6 |
| | <i>PPBP</i> | pro-platelet basic protein |
| | <i>CXCL8</i> | C-X-C motif chemokine ligand 8 |
| | <i>CXCL9</i> | C-X-C motif chemokine ligand 9 |
| | <i>CXCL10</i> | C-X-C motif chemokine ligand 10 |
| | <i>CXCL11</i> | C-X-C motif chemokine ligand 11 |
| | <i>CXCL12</i> | C-X-C motif chemokine ligand 12 |
| | <i>CXCL13</i> | C-X-C motif chemokine ligand 13 |
| | <i>CXCL16</i> | C-X-C motif chemokine ligand 16 |
| | <i>PF4</i> | platelet factor 4 |
| | <i>PF4V1</i> | platelet factor 4 variant 1 |
| | <i>CXCL14</i> | C-X-C motif chemokine ligand 14 |
| | <i>XCL1</i> | X-C motif chemokine ligand 1 |
| | <i>XCL2</i> | X-C motif chemokine ligand 2 |
| | <i>CX3CL1</i> | C-X3-C motif chemokine ligand 1 |
| | <i>CCL1</i> | C-C motif chemokine ligand 1 |
| | <i>CCL20</i> | C-C motif chemokine ligand 20 |
| | <i>CCL25</i> | C-C motif chemokine ligand 25 |
| | <i>CCL17</i> | C-C motif chemokine ligand 17 |
| | <i>CCL22</i> | C-C motif chemokine ligand 22 |
| | <i>CCL19</i> | C-C motif chemokine ligand 19 |
| | <i>CCL21</i> | C-C motif chemokine ligand 21 |
| | <i>CCL2</i> | C-C motif chemokine ligand 2 |
| | <i>CCL4</i> | C-C motif chemokine ligand 4 |
| | <i>CCL4L2</i> | C-C motif chemokine ligand 4 like 2 |
| | <i>CCL4L1</i> | C-C motif chemokine ligand 4 like 1 |
| | <i>CCL3</i> | C-C motif chemokine ligand 3 |
| | <i>CCL3L1</i> | C-C motif chemokine ligand 3 like 1 |
| | <i>CCL3L3</i> | C-C motif chemokine ligand 3 like 3 |
| | <i>CCL13</i> | C-C motif chemokine ligand 13 |
| | <i>CCL7</i> | C-C motif chemokine ligand 7 |
| | <i>CCL5</i> | C-C motif chemokine ligand 5 |
| | <i>CCL14</i> | C-C motif chemokine ligand 14 |
| | <i>CCL16</i> | C-C motif chemokine ligand 16 |
| | <i>CCL15</i> | C-C motif chemokine ligand 15 |
| | <i>CCL23</i> | C-C motif chemokine ligand 23 |
| | <i>CCL8</i> | C-C motif chemokine ligand 8 |
| | <i>CCL11</i> | C-C motif chemokine ligand 11 |
| | <i>CCL24</i> | C-C motif chemokine ligand 24 |
| | <i>CCL26</i> | C-C motif chemokine ligand 26 |
| | <i>CCL28</i> | C-C motif chemokine ligand 28 |
| | <i>CCL27</i> | C-C motif chemokine ligand 27 |
| | <i>CCL18</i> | C-C motif chemokine ligand 18 |
| | <i>IL6</i> | interleukin 6 |
| | <i>IL11</i> | interleukin 11 |
| | <i>OSM</i> | oncostatin M |
| | <i>LIF</i> | LIF, interleukin 6 family cytokine |
| | <i>CNTF</i> | ciliary neurotrophic factor |
| | <i>CLCF1</i> | cardiotrophin like cytokine factor 1 |
| | <i>CTF1</i> | cardiotrophin 1 |
| | <i>CSF3</i> | colony stimulating factor 3 |
| | <i>LEP</i> | leptin |
| | <i>IL4</i> | interleukin 4 |
| | <i>IL13</i> | interleukin 13 |
| | <i>IL12A</i> | interleukin 12A |
| | <i>IL12B</i> | interleukin 12B |
| | <i>IL23A</i> | interleukin 23 subunit alpha |
| | <i>CSF2</i> | colony stimulating factor 2 |
| | <i>IL3</i> | interleukin 3 |
| | <i>IL5</i> | interleukin 5 |
| | <i>IL2</i> | interleukin 2 |
| | <i>IL7</i> | interleukin 7 |
| | <i>IL9</i> | interleukin 9 |
| | <i>IL15</i> | interleukin 15 |
| | <i>IL21</i> | interleukin 21 |
| | <i>TSLP</i> | thymic stromal lymphopoietin |
| | <i>EPO</i> | erythropoietin |
| | <i>GH1</i> | growth hormone 1 |
| | <i>GH2</i> | growth hormone 2 |
| | <i>PRL</i> | prolactin |
| | <i>THPO</i> | thrombopoietin |
| | <i>PDGFC</i> | platelet derived growth factor C |
| | <i>PDGFA</i> | platelet derived growth factor subunit A |
| | <i>PDGFB</i> | platelet derived growth factor subunit B |
| | <i>VEGFA</i> | vascular endothelial growth factor A |
| | <i>VEGFB</i> | vascular endothelial growth factor B |
| | <i>VEGFC</i> | vascular endothelial growth factor C |
| | <i>VEGFD</i> | vascular endothelial growth factor D |

| | |
|-----------------|--|
| <i>HGF</i> | hepatocyte growth factor |
| <i>EGF</i> | epidermal growth factor |
| <i>CSF1</i> | colony stimulating factor 1 |
| <i>KITLG</i> | KIT ligand |
| <i>FLT3LG</i> | fms related tyrosine kinase 3 ligand |
| <i>IFNA1</i> | interferon alpha 1 |
| <i>IFNA2</i> | interferon alpha 2 |
| <i>IFNA4</i> | interferon alpha 4 |
| <i>IFNA5</i> | interferon alpha 5 |
| <i>IFNA6</i> | interferon alpha 6 |
| <i>IFNA7</i> | interferon alpha 7 |
| <i>IFNA8</i> | interferon alpha 8 |
| <i>IFNA10</i> | interferon alpha 10 |
| <i>IFNA13</i> | interferon alpha 13 |
| <i>IFNA14</i> | interferon alpha 14 |
| <i>IFNA16</i> | interferon alpha 16 |
| <i>IFNA17</i> | interferon alpha 17 |
| <i>IFNA21</i> | interferon alpha 21 |
| <i>IFNB1</i> | interferon beta 1 |
| <i>IFNW1</i> | interferon omega 1 |
| <i>IFNK</i> | interferon kappa |
| <i>IFNE</i> | interferon epsilon |
| <i>IFNG</i> | interferon gamma |
| <i>IL10</i> | interleukin 10 |
| <i>IL19</i> | interleukin 19 |
| <i>IL20</i> | interleukin 20 |
| <i>IL24</i> | interleukin 24 |
| <i>IL22</i> | interleukin 22 |
| <i>IFNL2</i> | interferon lambda 2 |
| <i>IFNL3</i> | interferon lambda 3 |
| <i>IFNL1</i> | interferon lambda 1 |
| <i>IL26</i> | interleukin 26 |
| <i>TNFSF15</i> | TNF superfamily member 15 |
| <i>TNFSF10</i> | TNF superfamily member 10 |
| <i>TNFSF11</i> | TNF superfamily member 11 |
| <i>TNFSF12</i> | TNF superfamily member 12 |
| <i>TNF</i> | tumor necrosis factor |
| <i>LTA</i> | lymphotoxin alpha |
| <i>LTB</i> | lymphotoxin beta |
| <i>TNFSF14</i> | TNF superfamily member 14 |
| <i>FASLG</i> | Fas ligand |
| <i>CD40LG</i> | CD40 ligand |
| <i>CD70</i> | CD70 molecule |
| <i>TNFSF8</i> | TNF superfamily member 8 |
| <i>TNFSF9</i> | TNF superfamily member 9 |
| <i>TNFSF4</i> | TNF superfamily member 4 |
| <i>TNFSF18</i> | TNF superfamily member 18 |
| <i>TNFSF13</i> | TNF superfamily member 13 |
| <i>TNFSF13B</i> | TNF superfamily member 13b |
| <i>EDA</i> | ectodysplasin A |
| <i>TGFB1</i> | transforming growth factor beta 1 |
| <i>TGFB2</i> | transforming growth factor beta 2 |
| <i>TGFB3</i> | transforming growth factor beta 3 |
| <i>INHBA</i> | inhibin beta A subunit |
| <i>INHBB</i> | inhibin beta B subunit |
| <i>INHBC</i> | inhibin beta C subunit |
| <i>INHBE</i> | inhibin beta E subunit |
| <i>AMH</i> | anti-Mullerian hormone |
| <i>BMP2</i> | bone morphogenetic protein 2 |
| <i>BMP7</i> | bone morphogenetic protein 7 |
| <i>GDF5</i> | growth differentiation factor 5 |
| <i>IL1A</i> | interleukin 1 alpha |
| <i>IL1B</i> | interleukin 1 beta |
| <i>IL18</i> | interleukin 18 |
| <i>IL25</i> | interleukin 25 |
| <i>IL17A</i> | interleukin 17A |
| <i>IL17F</i> | interleukin 17F |
| <i>IL17C</i> | interleukin 17C |
| <i>IL17B</i> | interleukin 17B |
| <i>IL17D</i> | interleukin 17D |
| <i>CXCR2</i> | C-X-C motif chemokine receptor 2 |
| <i>CXCR1</i> | C-X-C motif chemokine receptor 1 |
| <i>CXCR3</i> | C-X-C motif chemokine receptor 3 |
| <i>CXCR4</i> | C-X-C motif chemokine receptor 4 |
| <i>CXCR5</i> | C-X-C motif chemokine receptor 5 |
| <i>CXCR6</i> | C-X-C motif chemokine receptor 6 |
| <i>ACKR3</i> | atypical chemokine receptor 3 |
| <i>XCR1</i> | X-C motif chemokine receptor 1 |
| <i>CX3CR1</i> | C-X3-C motif chemokine receptor 1 |
| <i>CCR8</i> | C-C motif chemokine receptor 8 |
| <i>CCR6</i> | C-C motif chemokine receptor 6 |
| <i>CCR9</i> | C-C motif chemokine receptor 9 |
| <i>CCR4</i> | C-C motif chemokine receptor 4 |
| <i>CCR7</i> | C-C motif chemokine receptor 7 |
| <i>CCR2</i> | C-C motif chemokine receptor 2 |
| <i>CCR5</i> | C-C motif chemokine receptor 5 (gene/pseudogene) |
| <i>CCR1</i> | C-C motif chemokine receptor 1 |
| <i>CCR3</i> | C-C motif chemokine receptor 3 |
| <i>CCR10</i> | C-C motif chemokine receptor 10 |

| | |
|------------------|--|
| <i>IL6R</i> | interleukin 6 receptor |
| <i>IL6ST</i> | interleukin 6 signal transducer |
| <i>IL11RA</i> | interleukin 11 receptor subunit alpha |
| <i>LIFR</i> | LIF receptor alpha |
| <i>OSMR</i> | oncostatin M receptor |
| <i>CNTFR</i> | ciliary neurotrophic factor receptor |
| <i>CSF3R</i> | colony stimulating factor 3 receptor |
| <i>LEPR</i> | leptin receptor |
| <i>IL4R</i> | interleukin 4 receptor |
| <i>IL13RA1</i> | interleukin 13 receptor subunit alpha 1 |
| <i>IL12RB1</i> | interleukin 12 receptor subunit beta 1 |
| <i>IL12RB2</i> | interleukin 12 receptor subunit beta 2 |
| <i>IL23R</i> | interleukin 23 receptor |
| <i>CSF2RA</i> | colony stimulating factor 2 receptor alpha subunit |
| <i>CSF2RB</i> | colony stimulating factor 2 receptor beta common subunit |
| <i>IL3RA</i> | interleukin 3 receptor subunit alpha |
| <i>IL5RA</i> | interleukin 5 receptor subunit alpha |
| <i>IL2RA</i> | interleukin 2 receptor subunit alpha |
| <i>IL2RB</i> | interleukin 2 receptor subunit beta |
| <i>IL2RG</i> | interleukin 2 receptor subunit gamma |
| <i>IL7R</i> | interleukin 7 receptor |
| <i>IL9R</i> | interleukin 9 receptor |
| <i>IL15RA</i> | interleukin 15 receptor subunit alpha |
| <i>IL21R</i> | interleukin 21 receptor |
| <i>CRLF2</i> | cytokine receptor like factor 2 |
| <i>EPOR</i> | erythropoietin receptor |
| <i>GHR</i> | growth hormone receptor |
| <i>PRLR</i> | prolactin receptor |
| <i>MPL</i> | MPL proto-oncogene, thrombopoietin receptor |
| <i>PDGFRA</i> | platelet derived growth factor receptor alpha |
| <i>PDGFRB</i> | platelet derived growth factor receptor beta |
| <i>FLT1</i> | fms related tyrosine kinase 1 |
| <i>KDR</i> | kinase insert domain receptor |
| <i>FLT4</i> | fms related tyrosine kinase 4 |
| <i>MET</i> | MET proto-oncogene, receptor tyrosine kinase |
| <i>EGFR</i> | epidermal growth factor receptor |
| <i>CSF1R</i> | colony stimulating factor 1 receptor |
| <i>KIT</i> | KIT proto-oncogene receptor tyrosine kinase |
| <i>FLT3</i> | fms related tyrosine kinase 3 |
| <i>IFNAR1</i> | interferon alpha and beta receptor subunit 1 |
| <i>IFNAR2</i> | interferon alpha and beta receptor subunit 2 |
| <i>IFNGR1</i> | interferon gamma receptor 1 |
| <i>IFNGR2</i> | interferon gamma receptor 2 |
| <i>IL10RA</i> | interleukin 10 receptor subunit alpha |
| <i>IL10RB</i> | interleukin 10 receptor subunit beta |
| <i>IL20RA</i> | interleukin 20 receptor subunit alpha |
| <i>IL20RB</i> | interleukin 20 receptor subunit beta |
| <i>IL22RA1</i> | interleukin 22 receptor subunit alpha 1 |
| <i>IL22RA2</i> | interleukin 22 receptor subunit alpha 2 |
| <i>IFNLR1</i> | interferon lambda receptor 1 |
| <i>TNFRSF10A</i> | TNF receptor superfamily member 10a |
| <i>TNFRSF10B</i> | TNF receptor superfamily member 10b |
| <i>TNFRSF10C</i> | TNF receptor superfamily member 10c |
| <i>TNFRSF10D</i> | TNF receptor superfamily member 10d |
| <i>TNFRSF11B</i> | TNF receptor superfamily member 11b |
| <i>TNFRSF11A</i> | TNF receptor superfamily member 11a |
| <i>TNFRSF25</i> | TNF receptor superfamily member 25 |
| <i>TNFRSF12A</i> | TNF receptor superfamily member 12A |
| <i>TNFRSF21</i> | TNF receptor superfamily member 21 |
| <i>NGFR</i> | nerve growth factor receptor |
| <i>TNFRSF1B</i> | TNF receptor superfamily member 1B |
| <i>TNFRSF1A</i> | TNF receptor superfamily member 1A |
| <i>LTBR</i> | lymphotoxin beta receptor |
| <i>TNFRSF14</i> | TNF receptor superfamily member 14 |
| <i>TNFRSF6B</i> | TNF receptor superfamily member 6b |
| <i>FAS</i> | Fas cell surface death receptor |
| <i>CD40</i> | CD40 molecule |
| <i>CD27</i> | CD27 molecule |
| <i>TNFRSF8</i> | TNF receptor superfamily member 8 |
| <i>TNFRSF9</i> | TNF receptor superfamily member 9 |
| <i>TNFRSF4</i> | TNF receptor superfamily member 4 |
| <i>TNFRSF18</i> | TNF receptor superfamily member 18 |
| <i>TNFRSF17</i> | TNF receptor superfamily member 17 |
| <i>TNFRSF13B</i> | TNF receptor superfamily member 13B |
| <i>TNFRSF13C</i> | TNF receptor superfamily member 13C |
| <i>EDAR</i> | ectodysplasin A receptor |
| <i>EDA2R</i> | ectodysplasin A2 receptor |
| <i>TNFRSF19</i> | TNF receptor superfamily member 19 |
| <i>RELT</i> | RELT, TNF receptor |
| <i>TGFBR2</i> | transforming growth factor beta receptor 2 |
| <i>TGFBR1</i> | transforming growth factor beta receptor 1 |
| <i>ACVR2A</i> | activin A receptor type 2A |
| <i>ACVR2B</i> | activin A receptor type 2B |
| <i>ACVR1</i> | activin A receptor type 1 |
| <i>ACVR1B</i> | activin A receptor type 1B |
| <i>AMHR2</i> | anti-Mullerian hormone receptor type 2 |
| <i>BMPR2</i> | bone morphogenetic protein receptor type 2 |
| <i>BMPR1A</i> | bone morphogenetic protein receptor type 1A |
| <i>BMPR1B</i> | bone morphogenetic protein receptor type 1B |

| | | |
|------------------------|-----------------|---|
| | <i>IL1R1</i> | interleukin 1 receptor type 1 |
| | <i>IL1RAP</i> | interleukin 1 receptor accessory protein |
| | <i>IL1R2</i> | interleukin 1 receptor type 2 |
| | <i>IL18R1</i> | interleukin 18 receptor 1 |
| | <i>IL18RAP</i> | interleukin 18 receptor accessory protein |
| | <i>IL17RA</i> | interleukin 17 receptor A |
| | <i>IL17RB</i> | interleukin 17 receptor B |
| | <i>IL17RC</i> | interleukin 17 receptor C |
| | <i>IL17RE</i> | interleukin 17 receptor E |
| | <i>PLEKHO2</i> | pleckstrin homology domain containing O2 |
| MapK signaling pathway | <i>CACNA1A</i> | calcium voltage-gated channel subunit alpha1 A |
| | <i>CACNA1B</i> | calcium voltage-gated channel subunit alpha1 B |
| | <i>CACNA1C</i> | calcium voltage-gated channel subunit alpha1 C |
| | <i>CACNA1D</i> | calcium voltage-gated channel subunit alpha1 D |
| | <i>CACNA1E</i> | calcium voltage-gated channel subunit alpha1 E |
| | <i>CACNA1F</i> | calcium voltage-gated channel subunit alpha1 F |
| | <i>CACNA1G</i> | calcium voltage-gated channel subunit alpha1 G |
| | <i>CACNA1H</i> | calcium voltage-gated channel subunit alpha1 H |
| | <i>CACNA1I</i> | calcium voltage-gated channel subunit alpha1 I |
| | <i>CACNA1S</i> | calcium voltage-gated channel subunit alpha1 S |
| | <i>CACNA2D1</i> | calcium voltage-gated channel auxiliary subunit alpha2delta 1 |
| | <i>CACNA2D2</i> | calcium voltage-gated channel auxiliary subunit alpha2delta 2 |
| | <i>CACNA2D3</i> | calcium voltage-gated channel auxiliary subunit alpha2delta 3 |
| | <i>CACNA2D4</i> | calcium voltage-gated channel auxiliary subunit alpha2delta 4 |
| | <i>CACNB1</i> | calcium voltage-gated channel auxiliary subunit beta 1 |
| | <i>CACNB2</i> | calcium voltage-gated channel auxiliary subunit beta 2 |
| | <i>CACNB3</i> | calcium voltage-gated channel auxiliary subunit beta 3 |
| | <i>CACNB4</i> | calcium voltage-gated channel auxiliary subunit beta 4 |
| | <i>CACNG1</i> | calcium voltage-gated channel auxiliary subunit gamma 1 |
| | <i>CACNG2</i> | calcium voltage-gated channel auxiliary subunit gamma 2 |
| | <i>CACNG3</i> | calcium voltage-gated channel auxiliary subunit gamma 3 |
| | <i>CACNG4</i> | calcium voltage-gated channel auxiliary subunit gamma 4 |
| | <i>CACNG5</i> | calcium voltage-gated channel auxiliary subunit gamma 5 |
| | <i>CACNG6</i> | calcium voltage-gated channel auxiliary subunit gamma 6 |
| | <i>CACNG7</i> | calcium voltage-gated channel auxiliary subunit gamma 7 |
| | <i>CACNG8</i> | calcium voltage-gated channel auxiliary subunit gamma 8 |
| | <i>PRKACA</i> | protein kinase cAMP-activated catalytic subunit alpha |
| | <i>PRKACB</i> | protein kinase cAMP-activated catalytic subunit beta |
| | <i>PRKACG</i> | protein kinase cAMP-activated catalytic subunit gamma |
| | <i>PRKCA</i> | protein kinase C alpha |
| | <i>PRKCB</i> | protein kinase C beta |
| | <i>PRKCG</i> | protein kinase C gamma |
| | <i>GNA12</i> | G protein subunit alpha 12 |
| | <i>GNG12</i> | G protein subunit gamma 12 |
| | <i>PPP3CA</i> | protein phosphatase 3 catalytic subunit alpha |
| | <i>PPP3CB</i> | protein phosphatase 3 catalytic subunit beta |
| | <i>PPP3CC</i> | protein phosphatase 3 catalytic subunit gamma |
| | <i>PPP3R1</i> | protein phosphatase 3 regulatory subunit B, alpha |
| | <i>PPP3R2</i> | protein phosphatase 3 regulatory subunit B, beta |
| | <i>RASGRF1</i> | Ras protein specific guanine nucleotide releasing factor 1 |
| | <i>RASGRF2</i> | Ras protein specific guanine nucleotide releasing factor 2 |
| | <i>RASGRP1</i> | RAS guanyl releasing protein 1 |
| | <i>RASGRP2</i> | RAS guanyl releasing protein 2 |
| | <i>RASGRP3</i> | RAS guanyl releasing protein 3 |
| | <i>RASGRP4</i> | RAS guanyl releasing protein 4 |
| | <i>RAPGEF2</i> | Rap guanine nucleotide exchange factor 2 |
| | <i>NF1</i> | neurofibromin 1 |
| | <i>RASA1</i> | RAS p21 protein activator 1 |
| | <i>RASA2</i> | RAS p21 protein activator 2 |
| | <i>RAP1A</i> | RAP1A, member of RAS oncogene family |
| | <i>RAP1B</i> | RAP1B, member of RAS oncogene family |
| | <i>NGF</i> | nerve growth factor |
| | <i>BDNF</i> | brain derived neurotrophic factor |
| | <i>NTF3</i> | neurotrophin 3 |
| | <i>NTF4</i> | neurotrophin 4 |
| | <i>EGF</i> | epidermal growth factor |
| | <i>FGF1</i> | fibroblast growth factor 1 |
| | <i>FGF2</i> | fibroblast growth factor 2 |
| | <i>FGF3</i> | fibroblast growth factor 3 |
| | <i>FGF4</i> | fibroblast growth factor 4 |
| | <i>FGF17</i> | fibroblast growth factor 17 |
| | <i>FGF6</i> | fibroblast growth factor 6 |
| | <i>FGF7</i> | fibroblast growth factor 7 |
| | <i>FGF8</i> | fibroblast growth factor 8 |
| | <i>FGF9</i> | fibroblast growth factor 9 |
| | <i>FGF10</i> | fibroblast growth factor 10 |
| | <i>FGF11</i> | fibroblast growth factor 11 |
| | <i>FGF12</i> | fibroblast growth factor 12 |
| | <i>FGF13</i> | fibroblast growth factor 13 |
| | <i>FGF14</i> | fibroblast growth factor 14 |
| | <i>FGF16</i> | fibroblast growth factor 16 |
| | <i>FGF5</i> | fibroblast growth factor 5 |
| | <i>FGF18</i> | fibroblast growth factor 18 |
| | <i>FGF19</i> | fibroblast growth factor 19 |
| | <i>FGF20</i> | fibroblast growth factor 20 |
| | <i>FGF21</i> | fibroblast growth factor 21 |
| | <i>FGF22</i> | fibroblast growth factor 22 |
| | <i>FGF23</i> | fibroblast growth factor 23 |
| | <i>PDGFA</i> | platelet derived growth factor subunit A |

| | |
|---------------------|---|
| <i>PDGFB</i> | platelet derived growth factor subunit B |
| <i>NTRK1</i> | neurotrophic receptor tyrosine kinase 1 |
| <i>NTRK2</i> | neurotrophic receptor tyrosine kinase 2 |
| <i>EGFR</i> | epidermal growth factor receptor |
| <i>FGFR1</i> | fibroblast growth factor receptor 1 |
| <i>FGFR2</i> | fibroblast growth factor receptor 2 |
| <i>FGFR3</i> | fibroblast growth factor receptor 3 |
| <i>FGFR4</i> | fibroblast growth factor receptor 4 |
| <i>PDGFRA</i> | platelet derived growth factor receptor alpha |
| <i>PDGFRB</i> | platelet derived growth factor receptor beta |
| <i>GRB2</i> | growth factor receptor bound protein 2 |
| <i>SOS1</i> | SOS Ras/Rac guanine nucleotide exchange factor 1 |
| <i>SOS2</i> | SOS Ras/Rho guanine nucleotide exchange factor 2 |
| <i>HRAS</i> | HRas proto-oncogene, GTPase |
| <i>KRAS</i> | KRas proto-oncogene, GTPase |
| <i>NRAS</i> | NRas proto-oncogene, GTPase |
| <i>RRAS</i> | RAS related |
| <i>RRAS2</i> | RAS related 2 |
| <i>MRAS</i> | muscle RAS oncogene homolog |
| <i>BRAF</i> | B-Raf proto-oncogene, serine/threonine kinase |
| <i>RAF1</i> | Raf-1 proto-oncogene, serine/threonine kinase |
| <i>MOS</i> | MOS proto-oncogene, serine/threonine kinase |
| <i>MAP2K1</i> | mitogen-activated protein kinase kinase 1 |
| <i>MAP2K2</i> | mitogen-activated protein kinase kinase 2 |
| <i>LAMTOR3</i> | late endosomal/lysosomal adaptor, MAPK and MTOR activator 3 |
| <i>MAPK1</i> | mitogen-activated protein kinase 1 |
| <i>MAPK3</i> | mitogen-activated protein kinase 3 |
| <i>MKNK1</i> | MAP kinase interacting serine/threonine kinase 1 |
| <i>MKNK2</i> | MAP kinase interacting serine/threonine kinase 2 |
| <i>RPS6KA3</i> | ribosomal protein S6 kinase A3 |
| <i>RPS6KA1</i> | ribosomal protein S6 kinase A1 |
| <i>RPS6KA2</i> | ribosomal protein S6 kinase A2 |
| <i>RPS6KA6</i> | ribosomal protein S6 kinase A6 |
| <i>ATF4</i> | activating transcription factor 4 |
| <i>ELK1</i> | ELK1, ETS transcription factor |
| <i>ELK4</i> | ELK4, ETS transcription factor |
| <i>MYC</i> | MYC proto-oncogene, bHLH transcription factor |
| <i>SRF</i> | serum response factor |
| <i>FOS</i> | Fos proto-oncogene, AP-1 transcription factor subunit |
| <i>MAPT</i> | microtubule associated protein tau |
| <i>STMN1</i> | stathmin 1 |
| <i>PLA2G4E</i> | phospholipase A2 group IVE |
| <i>PLA2G4A</i> | phospholipase A2 group IVA |
| <i>JMD7-PLA2G4B</i> | JMD7-PLA2G4B readthrough |
| <i>PLA2G4B</i> | phospholipase A2 group IVB |
| <i>PLA2G4C</i> | phospholipase A2 group IVC |
| <i>PLA2G4D</i> | phospholipase A2 group IVD |
| <i>PLA2G4F</i> | phospholipase A2 group IVF |
| <i>TNF</i> | tumor necrosis factor |
| <i>IL1A</i> | interleukin 1 alpha |
| <i>IL1B</i> | interleukin 1 beta |
| <i>TGFB1</i> | transforming growth factor beta 1 |
| <i>TGFB2</i> | transforming growth factor beta 2 |
| <i>TGFB3</i> | transforming growth factor beta 3 |
| <i>TNFRSF1A</i> | TNF receptor superfamily member 1A |
| <i>IL1R1</i> | interleukin 1 receptor type 1 |
| <i>IL1R2</i> | interleukin 1 receptor type 2 |
| <i>TGFBR1</i> | transforming growth factor beta receptor 1 |
| <i>TGFBR2</i> | transforming growth factor beta receptor 2 |
| <i>FASLG</i> | Fas ligand |
| <i>FAS</i> | Fas cell surface death receptor |
| <i>CD14</i> | CD14 molecule |
| <i>RAC1</i> | Rac family small GTPase 1 |
| <i>RAC2</i> | Rac family small GTPase 2 |
| <i>RAC3</i> | Rac family small GTPase 3 |
| <i>CDC42</i> | cell division cycle 42 |
| <i>CASP3</i> | caspase 3 |
| <i>TRAF2</i> | TNF receptor associated factor 2 |
| <i>DAXX</i> | death domain associated protein |
| <i>TRAF6</i> | TNF receptor associated factor 6 |
| <i>GADD45A</i> | growth arrest and DNA damage inducible alpha |
| <i>GADD45B</i> | growth arrest and DNA damage inducible beta |
| <i>GADD45G</i> | growth arrest and DNA damage inducible gamma |
| <i>TAB1</i> | TGF-beta activated kinase 1 (MAP3K7) binding protein 1 |
| <i>TAB2</i> | TGF-beta activated kinase 1/MAP3K7 binding protein 2 |
| <i>ECSIT</i> | ECSIT signalling integrator |
| <i>MAP4K3</i> | mitogen-activated protein kinase kinase kinase kinase 3 |
| <i>MAP4K4</i> | mitogen-activated protein kinase kinase kinase kinase 4 |
| <i>MAP4K1</i> | mitogen-activated protein kinase kinase kinase kinase 1 |
| <i>PAK1</i> | p21 (RAC1) activated kinase 1 |
| <i>PAK2</i> | p21 (RAC1) activated kinase 2 |
| <i>STK4</i> | serine/threonine kinase 4 |
| <i>STK3</i> | serine/threonine kinase 3 |
| <i>MAP4K2</i> | mitogen-activated protein kinase kinase kinase kinase 2 |
| <i>MAP3K8</i> | mitogen-activated protein kinase kinase kinase 8 |
| <i>MAP3K1</i> | mitogen-activated protein kinase kinase kinase 1 |
| <i>MAP3K11</i> | mitogen-activated protein kinase kinase kinase 11 |
| <i>MAP3K2</i> | mitogen-activated protein kinase kinase kinase 2 |
| <i>MAP3K3</i> | mitogen-activated protein kinase kinase kinase 3 |

| | | |
|------------------------|-----------------|--|
| | <i>MAP3K13</i> | mitogen-activated protein kinase kinase kinase 13 |
| | <i>MAP3K12</i> | mitogen-activated protein kinase kinase kinase 12 |
| | <i>MAP3K20</i> | mitogen-activated protein kinase kinase kinase 20 |
| | <i>MAP3K6</i> | mitogen-activated protein kinase kinase kinase 6 |
| | <i>MAP3K5</i> | mitogen-activated protein kinase kinase kinase 5 |
| | <i>MAP3K7</i> | mitogen-activated protein kinase kinase kinase 7 |
| | <i>MAP3K4</i> | mitogen-activated protein kinase kinase kinase 4 |
| | <i>TAOK2</i> | TAO kinase 2 |
| | <i>TAOK3</i> | TAO kinase 3 |
| | <i>TAOK1</i> | TAO kinase 1 |
| | <i>MAP2K4</i> | mitogen-activated protein kinase kinase 4 |
| | <i>MAP2K7</i> | mitogen-activated protein kinase kinase 7 |
| | <i>MAP2K3</i> | mitogen-activated protein kinase kinase 3 |
| | <i>MAP2K6</i> | mitogen-activated protein kinase kinase 6 |
| | <i>MAPK8IP1</i> | mitogen-activated protein kinase 8 interacting protein 1 |
| | <i>MAPK8IP2</i> | mitogen-activated protein kinase 8 interacting protein 2 |
| | <i>MAPK8IP3</i> | mitogen-activated protein kinase 8 interacting protein 3 |
| | <i>FLNA</i> | filamin A |
| | <i>FLNC</i> | filamin C |
| | <i>FLNB</i> | filamin B |
| | <i>CRK</i> | CRK proto-oncogene, adaptor protein |
| | <i>CRKL</i> | CRK like proto-oncogene, adaptor protein |
| | <i>ARRB1</i> | arrestin beta 1 |
| | <i>ARRB2</i> | arrestin beta 2 |
| | <i>MAPK8</i> | mitogen-activated protein kinase 8 |
| | <i>MAPK10</i> | mitogen-activated protein kinase 10 |
| | <i>MAPK9</i> | mitogen-activated protein kinase 9 |
| | <i>MAPK11</i> | mitogen-activated protein kinase 11 |
| | <i>MAPK12</i> | mitogen-activated protein kinase 12 |
| | <i>MAPK13</i> | mitogen-activated protein kinase 13 |
| | <i>MAPK14</i> | mitogen-activated protein kinase 14 |
| | <i>MAPKAPK5</i> | mitogen-activated protein kinase-activated protein kinase 5 |
| | <i>MAPKAPK2</i> | mitogen-activated protein kinase-activated protein kinase 2 |
| | <i>MAPKAPK3</i> | mitogen-activated protein kinase-activated protein kinase 3 |
| | <i>RPS6KA5</i> | ribosomal protein S6 kinase A5 |
| | <i>RPS6KA4</i> | ribosomal protein S6 kinase A4 |
| | <i>CDC25B</i> | cell division cycle 25B |
| | <i>NFATC1</i> | nuclear factor of activated T-cells 1 |
| | <i>NFATC3</i> | nuclear factor of activated T-cells 3 |
| | <i>JUN</i> | Jun proto-oncogene, AP-1 transcription factor subunit |
| | <i>JUND</i> | JunD proto-oncogene, AP-1 transcription factor subunit |
| | <i>ATF2</i> | activating transcription factor 2 |
| | <i>TP53</i> | tumor protein p53 |
| | <i>DDIT3</i> | DNA damage inducible transcript 3 |
| | <i>MAX</i> | MYC associated factor X |
| | <i>MEF2C</i> | myocyte enhancer factor 2C |
| | <i>HSPB1</i> | heat shock protein family B (small) member 1 |
| | <i>AKT1</i> | AKT serine/threonine kinase 1 |
| | <i>AKT2</i> | AKT serine/threonine kinase 2 |
| | <i>AKT3</i> | AKT serine/threonine kinase 3 |
| | <i>PPM1A</i> | protein phosphatase, Mg ²⁺ /Mn ²⁺ dependent 1A |
| | <i>PTPRR</i> | protein tyrosine phosphatase, receptor type R |
| | <i>PTPN5</i> | protein tyrosine phosphatase, non-receptor type 5 |
| | <i>PTPN7</i> | protein tyrosine phosphatase, non-receptor type 7 |
| | <i>DUSP1</i> | dual specificity phosphatase 1 |
| | <i>DUSP4</i> | dual specificity phosphatase 4 |
| | <i>DUSP2</i> | dual specificity phosphatase 2 |
| | <i>DUSP7</i> | dual specificity phosphatase 7 |
| | <i>DUSP8</i> | dual specificity phosphatase 8 |
| | <i>DUSP5</i> | dual specificity phosphatase 5 |
| | <i>DUSP16</i> | dual specificity phosphatase 16 |
| | <i>DUSP6</i> | dual specificity phosphatase 6 |
| | <i>DUSP9</i> | dual specificity phosphatase 9 |
| | <i>DUSP10</i> | dual specificity phosphatase 10 |
| | <i>DUSP3</i> | dual specificity phosphatase 3 |
| | <i>PPP5C</i> | protein phosphatase 5 catalytic subunit |
| | <i>PPP5D1</i> | PPP5 tetratricopeptide repeat domain containing 1 |
| | <i>PPM1B</i> | protein phosphatase, Mg ²⁺ /Mn ²⁺ dependent 1B |
| | <i>HSPA8</i> | heat shock protein family A (Hsp70) member 8 |
| | <i>HSPA1A</i> | heat shock protein family A (Hsp70) member 1A |
| | <i>HSPA2</i> | heat shock protein family A (Hsp70) member 2 |
| | <i>HSPA1L</i> | heat shock protein family A (Hsp70) member 1 like |
| | <i>HSPA1B</i> | heat shock protein family A (Hsp70) member 1B |
| | <i>HSPA6</i> | heat shock protein family A (Hsp70) member 6 |
| | <i>MECOM</i> | MDS1 and EVI1 complex locus |
| | <i>MAP2K5</i> | mitogen-activated protein kinase kinase 5 |
| | <i>MAPK7</i> | mitogen-activated protein kinase 7 |
| | <i>NR4A1</i> | nuclear receptor subfamily 4 group A member 1 |
| | <i>MAP3K14</i> | mitogen-activated protein kinase kinase kinase 14 |
| | <i>CHUK</i> | conserved helix-loop-helix ubiquitous kinase |
| | <i>IKBKB</i> | inhibitor of nuclear factor kappa B kinase subunit beta |
| | <i>IKBKG</i> | inhibitor of nuclear factor kappa B kinase subunit gamma |
| | <i>NLK</i> | nemo like kinase |
| | <i>NFKB1</i> | nuclear factor kappa B subunit 1 |
| | <i>NFKB2</i> | nuclear factor kappa B subunit 2 |
| | <i>RELA</i> | RELA proto-oncogene, NF-κB subunit |
| | <i>RELB</i> | RELB proto-oncogene, NF-κB subunit |
| PPAR signaling pathway | <i>CD36</i> | CD36 molecule |
| | <i>SLC27A1</i> | solute carrier family 27 member 1 |

| | | |
|------------|----------------|---|
| | <i>SLC27A4</i> | solute carrier family 27 member 4 |
| | <i>SLC27A2</i> | solute carrier family 27 member 2 |
| | <i>SLC27A5</i> | solute carrier family 27 member 5 |
| | <i>SLC27A6</i> | solute carrier family 27 member 6 |
| | <i>FABP1</i> | fatty acid binding protein 1 |
| | <i>FABP2</i> | fatty acid binding protein 2 |
| | <i>FABP3</i> | fatty acid binding protein 3 |
| | <i>FABP4</i> | fatty acid binding protein 4 |
| | <i>FABP5</i> | fatty acid binding protein 5 |
| | <i>FABP6</i> | fatty acid binding protein 6 |
| | <i>FABP7</i> | fatty acid binding protein 7 |
| | <i>PPARA</i> | peroxisome proliferator activated receptor alpha |
| | <i>RXRA</i> | retinoid X receptor alpha |
| | <i>RXRB</i> | retinoid X receptor beta |
| | <i>RXRG</i> | retinoid X receptor gamma |
| | <i>PPARD</i> | peroxisome proliferator activated receptor delta |
| | <i>PPARG</i> | peroxisome proliferator activated receptor gamma |
| | <i>APOA1</i> | apolipoprotein A1 |
| | <i>APOA2</i> | apolipoprotein A2 |
| | <i>APOC3</i> | apolipoprotein C3 |
| | <i>APOA5</i> | apolipoprotein A5 |
| | <i>PLTP</i> | phospholipid transfer protein |
| | <i>FADS2</i> | fatty acid desaturase 2 |
| | <i>SCD</i> | stearoyl-CoA desaturase |
| | <i>SCDS</i> | stearoyl-CoA desaturase 5 |
| | <i>CYP7A1</i> | cytochrome P450 family 7 subfamily A member 1 |
| | <i>CYP8B1</i> | cytochrome P450 family 8 subfamily B member 1 |
| | <i>NR1H3</i> | nuclear receptor subfamily 1 group H member 3 |
| | <i>CYP27A1</i> | cytochrome P450 family 27 subfamily A member 1 |
| | <i>DBI</i> | diazepam binding inhibitor, acyl-CoA binding protein |
| | <i>LPL</i> | lipoprotein lipase |
| | <i>ACSL6</i> | acyl-CoA synthetase long chain family member 6 |
| | <i>ACSL4</i> | acyl-CoA synthetase long chain family member 4 |
| | <i>ACSL1</i> | acyl-CoA synthetase long chain family member 1 |
| | <i>ACSL5</i> | acyl-CoA synthetase long chain family member 5 |
| | <i>ACSL3</i> | acyl-CoA synthetase long chain family member 3 |
| | <i>ACSBG1</i> | acyl-CoA synthetase bubblegum family member 1 |
| | <i>ACSBG2</i> | acyl-CoA synthetase bubblegum family member 2 |
| | <i>OLR1</i> | oxidized low density lipoprotein receptor 1 |
| | <i>EHHADH</i> | enoyl-CoA hydratase and 3-hydroxyacyl CoA dehydrogenase |
| | <i>ACAA1</i> | acyl-CoA acyltransferase 1 |
| | <i>SCP2</i> | sterol carrier protein 2 |
| | <i>ACOX3</i> | acyl-CoA oxidase 3, pristanoyl |
| | <i>ACOX1</i> | acyl-CoA oxidase 1 |
| | <i>ACOX2</i> | acyl-CoA oxidase 2 |
| | <i>CPT1A</i> | carnitine palmitoyltransferase 1A |
| | <i>CPT1B</i> | carnitine palmitoyltransferase 1B |
| | <i>CPT1C</i> | carnitine palmitoyltransferase 1C |
| | <i>CPT2</i> | carnitine palmitoyltransferase 2 |
| | <i>ACADM</i> | acyl-CoA dehydrogenase, long chain |
| | <i>ANGPTL4</i> | angiopoietin like 4 |
| | <i>SORBS1</i> | sorbin and SH3 domain containing 1 |
| | <i>PLIN1</i> | perilipin 1 |
| | <i>PLIN2</i> | perilipin 2 |
| | <i>PLIN4</i> | perilipin 4 |
| | <i>PLIN5</i> | perilipin 5 |
| | <i>ADIPOQ</i> | adiponectin, C1Q and collagen domain containing |
| | <i>MMP1</i> | matrix metalloproteinase 1 |
| | <i>UCP1</i> | uncoupling protein 1 |
| | <i>ILK</i> | integrin linked kinase |
| | <i>PDPK1</i> | 3-phosphoinositide dependent protein kinase 1 |
| | <i>UBC</i> | ubiquitin C |
| | <i>PCK1</i> | phosphoenolpyruvate carboxykinase 1 |
| | <i>PCK2</i> | phosphoenolpyruvate carboxykinase 2, mitochondrial |
| | <i>GK2</i> | glycerol kinase 2 |
| | <i>GK</i> | glycerol kinase |
| | <i>AQP7</i> | aquaporin 7 |
| | <i>HMGCS2</i> | 3-hydroxy-3-methylglutaryl-CoA synthase 2 |
| | <i>ME1</i> | malic enzyme 1 |
| Cell cycle | <i>CCND1</i> | cyclin D1 |
| | <i>CCND2</i> | cyclin D2 |
| | <i>CCND3</i> | cyclin D3 |
| | <i>CDK4</i> | cyclin dependent kinase 4 |
| | <i>CDK6</i> | cyclin dependent kinase 6 |
| | <i>RB1</i> | RB transcriptional corepressor 1 |
| | <i>RBL1</i> | RB transcriptional corepressor like 1 |
| | <i>RBL2</i> | RB transcriptional corepressor like 2 |
| | <i>ABL1</i> | ABL proto-oncogene 1, non-receptor tyrosine kinase |
| | <i>HDAC1</i> | histone deacetylase 1 |
| | <i>HDAC2</i> | histone deacetylase 2 |
| | <i>E2F1</i> | E2F transcription factor 1 |
| | <i>E2F2</i> | E2F transcription factor 2 |
| | <i>E2F3</i> | E2F transcription factor 3 |
| | <i>E2F4</i> | E2F transcription factor 4 |
| | <i>E2F5</i> | E2F transcription factor 5 |
| | <i>TFDP1</i> | transcription factor Dp-1 |
| | <i>TFDP2</i> | transcription factor Dp-2 |
| | <i>GSK3B</i> | glycogen synthase kinase 3 beta |

| | |
|----------------|--|
| <i>TGFB1</i> | transforming growth factor beta 1 |
| <i>TGFB2</i> | transforming growth factor beta 2 |
| <i>TGFB3</i> | transforming growth factor beta 3 |
| <i>SMAD2</i> | SMAD family member 2 |
| <i>SMAD3</i> | SMAD family member 3 |
| <i>SMAD4</i> | SMAD family member 4 |
| <i>MYC</i> | MYC proto-oncogene, bHLH transcription factor |
| <i>ZBTB17</i> | zinc finger and BTB domain containing 17 |
| <i>CDKN2A</i> | cyclin dependent kinase inhibitor 2A |
| <i>CDKN2B</i> | cyclin dependent kinase inhibitor 2B |
| <i>CDKN2C</i> | cyclin dependent kinase inhibitor 2C |
| <i>CDKN2D</i> | cyclin dependent kinase inhibitor 2D |
| <i>CDKN1B</i> | cyclin dependent kinase inhibitor 1B |
| <i>CDKN1C</i> | cyclin dependent kinase inhibitor 1C |
| <i>CDKN1A</i> | cyclin dependent kinase inhibitor 1A |
| <i>CCNE1</i> | cyclin E1 |
| <i>CCNE2</i> | cyclin E2 |
| <i>CDK2</i> | cyclin dependent kinase 2 |
| <i>SKP1</i> | S-phase kinase associated protein 1 |
| <i>CUL1</i> | cullin 1 |
| <i>RBX1</i> | ring-box 1 |
| <i>SKP2</i> | S-phase kinase associated protein 2 |
| <i>CCNA2</i> | cyclin A2 |
| <i>CCNA1</i> | cyclin A1 |
| <i>CDC6</i> | cell division cycle 6 |
| <i>CDC45</i> | cell division cycle 45 |
| <i>CDC7</i> | cell division cycle 7 |
| <i>DBF4</i> | DBF4 zinc finger |
| <i>CDK1</i> | cyclin dependent kinase 1 |
| <i>CCNB1</i> | cyclin B1 |
| <i>CCNB2</i> | cyclin B2 |
| <i>CCNB3</i> | cyclin B3 |
| <i>CDC25B</i> | cell division cycle 25B |
| <i>CDC25C</i> | cell division cycle 25C |
| <i>YWHAZ</i> | tyrosine 3-monoxygenase/tryptophan 5-monoxygenase activation protein zeta |
| <i>YWHAB</i> | tyrosine 3-monoxygenase/tryptophan 5-monoxygenase activation protein beta |
| <i>YWHAQ</i> | tyrosine 3-monoxygenase/tryptophan 5-monoxygenase activation protein theta |
| <i>YWHAE</i> | tyrosine 3-monoxygenase/tryptophan 5-monoxygenase activation protein epsilon |
| <i>YWHAH</i> | tyrosine 3-monoxygenase/tryptophan 5-monoxygenase activation protein eta |
| <i>YWHAG</i> | tyrosine 3-monoxygenase/tryptophan 5-monoxygenase activation protein gamma |
| <i>PLK1</i> | pole like kinase 1 |
| <i>WEE1</i> | WEE1 G2 checkpoint kinase |
| <i>WEE2</i> | WEE1 homolog 2 |
| <i>PKMYT1</i> | protein kinase, membrane associated tyrosine/threonine 1 |
| <i>CCNH</i> | cyclin H |
| <i>CDK7</i> | cyclin dependent kinase 7 |
| <i>ANAPC1</i> | anaphase promoting complex subunit 1 |
| <i>ANAPC2</i> | anaphase promoting complex subunit 2 |
| <i>CDC27</i> | cell division cycle 27 |
| <i>ANAPC4</i> | anaphase promoting complex subunit 4 |
| <i>ANAPC5</i> | anaphase promoting complex subunit 5 |
| <i>CDC16</i> | cell division cycle 16 |
| <i>ANAPC7</i> | anaphase promoting complex subunit 7 |
| <i>CDC23</i> | cell division cycle 23 |
| <i>ANAPC10</i> | anaphase promoting complex subunit 10 |
| <i>ANAPC11</i> | anaphase promoting complex subunit 11 |
| <i>CDC26</i> | cell division cycle 26 |
| <i>ANAPC13</i> | anaphase promoting complex subunit 13 |
| <i>CDC20</i> | cell division cycle 20 |
| <i>PTTG1</i> | pituitary tumor-transforming 1 |
| <i>PTTG2</i> | pituitary tumor-transforming 2 |
| <i>ESPL1</i> | extra spindle pole bodies like 1, separate |
| <i>SMC1A</i> | structural maintenance of chromosomes 1A |
| <i>SMC1B</i> | structural maintenance of chromosomes 1B |
| <i>SMC3</i> | structural maintenance of chromosomes 3 |
| <i>STAG2</i> | stromal antigen 2 |
| <i>STAG1</i> | stromal antigen 1 |
| <i>RAD21</i> | RAD21 cohesin complex component |
| <i>TTK</i> | TTK protein kinase |
| <i>BUB1</i> | BUB1 mitotic checkpoint serine/threonine kinase |
| <i>BUB3</i> | BUB3, mitotic checkpoint protein |
| <i>BUB1B</i> | BUB1 mitotic checkpoint serine/threonine kinase B |
| <i>MAD1L1</i> | MAD1 mitotic arrest deficient like 1 |
| <i>MAD2L1</i> | mitotic arrest deficient 2 like 1 |
| <i>MAD2L2</i> | mitotic arrest deficient 2 like 2 |
| <i>FZR1</i> | fizzy and cell division cycle 20 related 1 |
| <i>CDC14B</i> | cell division cycle 14B |
| <i>CDC14A</i> | cell division cycle 14A |
| <i>ATR</i> | ATR serine/threonine kinase |
| <i>ATM</i> | ATM serine/threonine kinase |
| <i>TP53</i> | tumor protein p53 |
| <i>CHEK1</i> | checkpoint kinase 1 |
| <i>CHEK2</i> | checkpoint kinase 2 |
| <i>CREBBP</i> | CREB binding protein |
| <i>EP300</i> | E1A binding protein p300 |
| <i>PRKDC</i> | protein kinase, DNA-activated, catalytic polypeptide |
| <i>MDM2</i> | MDM2 proto-oncogene |
| <i>GADD45A</i> | growth arrest and DNA damage inducible alpha |
| <i>GADD45B</i> | growth arrest and DNA damage inducible beta |

| | | |
|------------------------|------------------|--|
| | <i>GADD45G</i> | growth arrest and DNA damage inducible gamma |
| | <i>PCNA</i> | proliferating cell nuclear antigen |
| | <i>SFN</i> | stratifin |
| | <i>CDC25A</i> | cell division cycle 25A |
| | <i>ORC1</i> | origin recognition complex subunit 1 |
| | <i>ORC2</i> | origin recognition complex subunit 2 |
| | <i>ORC3</i> | origin recognition complex subunit 3 |
| | <i>ORC4</i> | origin recognition complex subunit 4 |
| | <i>ORC5</i> | origin recognition complex subunit 5 |
| | <i>ORC6</i> | origin recognition complex subunit 6 |
| | <i>MCM2</i> | minichromosome maintenance complex component 2 |
| | <i>MCM3</i> | minichromosome maintenance complex component 3 |
| | <i>MCM4</i> | minichromosome maintenance complex component 4 |
| | <i>MCM5</i> | minichromosome maintenance complex component 5 |
| | <i>MCM6</i> | minichromosome maintenance complex component 6 |
| | <i>MCM7</i> | minichromosome maintenance complex component 7 |
| p53 signaling pathway | <i>ATM</i> | ATM serine/threonine kinase |
| | <i>CHEK2</i> | checkpoint kinase 2 |
| | <i>ATR</i> | ATR serine/threonine kinase |
| | <i>CHEK1</i> | checkpoint kinase 1 |
| | <i>GORAB</i> | golgin, RAB6 interacting |
| | <i>CDKN2A</i> | cyclin dependent kinase inhibitor 2A |
| | <i>MDM2</i> | MDM2 proto-oncogene |
| | <i>MDM4</i> | MDM4, p53 regulator |
| | <i>TP53</i> | tumor protein p53 |
| | <i>CDKN1A</i> | cyclin dependent kinase inhibitor 1A |
| | <i>CCND1</i> | cyclin D1 |
| | <i>CCND2</i> | cyclin D2 |
| | <i>CCND3</i> | cyclin D3 |
| | <i>CDK4</i> | cyclin dependent kinase 4 |
| | <i>CDK6</i> | cyclin dependent kinase 6 |
| | <i>CCNE1</i> | cyclin E1 |
| | <i>CCNE2</i> | cyclin E2 |
| | <i>CDK2</i> | cyclin dependent kinase 2 |
| | <i>SFN</i> | stratifin |
| | <i>RPRM</i> | reproto, TP53 dependent G2 arrest mediator homolog |
| | <i>CCNB1</i> | cyclin B1 |
| | <i>CCNB2</i> | cyclin B2 |
| | <i>CDK1</i> | cyclin dependent kinase 1 |
| | <i>GADD45A</i> | growth arrest and DNA damage inducible alpha |
| | <i>GADD45B</i> | growth arrest and DNA damage inducible beta |
| | <i>GADD45G</i> | growth arrest and DNA damage inducible gamma |
| | <i>GTSE1</i> | G2 and S-phase expressed 1 |
| | <i>FAS</i> | Fas cell surface death receptor |
| | <i>PIDD1</i> | p53-induced death domain protein 1 |
| | <i>CASP8</i> | caspase 8 |
| | <i>BID</i> | BH3 interacting domain death agonist |
| | <i>BAX</i> | BCL2 associated X, apoptosis regulator |
| | <i>PMAIP1</i> | phorbol-12-myristate-13-acetate-induced protein 1 |
| | <i>BBC3</i> | BCL2 binding component 3 |
| | <i>TP53AI1</i> | tumor protein p53 regulated apoptosis inducing protein 1 |
| | <i>TP53I3</i> | tumor protein p53 inducible protein 3 |
| | <i>E124</i> | E124, autophagy associated transmembrane protein |
| | <i>SHISA5</i> | shisa family member 5 |
| | <i>PERP</i> | PERP, TP53 apoptosis effector |
| | <i>ZMAT3</i> | zinc finger matrin-type 3 |
| | <i>SIAH1</i> | siah E3 ubiquitin protein ligase 1 |
| | <i>CYCS</i> | cytochrome c, somatic |
| | <i>APAF1</i> | apoptotic peptidase activating factor 1 |
| | <i>CASP9</i> | caspase 9 |
| | <i>CASP3</i> | caspase 3 |
| | <i>IGFBP3</i> | insulin like growth factor binding protein 3 |
| | <i>IGF1</i> | insulin like growth factor 1 |
| | <i>SERPINE1</i> | serpin family E member 1 |
| | <i>ADGRB1</i> | adhesion G protein-coupled receptor B1 |
| | <i>CD82</i> | CD82 molecule |
| | <i>THBS1</i> | thrombospondin 1 |
| | <i>SERPINB5</i> | Serpin family B member 5 |
| | <i>DDB2</i> | damage specific DNA binding protein 2 |
| | <i>RRM2B</i> | ribonucleotide reductase regulatory TP53 inducible subunit M2B |
| | <i>RRM2</i> | ribonucleotide reductase regulatory subunit M2 |
| | <i>SESN1</i> | sestrin 1 |
| | <i>SESN3</i> | sestrin 3 |
| | <i>SESN2</i> | sestrin 2 |
| | <i>PTEN</i> | phosphatase and tensin homolog |
| | <i>TSC2</i> | TSC complex subunit 2 |
| | <i>STEAP3</i> | STEAP3 metalloreductase |
| | <i>RFWD2</i> | ring finger and WD repeat domain 2 |
| | <i>RCHY1</i> | ring finger and CHY zinc finger domain containing 1 |
| | <i>CCNG1</i> | cyclin G1 |
| | <i>CCNG2</i> | cyclin G2 |
| | <i>PPM1D</i> | protein phosphatase, Mg ²⁺ /Mn ²⁺ dependent 1D |
| | <i>TP73</i> | tumor protein p73 |
| | <i>TNFRSF10B</i> | TNF receptor superfamily member 10b |
| VEGF signaling pathway | <i>VEGFA</i> | vascular endothelial growth factor A |
| | <i>KDR</i> | kinase insert domain receptor |
| | <i>SH2D2A</i> | SH2 domain containing 2A |
| | <i>PLCG1</i> | phospholipase C gamma 1 |
| | <i>PLCG2</i> | phospholipase C gamma 2 |

| | | |
|-----------|---------------------|--|
| | <i>PRKCA</i> | protein kinase C alpha |
| | <i>PRKCB</i> | protein kinase C beta |
| | <i>PRKCG</i> | protein kinase C gamma |
| | <i>SPHK1</i> | sphingosine kinase 1 |
| | <i>SPHK2</i> | sphingosine kinase 2 |
| | <i>HRAS</i> | HRAS proto-oncogene, GTPase |
| | <i>KRAS</i> | KRAS proto-oncogene, GTPase |
| | <i>NRAS</i> | NRAS proto-oncogene, GTPase |
| | <i>RAF1</i> | Raf-1 proto-oncogene, serine/threonine kinase |
| | <i>MAP2K1</i> | mitogen-activated protein kinase kinase 1 |
| | <i>MAP2K2</i> | mitogen-activated protein kinase kinase 2 |
| | <i>MAPK1</i> | mitogen-activated protein kinase 1 |
| | <i>MAPK3</i> | mitogen-activated protein kinase 3 |
| | <i>PLA2G4E</i> | phospholipase A2 group IVE |
| | <i>PLA2G4A</i> | phospholipase A2 group IVA |
| | <i>JMD7-PLA2G4B</i> | JMD7-PLA2G4B readthrough |
| | <i>PLA2G4B</i> | phospholipase A2 group IVB |
| | <i>PLA2G4C</i> | phospholipase A2 group IVC |
| | <i>PLA2G4D</i> | phospholipase A2 group IVD |
| | <i>PLA2G4F</i> | phospholipase A2 group IVF |
| | <i>PPP3CA</i> | protein phosphatase 3 catalytic subunit alpha |
| | <i>PPP3CB</i> | protein phosphatase 3 catalytic subunit beta |
| | <i>PPP3CC</i> | protein phosphatase 3 catalytic subunit gamma |
| | <i>PPP3R1</i> | protein phosphatase 3 regulatory subunit B, alpha |
| | <i>PPP3R2</i> | protein phosphatase 3 regulatory subunit B, beta |
| | <i>NFATC2</i> | nuclear factor of activated T-cells 2 |
| | <i>PTGS2</i> | prostaglandin-endoperoxide synthase 2 |
| | <i>PTK2</i> | protein tyrosine kinase 2 |
| | <i>SHC2</i> | SHC adaptor protein 2 |
| | <i>PXN</i> | paxillin |
| | <i>CDC42</i> | cell division cycle 42 |
| | <i>MAPK11</i> | mitogen-activated protein kinase 11 |
| | <i>MAPK12</i> | mitogen-activated protein kinase 12 |
| | <i>MAPK13</i> | mitogen-activated protein kinase 13 |
| | <i>MAPK14</i> | mitogen-activated protein kinase 14 |
| | <i>MAPKAPK2</i> | mitogen-activated protein kinase-activated protein kinase 2 |
| | <i>MAPKAPK3</i> | mitogen-activated protein kinase-activated protein kinase 3 |
| | <i>HSPB1</i> | heat shock protein family B (small) member 1 |
| | <i>SRC</i> | SRC proto-oncogene, non-receptor tyrosine kinase |
| | <i>PIK3CA</i> | phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha |
| | <i>PIK3CD</i> | phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta |
| | <i>PIK3CB</i> | phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta |
| | <i>PIK3R1</i> | phosphoinositide-3-kinase regulatory subunit 1 |
| | <i>PIK3R2</i> | phosphoinositide-3-kinase regulatory subunit 2 |
| | <i>PIK3R3</i> | phosphoinositide-3-kinase regulatory subunit 3 |
| | <i>RAC1</i> | Rac family small GTPase 1 |
| | <i>RAC2</i> | Rac family small GTPase 2 |
| | <i>RAC3</i> | Rac family small GTPase 3 |
| | <i>AKT1</i> | AKT serine/threonine kinase 1 |
| | <i>AKT2</i> | AKT serine/threonine kinase 2 |
| | <i>AKT3</i> | AKT serine/threonine kinase 3 |
| | <i>NOS3</i> | nitric oxide synthase 3 |
| | <i>CASP9</i> | caspase 9 |
| | <i>BAD</i> | BCL2 associated agonist of cell death |
| Apoptosis | <i>TNFSF10</i> | TNF superfamily member 10 |
| | <i>TNFRSF10A</i> | TNF receptor superfamily member 10a |
| | <i>TNFRSF10B</i> | TNF receptor superfamily member 10b |
| | <i>TNFRSF10C</i> | TNF receptor superfamily member 10c |
| | <i>TNFRSF10D</i> | TNF receptor superfamily member 10d |
| | <i>FASLG</i> | Fas ligand |
| | <i>FAS</i> | Fas cell surface death receptor |
| | <i>FADD</i> | Fas associated via death domain |
| | <i>TNF</i> | tumor necrosis factor |
| | <i>TNFRSF1A</i> | TNF receptor superfamily member 1A |
| | <i>TRADD</i> | TNFRSF1A associated via death domain |
| | <i>CFLAR</i> | CASP8 and FADD like apoptosis regulator |
| | <i>CASP8</i> | caspase 8 |
| | <i>CASP10</i> | caspase 10 |
| | <i>CASP6</i> | caspase 6 |
| | <i>CASP3</i> | caspase 3 |
| | <i>CASP7</i> | caspase 7 |
| | <i>BID</i> | BH3 interacting domain death agonist |
| | <i>BAX</i> | BCL2 associated X, apoptosis regulator |
| | <i>BAK1</i> | BCL2 antagonist/killer 1 |
| | <i>DIABLO</i> | diablo IAP-binding mitochondrial protein |
| | <i>38231</i> | septin 4 |
| | <i>HTRA2</i> | HtrA serine peptidase 2 |
| | <i>CYCS</i> | cytochrome c, somatic |
| | <i>APAF1</i> | apoptotic peptidase activating factor 1 |
| | <i>CASP9</i> | caspase 9 |
| | <i>PRF1</i> | perforin 1 |
| | <i>GZMB</i> | granzyme B |
| | <i>TUBA1B</i> | tubulin alpha 1b |
| | <i>TUBA4A</i> | tubulin alpha 4a |
| | <i>TUBA3C</i> | tubulin alpha 3c |
| | <i>TUBA1A</i> | tubulin alpha 1a |
| | <i>TUBA1C</i> | tubulin alpha 1c |
| | <i>TUBA8</i> | tubulin alpha 8 |
| | <i>TUBA3E</i> | tubulin alpha 3e |

| | |
|------------------|--|
| <i>TUBA3D</i> | tubulin alpha 3d |
| <i>TUBAL3</i> | tubulin alpha like 3 |
| <i>MCL1</i> | MCL1, BCL2 family apoptosis regulator |
| <i>ACTB</i> | actin beta |
| <i>ACTG1</i> | actin gamma 1 |
| <i>SPTA1</i> | spectrin alpha, erythrocytic 1 |
| <i>SPTAN1</i> | spectrin alpha, non-erythrocytic 1 |
| <i>LMPNA</i> | lamin A/C |
| <i>LMPNB1</i> | lamin B1 |
| <i>LMPNB2</i> | lamin B2 |
| <i>PARP2</i> | poly(ADP-ribose) polymerase 2 |
| <i>PARP1</i> | poly(ADP-ribose) polymerase 1 |
| <i>PARP3</i> | poly(ADP-ribose) polymerase family member 3 |
| <i>PARP4</i> | poly(ADP-ribose) polymerase family member 4 |
| <i>DFFA</i> | DNA fragmentation factor subunit alpha |
| <i>DFFB</i> | DNA fragmentation factor subunit beta |
| <i>ENDOG</i> | endonuclease G |
| <i>AIFM1</i> | apoptosis inducing factor mitochondria associated 1 |
| <i>ERN1</i> | endoplasmic reticulum to nucleus signaling 1 |
| <i>TRAF2</i> | TNF receptor associated factor 2 |
| <i>ITPR1</i> | inositol 1,4,5-trisphosphate receptor type 1 |
| <i>ITPR2</i> | inositol 1,4,5-trisphosphate receptor type 2 |
| <i>ITPR3</i> | inositol 1,4,5-trisphosphate receptor type 3 |
| <i>CAPN1</i> | calpain 1 |
| <i>CAPN2</i> | calpain 2 |
| <i>CASP12</i> | caspase 12 (gene/pseudogene) |
| <i>EIF2AK3</i> | eukaryotic translation initiation factor 2 alpha kinase 3 |
| <i>EIF2S1</i> | eukaryotic translation initiation factor 2 subunit alpha |
| <i>ATF4</i> | activating transcription factor 4 |
| <i>DDIT3</i> | DNA damage inducible transcript 3 |
| <i>CTSB</i> | cathepsin B |
| <i>CTSC</i> | cathepsin C |
| <i>CTSD</i> | cathepsin D |
| <i>CTSF</i> | cathepsin F |
| <i>CTSH</i> | cathepsin H |
| <i>CTSK</i> | cathepsin K |
| <i>CTSL</i> | cathepsin L |
| <i>CTSO</i> | cathepsin O |
| <i>CTSS</i> | cathepsin S |
| <i>CTSV</i> | cathepsin V |
| <i>CTSW</i> | cathepsin W |
| <i>CTSZ</i> | cathepsin Z |
| <i>BIRC2</i> | baculoviral IAP repeat containing 2 |
| <i>BIRC3</i> | baculoviral IAP repeat containing 3 |
| <i>XIAP</i> | X-linked inhibitor of apoptosis |
| <i>BIRC5</i> | baculoviral IAP repeat containing 5 |
| <i>BCL2L11</i> | BCL2 like 11 |
| <i>BCL2L1</i> | BCL2 like 1 |
| <i>BCL2</i> | BCL2, apoptosis regulator |
| <i>DAXX</i> | death domain associated protein |
| <i>RIPK1</i> | receptor interacting serine/threonine kinase 1 |
| <i>DAB2IP</i> | DAB2 interacting protein |
| <i>MAP3K5</i> | mitogen-activated protein kinase kinase kinase 5 |
| <i>MAPK8</i> | mitogen-activated protein kinase 8 |
| <i>MAPK10</i> | mitogen-activated protein kinase 10 |
| <i>MAPK9</i> | mitogen-activated protein kinase 9 |
| <i>BAD</i> | BCL2 associated agonist of cell death |
| <i>JUN</i> | Jun proto-oncogene, AP-1 transcription factor subunit |
| <i>FOS</i> | Fos proto-oncogene, AP-1 transcription factor subunit |
| <i>TP53</i> | tumor protein p53 |
| <i>HRK</i> | harakiri, BCL2 interacting protein |
| <i>MAP3K14</i> | mitogen-activated protein kinase kinase kinase 14 |
| <i>CHUK</i> | conserved helix-loop-helix ubiquitous kinase |
| <i>IKBKB</i> | inhibitor of nuclear factor kappa B kinase subunit beta |
| <i>IKBKG</i> | inhibitor of nuclear factor kappa B kinase subunit gamma |
| <i>NFKBIA</i> | NFKB inhibitor alpha |
| <i>NFKB1</i> | nuclear factor kappa B subunit 1 |
| <i>RELA</i> | RELA proto-oncogene, NF-kB subunit |
| <i>PTPN13</i> | protein tyrosine phosphatase, non-receptor type 13 |
| <i>GADD45A</i> | growth arrest and DNA damage inducible alpha |
| <i>GADD45B</i> | growth arrest and DNA damage inducible beta |
| <i>GADD45G</i> | growth arrest and DNA damage inducible gamma |
| <i>TRAF1</i> | TNF receptor associated factor 1 |
| <i>BCL2A1</i> | BCL2 related protein A1 |
| <i>ATM</i> | ATM serine/threonine kinase |
| <i>PIDD1</i> | p53-induced death domain protein 1 |
| <i>TP53AIPI1</i> | tumor protein p53 regulated apoptosis inducing protein 1 |
| <i>BBC3</i> | BCL2 binding component 3 |
| <i>PMAIP1</i> | phorbol-12-myristate-13-acetate-induced protein 1 |
| <i>CASP2</i> | caspase 2 |
| <i>NGF</i> | nerve growth factor |
| <i>NTRK1</i> | neurotrophic receptor tyrosine kinase 1 |
| <i>IL3</i> | interleukin 3 |
| <i>IL3RA</i> | interleukin 3 receptor subunit alpha |
| <i>CSF2RB</i> | colony stimulating factor 2 receptor beta common subunit |
| <i>PIK3CA</i> | phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha |
| <i>PIK3CD</i> | phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta |
| <i>PIK3CB</i> | phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta |
| <i>PIK3R1</i> | phosphoinositide-3-kinase regulatory subunit 1 |

| | | |
|--------------------|--------------------|--|
| | <i>PIK3R2</i> | phosphoinositide-3-kinase regulatory subunit 2 |
| | <i>PIK3R3</i> | phosphoinositide-3-kinase regulatory subunit 3 |
| | <i>PDPK1</i> | 3-phosphoinositide dependent protein kinase 1 |
| | <i>AKT1</i> | AKT serine/threonine kinase 1 |
| | <i>AKT2</i> | AKT serine/threonine kinase 2 |
| | <i>AKT3</i> | AKT serine/threonine kinase 3 |
| | <i>HRAS</i> | HRas proto-oncogene, GTPase |
| | <i>KRAS</i> | KRas proto-oncogene, GTPase |
| | <i>NRAS</i> | NRas proto-oncogene, GTPase |
| | <i>RAF1</i> | Raf-1 proto-oncogene, serine/threonine kinase |
| | <i>MAP2K1</i> | mitogen-activated protein kinase kinase 1 |
| | <i>MAP2K2</i> | mitogen-activated protein kinase kinase 2 |
| | <i>MAPK1</i> | mitogen-activated protein kinase 1 |
| | <i>MAPK3</i> | mitogen-activated protein kinase 3 |
| | <i>CHRD</i> | chordin |
| | <i>NOG</i> | noggin |
| | <i>NBL1</i> | neuroblastoma 1, DAN family BMP antagonist |
| | <i>MINOS1-NBL1</i> | MINOS1-NBL1 readthrough |
| | <i>THBS1</i> | thrombospondin 1 |
| | <i>DCN</i> | decorin |
| | <i>LEFTY1</i> | left-right determination factor 1 |
| | <i>LEFTY2</i> | left-right determination factor 2 |
| | <i>FST</i> | follistatin |
| | <i>BMP2</i> | bone morphogenetic protein 2 |
| | <i>BMP4</i> | bone morphogenetic protein 4 |
| | <i>BMP5</i> | bone morphogenetic protein 5 |
| | <i>BMP6</i> | bone morphogenetic protein 6 |
| | <i>BMP7</i> | bone morphogenetic protein 7 |
| | <i>BMP8B</i> | bone morphogenetic protein 8b |
| | <i>BMP8A</i> | bone morphogenetic protein 8a |
| | <i>GDF5</i> | growth differentiation factor 5 |
| | <i>GDF6</i> | growth differentiation factor 6 |
| | <i>GDF7</i> | growth differentiation factor 7 |
| | <i>AMH</i> | anti-Mullerian hormone |
| | <i>LTPB1</i> | latent transforming growth factor beta binding protein 1 |
| | <i>TGFB1</i> | transforming growth factor beta 1 |
| | <i>TGFB2</i> | transforming growth factor beta 2 |
| | <i>TGFB3</i> | transforming growth factor beta 3 |
| | <i>INHBA</i> | inhibin beta A subunit |
| | <i>INHBB</i> | inhibin beta B subunit |
| | <i>INHBC</i> | inhibin beta C subunit |
| | <i>INHBE</i> | inhibin beta E subunit |
| | <i>NODAL</i> | nodal growth differentiation factor |
| | <i>BMPR2</i> | bone morphogenetic protein receptor type 2 |
| | <i>AMHR2</i> | anti-Mullerian hormone receptor type 2 |
| | <i>TGFBR2</i> | transforming growth factor beta receptor 2 |
| | <i>ACVR2A</i> | activin A receptor type 2A |
| | <i>ACVR2B</i> | activin A receptor type 2B |
| | <i>BMPR1A</i> | bone morphogenetic protein receptor type 1A |
| | <i>BMPR1B</i> | bone morphogenetic protein receptor type 1B |
| | <i>ACVR1</i> | activin A receptor type 1 |
| TGF-beta signaling | <i>TGFBR1</i> | transforming growth factor beta receptor 1 |
| | <i>ACVR1B</i> | activin A receptor type 1B |
| | <i>ACVR1C</i> | activin A receptor type 1C |
| | <i>BAMBI</i> | BMP and activin membrane bound inhibitor |
| | <i>SMAD1</i> | SMAD family member 1 |
| | <i>SMAD5</i> | SMAD family member 5 |
| | <i>SMAD9</i> | SMAD family member 9 |
| | <i>SMAD2</i> | SMAD family member 2 |
| | <i>SMAD3</i> | SMAD family member 3 |
| | <i>SMAD4</i> | SMAD family member 4 |
| | <i>SMAD6</i> | SMAD family member 6 |
| | <i>SMAD7</i> | SMAD family member 7 |
| | <i>SMURF1</i> | SMAD specific E3 ubiquitin protein ligase 1 |
| | <i>SMURF2</i> | SMAD specific E3 ubiquitin protein ligase 2 |
| | <i>ZFYVE9</i> | zinc finger FYVE-type containing 9 |
| | <i>ZFYVE16</i> | zinc finger FYVE-type containing 16 |
| | <i>ID1</i> | inhibitor of DNA binding 1, HLH protein |
| | <i>ID2</i> | inhibitor of DNA binding 2, HLH protein |
| | <i>ID3</i> | inhibitor of DNA binding 3, HLH protein |
| | <i>ID4</i> | inhibitor of DNA binding 4, HLH protein |
| | <i>RBL1</i> | RB transcriptional corepressor like 1 |
| | <i>E2F4</i> | E2F transcription factor 4 |
| | <i>E2F5</i> | E2F transcription factor 5 |
| | <i>TFDP1</i> | transcription factor Dp-1 |
| | <i>CREBBP</i> | CREB binding protein |
| | <i>EP300</i> | E1A binding protein p300 |
| | <i>SP1</i> | Sp1 transcription factor |
| | <i>TGIF1</i> | TGFB induced factor homeobox 1 |
| | <i>TGIF2</i> | TGFB induced factor homeobox 2 |
| | <i>MYC</i> | MYC proto-oncogene, bHLH transcription factor |
| | <i>CDKN2B</i> | cyclin dependent kinase inhibitor 2B |
| | <i>PITX2</i> | paired like homeodomain 2 |
| | <i>RBX1</i> | ring-box 1 |
| | <i>CUL1</i> | cullin 1 |
| | <i>SKP1</i> | S-phase kinase associated protein 1 |
| | <i>MAPK1</i> | mitogen-activated protein kinase 1 |
| | <i>MAPK3</i> | mitogen-activated protein kinase 3 |
| | <i>IFNG</i> | interferon gamma |

| | | |
|-------------|-----------------|--|
| | <i>TNF</i> | tumor necrosis factor |
| | <i>RHOA</i> | ras homolog family member A |
| | <i>ROCK1</i> | Rho associated coiled-coil containing protein kinase 1 |
| | <i>PPP2R1B</i> | protein phosphatase 2 scaffold subunit Abeta |
| | <i>PPP2R1A</i> | protein phosphatase 2 scaffold subunit Aalpha |
| | <i>PPP2CA</i> | protein phosphatase 2 catalytic subunit alpha |
| | <i>PPP2CB</i> | protein phosphatase 2 catalytic subunit beta |
| | <i>RPS6KB1</i> | ribosomal protein S6 kinase B1 |
| | <i>RPS6KB2</i> | ribosomal protein S6 kinase B2 |
| Spliceosoma | <i>RNU6-1</i> | RNA, U6 small nuclear 1 |
| | <i>DDX46</i> | DEAD-box helicase 46 |
| | <i>DDX39B</i> | DExD-box helicase 39B |
| | <i>DHX16</i> | DEAH-box helicase 16 |
| | <i>DHX38</i> | DEAH-box helicase 38 |
| | <i>CDC40</i> | cell division cycle 40 |
| | <i>PRPF18</i> | pre-mRNA processing factor 18 |
| | <i>DHX8</i> | DEAH-box helicase 8 |
| | <i>SLU7</i> | SLU7 homolog, splicing factor |
| | <i>DHX15</i> | DEAH-box helicase 15 |
| | <i>SNRPB</i> | small nuclear ribonucleoprotein polypeptides B and B1 |
| | <i>SNRPD1</i> | small nuclear ribonucleoprotein D1 polypeptide |
| | <i>SNRPD2</i> | small nuclear ribonucleoprotein D2 polypeptide |
| | <i>SNRPD3</i> | small nuclear ribonucleoprotein D3 polypeptide |
| | <i>SNRPE</i> | small nuclear ribonucleoprotein polypeptide E |
| | <i>SNRPF</i> | small nuclear ribonucleoprotein polypeptide F |
| | <i>SNRPG</i> | small nuclear ribonucleoprotein polypeptide G |
| | <i>SNRNP70</i> | small nuclear ribonucleoprotein U1 subunit 70 |
| | <i>SNRPA</i> | small nuclear ribonucleoprotein polypeptide A |
| | <i>SNRPC</i> | small nuclear ribonucleoprotein polypeptide C |
| | <i>PRPF40B</i> | pre-mRNA processing factor 40 homolog B |
| | <i>PRPF40A</i> | pre-mRNA processing factor 40 homolog A |
| | <i>RBM25</i> | RNA binding motif protein 25 |
| | <i>DDX5</i> | DEAD-box helicase 5 |
| | <i>TCERG1</i> | transcription elongation regulator 1 |
| | <i>SNRPA1</i> | small nuclear ribonucleoprotein polypeptide A' |
| | <i>SNRPB2</i> | small nuclear ribonucleoprotein polypeptide B2 |
| | <i>SF3A1</i> | splicing factor 3a subunit 1 |
| | <i>SF3A2</i> | splicing factor 3a subunit 2 |
| | <i>SF3A3</i> | splicing factor 3a subunit 3 |
| | <i>SF3B1</i> | splicing factor 3b subunit 1 |
| | <i>SF3B2</i> | splicing factor 3b subunit 2 |
| | <i>SF3B3</i> | splicing factor 3b subunit 3 |
| | <i>SF3B4</i> | splicing factor 3b subunit 4 |
| | <i>SF3B5</i> | splicing factor 3b subunit 5 |
| | <i>SF3B6</i> | splicing factor 3b subunit 6 |
| | <i>PHF5A</i> | PHD finger protein 5A |
| | <i>DDX42</i> | DEAD-box helicase 42 |
| | <i>U2AF1</i> | U2 small nuclear RNA auxiliary factor 1 |
| | <i>U2AF1L5</i> | U2 small nuclear RNA auxiliary factor 1 like 5 |
| | <i>U2AF1L4</i> | U2 small nuclear RNA auxiliary factor 1 like 4 |
| | <i>U2AF2</i> | U2 small nuclear RNA auxiliary factor 2 |
| | <i>PUF60</i> | poly(U) binding splicing factor 60 |
| | <i>SMNDC1</i> | survival motor neuron domain containing 1 |
| | <i>RBM17</i> | RNA binding motif protein 17 |
| | <i>CHERP</i> | calcium homeostasis endoplasmic reticulum protein |
| | <i>U2SURP</i> | U2 snRNP associated SURP domain containing |
| | <i>RP9</i> | RP9, pre-mRNA splicing factor |
| | <i>LSM2</i> | LSM2 homolog, U6 small nuclear RNA and mRNA degradation associated |
| | <i>LSM3</i> | LSM3 homolog, U6 small nuclear RNA and mRNA degradation associated |
| | <i>LSM4</i> | LSM4 homolog, U6 small nuclear RNA and mRNA degradation associated |
| | <i>LSM5</i> | LSM5 homolog, U6 small nuclear RNA and mRNA degradation associated |
| | <i>LSM6</i> | LSM6 homolog, U6 small nuclear RNA and mRNA degradation associated |
| | <i>LSM7</i> | LSM7 homolog, U6 small nuclear RNA and mRNA degradation associated |
| | <i>LSM8</i> | LSM8 homolog, U6 small nuclear RNA associated |
| | <i>PRPF3</i> | pre-mRNA processing factor 3 |
| | <i>PRPF4</i> | pre-mRNA processing factor 4 |
| | <i>PIPH</i> | peptidylprolyl isomerase H |
| | <i>PRPF31</i> | pre-mRNA processing factor 31 |
| | <i>SNU13</i> | small nuclear ribonucleoprotein 13 |
| | <i>SNRNP27</i> | small nuclear ribonucleoprotein U4/U6.U5 subunit 27 |
| | <i>USP39</i> | ubiquitin specific peptidase 39 |
| | <i>SART1</i> | SART1, U4/U6.U5 tri-snRNP-associated protein 1 |
| | <i>ZMAT2</i> | zinc finger matrin-type 2 |
| | <i>PRPF38A</i> | pre-mRNA processing factor 38A |
| | <i>PRPF38B</i> | pre-mRNA processing factor 38B |
| | <i>EFTUD2</i> | elongation factor Tu GTP binding domain containing 2 |
| | <i>SNRNP200</i> | small nuclear ribonucleoprotein U5 subunit 200 |
| | <i>PRPF6</i> | pre-mRNA processing factor 6 |
| | <i>PRPF8</i> | pre-mRNA processing factor 8 |
| | <i>SNRNP40</i> | small nuclear ribonucleoprotein U5 subunit 40 |
| | <i>DDX23</i> | DEAD-box helicase 23 |
| | <i>TXNL4A</i> | thioredoxin like 4A |
| | <i>PRPF19</i> | pre-mRNA processing factor 19 |
| | <i>CDC5L</i> | cell division cycle 5 like |
| | <i>BCAS2</i> | BCAS2, pre-mRNA processing factor |
| | <i>PLRG1</i> | pleiotropic regulator 1 |
| | <i>CWC15</i> | CWC15 spliceosome associated protein homolog |
| | <i>CTNBL1</i> | catenin beta like 1 |
| | <i>HSPA8</i> | heat shock protein family A (Hsp70) member 8 |

| | | |
|----------------------------|-------------------|--|
| | <i>HSPA1A</i> | heat shock protein family A (Hsp70) member 1A |
| | <i>HSPA2</i> | heat shock protein family A (Hsp70) member 2 |
| | <i>HSPA1L</i> | heat shock protein family A (Hsp70) member 1 like |
| | <i>HSPA1B</i> | heat shock protein family A (Hsp70) member 1B |
| | <i>HSPA6</i> | heat shock protein family A (Hsp70) member 6 |
| | <i>PQBP1</i> | polyglutamine binding protein 1 |
| | <i>WBP11</i> | WW domain binding protein 11 |
| | <i>SNW1</i> | SNW domain containing 1 |
| | <i>XAB2</i> | XPA binding protein 2 |
| | <i>SYF2</i> | SYF2 pre-mRNA splicing factor |
| | <i>CRNKL1</i> | crooked neck pre-mRNA splicing factor 1 |
| | <i>ISY1</i> | ISY1 splicing factor homolog |
| | <i>ISY1-RAB43</i> | ISY1-RAB43 readthrough |
| | <i>PPIL1</i> | peptidylprolyl isomerase like 1 |
| | <i>PPIE</i> | peptidylprolyl isomerase E |
| | <i>CCDC12</i> | coiled-coil domain containing 12 |
| | <i>RBM22</i> | RNA binding motif protein 22 |
| | <i>BUD31</i> | BUD31 homolog |
| | <i>AQR</i> | aquarius intron-binding spliceosomal factor |
| | <i>ACIN1</i> | apoptotic chromatin condensation inducer 1 |
| | <i>EIF4A3</i> | eukaryotic translation initiation factor 4A3 |
| | <i>RBM8A</i> | RNA binding motif protein 8A |
| | <i>MAGOH</i> | mago homolog, exon junction complex core component |
| | <i>MAGOHB</i> | mago homolog B, exon junction complex core component |
| | <i>THOC1</i> | THO complex 1 |
| | <i>THOC2</i> | THO complex 2 |
| | <i>THOC3</i> | THO complex 3 |
| | <i>ALYREF</i> | Aly/Ref export factor |
| | <i>NCBP1</i> | nuclear cap binding protein subunit 1 |
| | <i>NCBP2</i> | nuclear cap binding protein subunit 2 |
| | <i>HNRNPA3</i> | heterogeneous nuclear ribonucleoprotein A3 |
| | <i>HNRNPA1</i> | heterogeneous nuclear ribonucleoprotein A1 |
| | <i>HNRNPA1L2</i> | heterogeneous nuclear ribonucleoprotein A1-like 2 |
| | <i>HNRNPC</i> | heterogeneous nuclear ribonucleoprotein C (C1/C2) |
| | <i>RBMX</i> | RNA binding motif protein, X-linked |
| | <i>RBMXL1</i> | RNA binding motif protein, X-linked like 1 |
| | <i>RBMXL2</i> | RNA binding motif protein, X-linked like 2 |
| | <i>RBMXL3</i> | RNA binding motif protein, X-linked like 3 |
| | <i>HNRNPK</i> | heterogeneous nuclear ribonucleoprotein K |
| | <i>HNRNPM</i> | heterogeneous nuclear ribonucleoprotein M |
| | <i>HNRNPU</i> | heterogeneous nuclear ribonucleoprotein U |
| | <i>PCBP1</i> | poly(rC) binding protein 1 |
| | <i>SRSF1</i> | serine and arginine rich splicing factor 1 |
| | <i>SRSF2</i> | serine and arginine rich splicing factor 2 |
| | <i>SRSF8</i> | serine and arginine rich splicing factor 8 |
| | <i>SRSF3</i> | serine and arginine rich splicing factor 3 |
| | <i>SRSF4</i> | serine and arginine rich splicing factor 4 |
| | <i>SRSF5</i> | serine and arginine rich splicing factor 5 |
| | <i>SRSF6</i> | serine and arginine rich splicing factor 6 |
| | <i>SRSF7</i> | serine and arginine rich splicing factor 7 |
| | <i>SRSF9</i> | serine and arginine rich splicing factor 9 |
| | <i>TRA2A</i> | transformer 2 alpha homolog |
| | <i>TRA2B</i> | transformer 2 beta homolog |
| | <i>SRSF10</i> | serine and arginine rich splicing factor 10 |
| Hematopoietic cell lineage | <i>KITLG</i> | KIT ligand |
| | <i>IL7</i> | interleukin 7 |
| | <i>IL4</i> | interleukin 4 |
| | <i>CSF2</i> | colony stimulating factor 2 |
| | <i>FLT3LG</i> | fms related tyrosine kinase 3 ligand |
| | <i>IL5</i> | interleukin 5 |
| | <i>CSF3</i> | colony stimulating factor 3 |
| | <i>IL3</i> | interleukin 3 |
| | <i>IL6</i> | interleukin 6 |
| | <i>IL11</i> | interleukin 11 |
| | <i>IL1A</i> | interleukin 1 alpha |
| | <i>IL1B</i> | interleukin 1 beta |
| | <i>TNF</i> | tumor necrosis factor |
| | <i>CSF1</i> | colony stimulating factor 1 |
| | <i>EPO</i> | erythropoietin |
| | <i>THPO</i> | thrombopoietin |
| | <i>CD34</i> | CD34 molecule |
| | <i>FLT3</i> | fms related tyrosine kinase 3 |
| | <i>DNTT</i> | DNA nucleotidyltransferase |
| | <i>HLA-DMA</i> | major histocompatibility complex, class II, DM alpha |
| | <i>HLA-DMB</i> | major histocompatibility complex, class II, DM beta |
| | <i>HLA-DOA</i> | major histocompatibility complex, class II, DO alpha |
| | <i>HLA-DOB</i> | major histocompatibility complex, class II, DO beta |
| | <i>HLA-DPA1</i> | major histocompatibility complex, class II, DP alpha 1 |
| | <i>HLA-DPB1</i> | major histocompatibility complex, class II, DP beta 1 |
| | <i>HLA-DQA1</i> | major histocompatibility complex, class II, DQ alpha 1 |
| | <i>HLA-DQA2</i> | major histocompatibility complex, class II, DQ alpha 2 |
| | <i>HLA-DQB1</i> | major histocompatibility complex, class II, DQ beta 1 |
| | <i>HLA-DRA</i> | major histocompatibility complex, class II, DR alpha |
| | <i>HLA-DRB1</i> | major histocompatibility complex, class II, DR beta 1 |
| | <i>HLA-DRB3</i> | major histocompatibility complex, class II, DR beta 3 |
| | <i>HLA-DRB4</i> | major histocompatibility complex, class II, DR beta 4 |
| | <i>HLA-DRB5</i> | major histocompatibility complex, class II, DR beta 5 |
| | <i>CD44</i> | CD44 molecule (Indian blood group) |
| | <i>KIT</i> | KIT proto-oncogene receptor tyrosine kinase |

| | | |
|------------------------|-----------------|--|
| | <i>IL2RA</i> | interleukin 2 receptor subunit alpha |
| | <i>IL7R</i> | interleukin 7 receptor |
| | <i>TFRC</i> | transferrin receptor |
| | <i>CD38</i> | CD38 molecule |
| | <i>CD7</i> | CD7 molecule |
| | <i>CD2</i> | CD2 molecule |
| | <i>CD5</i> | CD5 molecule |
| | <i>CD1A</i> | CD1a molecule |
| | <i>CD1B</i> | CD1b molecule |
| | <i>CD1C</i> | CD1c molecule |
| | <i>CD1D</i> | CD1d molecule |
| | <i>CD1E</i> | CD1e molecule |
| | <i>CD4</i> | CD4 molecule |
| | <i>CD8A</i> | CD8a molecule |
| | <i>CD8B</i> | CD8b molecule |
| | <i>CD3D</i> | CD3d molecule |
| | <i>CD3E</i> | CD3e molecule |
| | <i>CD3G</i> | CD3g molecule |
| | <i>MME</i> | membrane metalloendopeptidase |
| | <i>CD9</i> | CD9 molecule |
| | <i>CD19</i> | CD19 molecule |
| | <i>CD22</i> | CD22 molecule |
| | <i>CD24</i> | CD24 molecule |
| | <i>MS4A1</i> | membrane spanning 4-domains A1 |
| | <i>CR2</i> | complement C3d receptor 2 |
| | <i>CD37</i> | CD37 molecule |
| | <i>IGH</i> | putative V-set and immunoglobulin domain-containing-like protein IGHV4OR15-8 |
| | <i>FCER2</i> | Fc fragment of IgE receptor II |
| | <i>CR1</i> | complement C3b/C4b receptor 1 (Knops blood group) |
| | <i>CSF2RA</i> | colony stimulating factor 2 receptor alpha subunit |
| | <i>IL3RA</i> | interleukin 3 receptor subunit alpha |
| | <i>CD33</i> | CD33 molecule |
| | <i>IL4R</i> | interleukin 4 receptor |
| | <i>IL6R</i> | interleukin 6 receptor |
| | <i>FCGR1A</i> | Fc fragment of IgG receptor Ia |
| | <i>CSF1R</i> | colony stimulating factor 1 receptor |
| | <i>ANPEP</i> | alanyl aminopeptidase, membrane |
| | <i>ITGAM</i> | integrin subunit alpha M |
| | <i>CD14</i> | CD14 molecule |
| | <i>IL9R</i> | interleukin 9 receptor |
| | <i>IL1R1</i> | interleukin 1 receptor type 1 |
| | <i>IL1R2</i> | interleukin 1 receptor type 2 |
| | <i>CSF3R</i> | colony stimulating factor 3 receptor |
| | <i>IL5RA</i> | interleukin 5 receptor subunit alpha |
| | <i>EPOR</i> | erythropoietin receptor |
| | <i>CD36</i> | CD36 molecule |
| | <i>GYPA</i> | glycophorin A (MNS blood group) |
| | <i>CD55</i> | CD55 molecule (Cromer blood group) |
| | <i>CD59</i> | CD59 molecule (CD59 blood group) |
| | <i>IL11RA</i> | interleukin 11 receptor subunit alpha |
| | <i>ITGB3</i> | integrin subunit beta 3 |
| | <i>ITGA2B</i> | integrin subunit alpha 2b |
| | <i>GP9</i> | glycoprotein IX platelet |
| | <i>GP1BA</i> | glycoprotein Ib platelet alpha subunit |
| | <i>GP1BB</i> | glycoprotein Ib platelet beta subunit |
| | <i>GP5</i> | glycoprotein V platelet |
| | <i>ITGA1</i> | integrin subunit alpha 1 |
| | <i>ITGA2</i> | integrin subunit alpha 2 |
| | <i>ITGA3</i> | integrin subunit alpha 3 |
| | <i>ITGA4</i> | integrin subunit alpha 4 |
| | <i>ITGA5</i> | integrin subunit alpha 5 |
| | <i>ITGA6</i> | integrin subunit alpha 6 |
| Acute myeloid leukemia | <i>KIT</i> | KIT proto-oncogene receptor tyrosine kinase |
| | <i>FLT3</i> | fms related tyrosine kinase 3 |
| | <i>PIK3CA</i> | phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha |
| | <i>PIK3CD</i> | phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta |
| | <i>PIK3CB</i> | phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta |
| | <i>PIK3R1</i> | phosphoinositide-3-kinase regulatory subunit 1 |
| | <i>PIK3R2</i> | phosphoinositide-3-kinase regulatory subunit 2 |
| | <i>PIK3R3</i> | phosphoinositide-3-kinase regulatory subunit 3 |
| | <i>AKT1</i> | AKT serine/threonine kinase 1 |
| | <i>AKT2</i> | AKT serine/threonine kinase 2 |
| | <i>AKT3</i> | AKT serine/threonine kinase 3 |
| | <i>CHUK</i> | conserved helix-loop-helix ubiquitous kinase |
| | <i>IKBKB</i> | inhibitor of nuclear factor kappa B kinase subunit beta |
| | <i>IKBKG</i> | inhibitor of nuclear factor kappa B kinase subunit gamma |
| | <i>NFKB1</i> | nuclear factor kappa B subunit 1 |
| | <i>RELA</i> | RELA proto-oncogene, NF-kB subunit |
| | <i>BAD</i> | BCL2 associated agonist of cell death |
| | <i>MTOR</i> | mechanistic target of rapamycin kinase |
| | <i>EIF4EBP1</i> | eukaryotic translation initiation factor 4E binding protein 1 |
| | <i>RPS6KB1</i> | ribosomal protein S6 kinase B1 |
| | <i>RPS6KB2</i> | ribosomal protein S6 kinase B2 |
| | <i>GRB2</i> | growth factor receptor bound protein 2 |
| | <i>SOS1</i> | SOS Ras/Rac guanine nucleotide exchange factor 1 |
| | <i>SOS2</i> | SOS Ras/Rho guanine nucleotide exchange factor 2 |
| | <i>HRAS</i> | HRas proto-oncogene, GTPase |
| | <i>NRAS</i> | NRas proto-oncogene, GTPase |
| | <i>KRAS</i> | KRas proto-oncogene, GTPase |

| | | |
|---|----------------|---|
| | <i>ARAF</i> | A-Raf proto-oncogene, serine/threonine kinase |
| | <i>BRAF</i> | B-Raf proto-oncogene, serine/threonine kinase |
| | <i>RAF1</i> | Raf-1 proto-oncogene, serine/threonine kinase |
| | <i>MAP2K1</i> | mitogen-activated protein kinase kinase 1 |
| | <i>MAP2K2</i> | mitogen-activated protein kinase kinase 2 |
| | <i>MAPK1</i> | mitogen-activated protein kinase 1 |
| | <i>MAPK3</i> | mitogen-activated protein kinase 3 |
| | <i>STAT3</i> | signal transducer and activator of transcription 3 |
| | <i>STAT5A</i> | signal transducer and activator of transcription 5A |
| | <i>STAT5B</i> | signal transducer and activator of transcription 5B |
| | <i>PIM1</i> | Pim-1 proto-oncogene, serine/threonine kinase |
| | <i>PIM2</i> | Pim-2 proto-oncogene, serine/threonine kinase |
| | <i>RUNX1</i> | runt related transcription factor 1 |
| | <i>CSF1R</i> | colony stimulating factor 1 receptor |
| | <i>MPO</i> | myeloperoxidase |
| | <i>CSF2</i> | colony stimulating factor 2 |
| | <i>IL3</i> | interleukin 3 |
| | <i>RUNX1T1</i> | RUNX1 translocation partner 1 |
| | <i>PML</i> | promyelocytic leukemia |
| | <i>RARA</i> | retinoic acid receptor alpha |
| | <i>ZBTB16</i> | zinc finger and BTB domain containing 16 |
| | <i>CEBPA</i> | CCAAT/enhancer binding protein alpha |
| | <i>PER2</i> | period circadian clock 2 |
| | <i>SPI1</i> | Spi-1 proto-oncogene |
| | <i>CD14</i> | CD14 molecule |
| | <i>ITGAM</i> | integrin subunit alpha M |
| | <i>FCGR1A</i> | Fc fragment of IgG receptor Ia |
| | <i>CEBPE</i> | CCAAT/enhancer binding protein epsilon |
| | <i>BCL2A1</i> | BCL2 related protein A1 |
| | <i>MYC</i> | MYC proto-oncogene, bHLH transcription factor |
| | <i>DUSP6</i> | dual specificity phosphatase 6 |
| | <i>JUP</i> | junction plakoglobin |
| | <i>TCF7</i> | transcription factor 7 |
| | <i>TCF7L1</i> | transcription factor 7 like 1 |
| | <i>TCF7L2</i> | transcription factor 7 like 2 |
| | <i>LEF1</i> | lymphoid enhancer binding factor 1 |
| | <i>CCND1</i> | cyclin D1 |
| | <i>PPARD</i> | peroxisome proliferator activated receptor delta |
| | <i>CCNA1</i> | cyclin A1 |
| Transcriptional misregulation in cancer | <i>RUNX1</i> | runt related transcription factor 1 |
| | <i>CSF1R</i> | colony stimulating factor 1 receptor |
| | <i>MPO</i> | myeloperoxidase |
| | <i>CSF2</i> | colony stimulating factor 2 |
| | <i>IL3</i> | interleukin 3 |
| | <i>RUNX1T1</i> | RUNX1 translocation partner 1 |
| | <i>HDAC1</i> | histone deacetylase 1 |
| | <i>HDAC2</i> | histone deacetylase 2 |
| | <i>SIN3A</i> | SIN3 transcription regulator family member A |
| | <i>NCOR1</i> | nuclear receptor corepressor 1 |
| | <i>CEBPA</i> | CCAAT/enhancer binding protein alpha |
| | <i>PER2</i> | period circadian clock 2 |
| | <i>SPI1</i> | Spi-1 proto-oncogene |
| | <i>CD14</i> | CD14 molecule |
| | <i>ITGAM</i> | integrin subunit alpha M |
| | <i>FCGR1A</i> | Fc fragment of IgG receptor Ia |
| | <i>JUP</i> | junction plakoglobin |
| | <i>PML</i> | promyelocytic leukemia |
| | <i>RARA</i> | retinoic acid receptor alpha |
| | <i>CEBPE</i> | CCAAT/enhancer binding protein epsilon |
| | <i>BCL2A1</i> | BCL2 related protein A1 |
| | <i>ZBTB16</i> | zinc finger and BTB domain containing 16 |
| | <i>MYC</i> | MYC proto-oncogene, bHLH transcription factor |
| | <i>DUSP6</i> | dual specificity phosphatase 6 |
| | <i>TCF3</i> | transcription factor 3 |
| | <i>PBX1</i> | PBX homeobox 1 |
| | <i>WNT16</i> | Wnt family member 16 |
| | <i>ETV6</i> | ETS variant 6 |
| | <i>ETV7</i> | ETS variant 7 |
| | <i>ELANE</i> | elastase, neutrophil expressed |
| | <i>GZMB</i> | granzyme B |
| | <i>KMT2A</i> | lysine methyltransferase 2A |
| | <i>AF4F1</i> | AF4/FMR2 family member 1 |
| | <i>CDK9</i> | cyclin dependent kinase 9 |
| | <i>CCNT1</i> | cyclin T1 |
| | <i>CCNT2</i> | cyclin T2 |
| | <i>MLLT1</i> | MLLT1, super elongation complex subunit |
| | <i>MLLT3</i> | MLLT3, super elongation complex subunit |
| | <i>DOT1L</i> | DOT1 like histone lysine methyltransferase |
| | <i>LMO2</i> | LIM domain only 2 |
| | <i>PBX3</i> | PBX homeobox 3 |
| | <i>RUNX2</i> | runt related transcription factor 2 |
| | <i>SMAD1</i> | SMAD family member 1 |
| | <i>KLF3</i> | Kruppel like factor 3 |
| | <i>MEF2C</i> | myocyte enhancer factor 2C |
| | <i>HOXA9</i> | homeobox A9 |
| | <i>HOXA10</i> | homeobox A10 |
| | <i>JMD1C</i> | jumonji domain containing 1C |
| | <i>HMGAA2</i> | high mobility group AT-hook 2 |
| | <i>KDM6A</i> | lysine demethylase 6A |

| | |
|--------------------|--|
| UTY | ubiquitously transcribed tetratricopeptide repeat containing, Y-linked |
| <i>SUPT3H</i> | SPT3 homolog, SAGA and STAGA complex component |
| <i>PROM1</i> | prominin 1 |
| <i>FLT3</i> | fms related tyrosine kinase 3 |
| <i>BMP2K</i> | BMP2 inducible kinase |
| <i>IGF1R</i> | insulin like growth factor 1 receptor |
| <i>CDKN1B</i> | cyclin dependent kinase inhibitor 1B |
| <i>CDK14</i> | cyclin dependent kinase 14 |
| <i>MEIS1</i> | Meis homeobox 1 |
| <i>HOXA11</i> | homeobox A11 |
| <i>SIX1</i> | SIX homeobox 1 |
| <i>SIX4</i> | SIX homeobox 4 |
| <i>EYA1</i> | EYA transcriptional coactivator and phosphatase 1 |
| <i>CDKN2C</i> | cyclin dependent kinase inhibitor 2C |
| <i>HPGD</i> | 15-hydroxyprostaglandin dehydrogenase |
| <i>GRIA3</i> | glutamate ionotropic receptor AMPA type subunit 3 |
| <i>FUT8</i> | fucosyltransferase 8 |
| <i>TLX3</i> | T-cell leukemia homeobox 3 |
| <i>TLX1</i> | T-cell leukemia homeobox 1 |
| <i>BCL11B</i> | B-cell CLL/lymphoma 11B |
| <i>LDB1</i> | LIM domain binding 1 |
| <i>LYL1</i> | LYL1, basic helix-loop-helix family member |
| <i>HHEX</i> | hematopoietically expressed homeobox |
| <i>PTCRA</i> | pre T-cell antigen receptor alpha |
| <i>REL</i> | REL proto-oncogene, NF-kB subunit |
| <i>CCND2</i> | cyclin D2 |
| <i>TRAF1</i> | TNF receptor associated factor 1 |
| <i>BCL2L1</i> | BCL2 like 1 |
| <i>CD86</i> | CD86 molecule |
| <i>CD40</i> | CD40 molecule |
| <i>BCL6</i> | B-cell CLL/lymphoma 6 |
| <i>IGH</i> | putative V-set and immunoglobulin domain-containing-like protein IGHV4OR15-8 |
| <i>MAF</i> | MAF bZIP transcription factor |
| <i>ITGB7</i> | integrin subunit beta 7 |
| <i>NSD2</i> | nuclear receptor binding SET domain protein 2 |
| <i>H3F3C</i> | H3 histone family member 3C |
| <i>H3F3B</i> | H3 histone family member 3B |
| <i>HIST1H3D</i> | histone cluster 1 H3 family member d |
| <i>HIST1H3C</i> | histone cluster 1 H3 family member c |
| <i>HIST1H3A</i> | histone cluster 1 H3 family member a |
| <i>H3F3A</i> | H3 histone family member 3A |
| <i>HIST3H3</i> | histone cluster 3 H3 |
| <i>HIST2H3C</i> | histone cluster 2 H3 family member c |
| <i>HIST2H3A</i> | histone cluster 2 H3 family member a |
| <i>HIST2H3D</i> | histone cluster 2 H3 family member d |
| <i>HIST1H3E</i> | histone cluster 1 H3 family member e |
| <i>HIST1H3I</i> | histone cluster 1 H3 family member i |
| <i>HIST1H3G</i> | histone cluster 1 H3 family member g |
| <i>HIST1H3J</i> | histone cluster 1 H3 family member j |
| <i>HIST1H3H</i> | histone cluster 1 H3 family member h |
| <i>HIST1H3B</i> | histone cluster 1 H3 family member b |
| <i>HIST1H3F</i> | histone cluster 1 H3 family member f |
| <i>PAX5</i> | paired box 5 |
| <i>PAX8</i> | paired box 8 |
| <i>PPARG</i> | peroxisome proliferator activated receptor gamma |
| <i>RXRA</i> | retinoid X receptor alpha |
| <i>RXRB</i> | retinoid X receptor beta |
| <i>RXRG</i> | retinoid X receptor gamma |
| <i>PRCC</i> | papillary renal cell carcinoma (translocation-associated) |
| <i>TFE3</i> | transcription factor binding to IGHM enhancer 3 |
| <i>CDKN1A</i> | cyclin dependent kinase inhibitor 1A |
| <i>TMPRSS2</i> | transmembrane protease, serine 2 |
| <i>ERG</i> | ERG, ETS transcription factor |
| <i>PLAU</i> | plasminogen activator, urokinase |
| <i>PLAT</i> | plasminogen activator, tissue type |
| <i>MMP3</i> | matrix metallopeptidase 3 |
| <i>MMP9</i> | matrix metalloproteinase 9 |
| <i>IL1R2</i> | interleukin 1 receptor type 2 |
| <i>SPINT1</i> | serine peptidase inhibitor, Kunitz type 1 |
| <i>ETV1</i> | ETS variant 1 |
| <i>ETV4</i> | ETS variant 4 |
| <i>ETV5</i> | ETS variant 5 |
| <i>SLC45A3</i> | solute carrier family 45 member 3 |
| <i>ELK4</i> | ELK4, ETS transcription factor |
| <i>DDX5</i> | DEAD-box helicase 5 |
| <i>MYCN</i> | MYCN proto-oncogene, bHLH transcription factor |
| <i>MAX</i> | MYC associated factor X |
| <i>MDM2</i> | MDM2 proto-oncogene |
| <i>PTK2</i> | protein tyrosine kinase 2 |
| <i>TP53</i> | tumor protein p53 |
| <i>BMI1</i> | BMI1 proto-oncogene, polycomb ring finger |
| <i>COMMD3-BMI1</i> | COMMD3-BMI1 readthrough |
| <i>SP1</i> | Sp1 transcription factor |
| <i>ZBTB17</i> | zinc finger and BTB domain containing 17 |
| <i>NTRK1</i> | neurotrophic receptor tyrosine kinase 1 |
| <i>NGFR</i> | nerve growth factor receptor |
| <i>MEN1</i> | menin 1 |
| <i>EWSR1</i> | EWS RNA binding protein 1 |
| <i>FLI1</i> | Fli-1 proto-oncogene, ETS transcription factor |

| | | |
|--|----------------|--|
| | <i>IGF1</i> | insulin like growth factor 1 |
| | <i>ID2</i> | inhibitor of DNA binding 2, HLH protein |
| | <i>TGFBR2</i> | transforming growth factor beta receptor 2 |
| | <i>IGFBP3</i> | insulin like growth factor binding protein 3 |
| | <i>FEV</i> | FEV, ETS transcription factor |
| | <i>ATF1</i> | activating transcription factor 1 |
| | <i>ARNT2</i> | aryl hydrocarbon receptor nuclear translocator 2 |
| | <i>ATM</i> | ATM serine/threonine kinase |
| | <i>MITF</i> | melanogenesis associated transcription factor |
| | <i>WT1</i> | Wilms tumor 1 |
| | <i>PDGFA</i> | platelet derived growth factor subunit A |
| | <i>IL2RB</i> | interleukin 2 receptor subunit beta |
| | <i>BAIAP3</i> | BAI1 associated protein 3 |
| | <i>TSPAN7</i> | tetraspanin 7 |
| | <i>MLF1</i> | myeloid leukemia factor 1 |
| | <i>NR4A3</i> | nuclear receptor subfamily 4 group A member 3 |
| | <i>TAF15</i> | TATA-box binding protein associated factor 15 |
| | <i>FUS</i> | FUS RNA binding protein |
| | <i>DDIT3</i> | DNA damage inducible transcript 3 |
| | <i>CEBPB</i> | CCAAT/enhancer binding protein beta |
| | <i>IL6</i> | interleukin 6 |
| | <i>NFKBIZ</i> | NFKB inhibitor zeta |
| | <i>NFKB1</i> | nuclear factor kappa B subunit 1 |
| | <i>RELA</i> | RELA proto-oncogene, NF-kB subunit |
| | <i>CXCL8</i> | C-X-C motif chemokine ligand 8 |
| | <i>FOXO1</i> | forkhead box O1 |
| | <i>FLT1</i> | fms related tyrosine kinase 1 |
| | <i>SS18</i> | SS18, nBAF chromatin remodeling complex subunit |
| | <i>SSX1</i> | SSX family member 1 |
| | <i>SSX2</i> | SSX family member 2 |
| | <i>SSX2B</i> | SSX family member 2B |
| | <i>NUPR1</i> | nuclear protein 1, transcriptional regulator |
| | <i>ASPSKR1</i> | ASPSKR1, UBX domain containing tether for SLC2A4 |
| | <i>MET</i> | MET proto-oncogene, receptor tyrosine kinase |
| | <i>GADD45A</i> | growth arrest and DNA damage inducible alpha |
| | <i>GADD45B</i> | growth arrest and DNA damage inducible beta |
| | <i>GADD45G</i> | growth arrest and DNA damage inducible gamma |
| | <i>BAX</i> | BCL2 associated X, apoptosis regulator |
| | <i>BAK1</i> | BCL2 antagonist/killer 1 |
| | <i>DDB2</i> | damage specific DNA binding protein 2 |
| | <i>POLK</i> | DNA polymerase kappa |
| | <i>DEFA3</i> | defensin alpha 3 |
| | <i>BIRC3</i> | baculoviral IAP repeat containing 3 |
| | <i>PAX3</i> | paired box 3 |
| | <i>PAX7</i> | paired box 7 |
| | <i>ZEB1</i> | zinc finger E-box binding homeobox 1 |
| | <i>CCNA1</i> | cyclin A1 |
| Signaling pathways regulating pluripotency of stem cells | <i>LIF</i> | LIF, interleukin 6 family cytokine |
| | <i>LIFR</i> | LIF receptor alpha |
| | <i>IL6ST</i> | interleukin 6 signal transducer |
| | <i>JAK1</i> | Janus kinase 1 |
| | <i>JAK2</i> | Janus kinase 2 |
| | <i>JAK3</i> | Janus kinase 3 |
| | <i>STAT3</i> | signal transducer and activator of transcription 3 |
| | <i>KLF4</i> | Kruppel like factor 4 |
| | <i>SOX2</i> | SRY-box 2 |
| | <i>MYC</i> | MYC proto-oncogene, bHLH transcription factor |
| | <i>GRB2</i> | growth factor receptor bound protein 2 |
| | <i>MAP2K1</i> | mitogen-activated protein kinase kinase 1 |
| | <i>MAP2K2</i> | mitogen-activated protein kinase kinase 2 |
| | <i>MAPK1</i> | mitogen-activated protein kinase 1 |
| | <i>MAPK3</i> | mitogen-activated protein kinase 3 |
| | <i>PIK3CA</i> | phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha |
| | <i>PIK3CD</i> | phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta |
| | <i>PIK3CB</i> | phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta |
| | <i>PIK3R1</i> | phosphoinositide-3-kinase regulatory subunit 1 |
| | <i>PIK3R2</i> | phosphoinositide-3-kinase regulatory subunit 2 |
| | <i>PIK3R3</i> | phosphoinositide-3-kinase regulatory subunit 3 |
| | <i>AKT1</i> | AKT serine/threonine kinase 1 |
| | <i>AKT2</i> | AKT serine/threonine kinase 2 |
| | <i>AKT3</i> | AKT serine/threonine kinase 3 |
| | <i>TBX3</i> | T-box 3 |
| | <i>NANOG</i> | Nanog homeobox |
| | <i>INHBA</i> | inhibin beta A subunit |
| | <i>INHBB</i> | inhibin beta B subunit |
| | <i>INHBC</i> | inhibin beta C subunit |
| | <i>INHBE</i> | inhibin beta E subunit |
| | <i>NODAL</i> | nodal growth differentiation factor |
| | <i>ACVR1B</i> | activin A receptor type 1B |
| | <i>ACVR1C</i> | activin A receptor type 1C |
| | <i>ACVR2A</i> | activin A receptor type 2A |
| | <i>ACVR2B</i> | activin A receptor type 2B |
| | <i>SMAD2</i> | SMAD family member 2 |
| | <i>SMAD3</i> | SMAD family member 3 |
| | <i>BMP4</i> | bone morphogenetic protein 4 |
| | <i>BMPR1A</i> | bone morphogenetic protein receptor type 1A |
| | <i>BMPR1B</i> | bone morphogenetic protein receptor type 1B |
| | <i>ACVR1</i> | activin A receptor type 1 |
| | <i>BMPR2</i> | bone morphogenetic protein receptor type 2 |

| | |
|--------------------|---|
| <i>SMAD1</i> | SMAD family member 1 |
| <i>SMAD5</i> | SMAD family member 5 |
| <i>SMAD9</i> | SMAD family member 9 |
| <i>SMAD4</i> | SMAD family member 4 |
| <i>ID1</i> | inhibitor of DNA binding 1, HLH protein |
| <i>ID2</i> | inhibitor of DNA binding 2, HLH protein |
| <i>ID3</i> | inhibitor of DNA binding 3, HLH protein |
| <i>ID4</i> | inhibitor of DNA binding 4, HLH protein |
| <i>DUSP9</i> | dual specificity phosphatase 9 |
| <i>MAPK11</i> | mitogen-activated protein kinase 11 |
| <i>MAPK12</i> | mitogen-activated protein kinase 12 |
| <i>MAPK13</i> | mitogen-activated protein kinase 13 |
| <i>MAPK14</i> | mitogen-activated protein kinase 14 |
| <i>WNT1</i> | Wnt family member 1 |
| <i>WNT2</i> | Wnt family member 2 |
| <i>WNT2B</i> | Wnt family member 2B |
| <i>WNT3</i> | Wnt family member 3 |
| <i>WNT3A</i> | Wnt family member 3A |
| <i>WNT4</i> | Wnt family member 4 |
| <i>WNT5A</i> | Wnt family member 5A |
| <i>WNT5B</i> | Wnt family member 5B |
| <i>WNT6</i> | Wnt family member 6 |
| <i>WNT7A</i> | Wnt family member 7A |
| <i>WNT7B</i> | Wnt family member 7B |
| <i>WNT8A</i> | Wnt family member 8A |
| <i>WNT8B</i> | Wnt family member 8B |
| <i>WNT9A</i> | Wnt family member 9A |
| <i>WNT9B</i> | Wnt family member 9B |
| <i>WNT10B</i> | Wnt family member 10B |
| <i>WNT10A</i> | Wnt family member 10A |
| <i>WNT11</i> | Wnt family member 11 |
| <i>WNT16</i> | Wnt family member 16 |
| <i>FZD1</i> | frizzled class receptor 1 |
| <i>FZD7</i> | frizzled class receptor 7 |
| <i>FZD2</i> | frizzled class receptor 2 |
| <i>FZD3</i> | frizzled class receptor 3 |
| <i>FZD4</i> | frizzled class receptor 4 |
| <i>FZD5</i> | frizzled class receptor 5 |
| <i>FZD8</i> | frizzled class receptor 8 |
| <i>FZD6</i> | frizzled class receptor 6 |
| <i>FZD10</i> | frizzled class receptor 10 |
| <i>FZD9</i> | frizzled class receptor 9 |
| <i>DVL3</i> | dishevelled segment polarity protein 3 |
| <i>DVL2</i> | dishevelled segment polarity protein 2 |
| <i>DVL1</i> | dishevelled segment polarity protein 1 |
| <i>GSK3B</i> | glycogen synthase kinase 3 beta |
| <i>AXIN1</i> | axin 1 |
| <i>AXIN2</i> | axin 2 |
| <i>APC</i> | APC, WNT signaling pathway regulator |
| <i>APC2</i> | APC2, WNT signaling pathway regulator |
| <i>CTNNB1</i> | catenin beta 1 |
| <i>TCF3</i> | transcription factor 3 |
| <i>ESRRB</i> | estrogen related receptor beta |
| <i>HNF1A</i> | HNF1 homeobox A |
| <i>POU5F1</i> | POU class 5 homeobox 1 |
| <i>POU5F1B</i> | POU class 5 homeobox 1B |
| <i>FGF2</i> | fibroblast growth factor 2 |
| <i>FGFR1</i> | fibroblast growth factor receptor 1 |
| <i>FGFR2</i> | fibroblast growth factor receptor 2 |
| <i>FGFR3</i> | fibroblast growth factor receptor 3 |
| <i>FGFR4</i> | fibroblast growth factor receptor 4 |
| <i>HRAS</i> | HRas proto-oncogene, GTPase |
| <i>KRAS</i> | KRAS proto-oncogene, GTPase |
| <i>NRAS</i> | NRAS proto-oncogene, GTPase |
| <i>RAF1</i> | Raf-1 proto-oncogene, serine/threonine kinase |
| <i>IGF1</i> | insulin like growth factor 1 |
| <i>IGF1R</i> | insulin like growth factor 1 receptor |
| <i>HESX1</i> | HESX homeobox 1 |
| <i>ZIC3</i> | Zic family member 3 |
| <i>SKIL</i> | SKI like proto-oncogene |
| <i>SMARCAD1</i> | SWI/SNF-related, matrix-associated actin-dependent regulator of chromatin, subfamily a, containing DEAD/H box 1 |
| <i>KAT6A</i> | lysine acetyltransferase 6A |
| <i>SETDB1</i> | SET domain bifurcated 1 |
| <i>JARID2</i> | jumonji and AT-rich interaction domain containing 2 |
| <i>REST</i> | RE1 silencing transcription factor |
| <i>RIF1</i> | replication timing regulatory factor 1 |
| <i>PCGF1</i> | polycomb group ring finger 1 |
| <i>PCGF2</i> | polycomb group ring finger 2 |
| <i>PCGF3</i> | polycomb group ring finger 3 |
| <i>BMI1</i> | BMI1 proto-oncogene, polycomb ring finger |
| <i>COMMD3-BMI1</i> | COMMD3-BMI1 readthrough |
| <i>PCGF5</i> | polycomb group ring finger 5 |
| <i>PCGF6</i> | polycomb group ring finger 6 |
| <i>PAX6</i> | paired box 6 |
| <i>MEIS1</i> | Meis homeobox 1 |
| <i>LHX5</i> | LIM homeobox 5 |
| <i>OTX1</i> | orthodenticle homeobox 1 |
| <i>NEUROG1</i> | neurogenin 1 |
| <i>HAND1</i> | heart and neural crest derivatives expressed 1 |

| | | |
|-----------------------|----------------|---|
| | <i>DLX5</i> | distal-less homeobox 5 |
| | <i>MYF5</i> | myogenic factor 5 |
| | <i>ONECUT1</i> | one cut homeobox 1 |
| | <i>ISL1</i> | ISL LIM homeobox 1 |
| | <i>ZFHX3</i> | zinc finger homeobox 3 |
| | <i>ESX1</i> | ESX homeobox 1 |
| | <i>HOXB1</i> | homeobox B1 |
| | <i>LEFTY2</i> | left-right determination factor 2 |
| Myeloid genes | <i>FLT3</i> | fms related tyrosine kinase 3 |
| | <i>NPM1</i> | Nucleophosmin |
| | <i>DNMT3A</i> | DNA methyltransferase 3 alpha |
| | <i>NRAS</i> | NRAS proto-oncogene, GTPase |
| | <i>TET2</i> | Tet methylcytosine dioxygenase 2 |
| | <i>IDH2</i> | Isocitrate dehydrogenase (NADP(+)) 2 |
| | <i>CEBPA</i> | CCAAT/enhancer binding protein alpha |
| | <i>RUNX1</i> | runt related transcription factor 1 |
| | <i>PTPN11</i> | protein_tyrosine_phosphatase_non-receptor_type_11 |
| | <i>IDH1</i> | Isocitrate dehydrogenase (NADP(+)) 1 |
| | <i>TP53</i> | tumor protein p53 |
| | <i>SRSF2</i> | serine and arginine rich splicing factor 2 |
| | <i>WT1</i> | Wilms tumor 1 |
| | <i>KRAS</i> | KRAS proto-oncogene, GTPase |
| | <i>ASXL1</i> | Additional sex combs like 1, transcriptional regulator |
| | <i>KIT</i> | KIT proto-oncogene receptor tyrosine kinase |
| | <i>STAG2</i> | stromal antigen 2 |
| | <i>RAD21</i> | RAD21 cohesin complex component |
| | <i>EZH2</i> | Enhancer of zeste 2 polycomb |
| | <i>PHF6</i> | PHD finger protein 6 |
| | <i>SF3B1</i> | splicing factor 3b subunit 1 |
| | <i>GATA2</i> | GATA2 binding protein |
| | <i>BCOR</i> | BCL6 corepressor |
| | <i>CBL</i> | Cbl proto-oncogene |
| | <i>U2AF1</i> | U2 small nuclear RNA auxiliary factor 1 |
| | <i>NF1</i> | neurofibromin 1 |
| | <i>MYC</i> | v-myc_avian_myelocytomatis_viral_oncogene_homolog |
| | <i>EP300</i> | EA1 binding protein p300 |
| | <i>ETV6</i> | ETS variant 6 |
| | <i>KDM5A</i> | Lysine demethylase 5A |
| | <i>ZRSR2</i> | Zinc finger CCCH-type, RNA binding motif and serine/arginine rich 2 |
| | <i>JAK2</i> | Janus kinase 2 |
| | <i>CREBBP</i> | CREB binding protein |
| | <i>KDM6A</i> | lysine demethylase 6A |
| | <i>BRAF</i> | B-Raf proto-oncogene, serine/threonine kinase |
| | <i>FBXW7</i> | F-box and WD repeat domain containing 7 |
| | <i>ATRX</i> | ATRX, chromatin remodeler |
| | <i>CUX1</i> | Cut like homeobox 1 |
| | <i>RB1</i> | RB_transcriptional_corepressor_1 |
| | <i>MPL</i> | MPL proto-oncogene, thrombopoietin receptor |
| | <i>CDKN2A</i> | cyclin-dependent_kinase_inhibitor_2A |
| | <i>GNAS</i> | GNAS complex locus |
| | <i>SF1</i> | splicing factor 1 |
| | <i>U2AF2</i> | U2 small nuclear RNA auxiliary factor 2 |
| | <i>CBLB</i> | Cbl_proto-oncogene_B |
| | <i>IKZF1</i> | IKAROS_family_zinc_finger_1 |
| | <i>SF3A1</i> | splicing factor 3a subunit 1 |
| | <i>SH2B3</i> | SH2B adaptor protein 3 |
| | <i>KMT2A</i> | lysine methyltransferase 2A |
| | <i>KMT2B</i> | lysine methyltransferase 2B |
| | <i>KMT2C</i> | lysine methyltransferase 2C |
| | <i>KMT2E</i> | lysine methyltransferase 2E |
| | <i>KMT2D</i> | lysine methyltransferase 2D |
| Cancer predisposition | <i>ACD</i> | ACD, shelterin complex subunit and telomerase recruitment factor |
| | <i>AIP</i> | Aryl hydrocarbon receptor interacting protein |
| | <i>APC</i> | APC, WNT signaling pathway regulator |
| | <i>ATM</i> | ATM serine/threonine kinase |
| | <i>ATR</i> | ATR serine/threonine kinase |
| | <i>AXIN2</i> | axin 2 |
| | <i>BAP1</i> | BRCA1 associated protein 1 |
| | <i>BARD1</i> | BRCA1 associated ring domain 1 |
| | <i>BLM</i> | Bloom syndrome RecQ like helicase |
| | <i>BMPR1A</i> | bone morphogenetic protein receptor type 1A |
| | <i>BRCA1</i> | BRCA1_DNA_repair_associated |
| | <i>BRCA2</i> | BRCA2_DNA_repair_associated |
| | <i>BRIP1</i> | BRCA1 interacting_protein_C-terminal helicase 1 |
| | <i>BUB1</i> | BUB1 mitotic checkpoint serine/threonine kinase |
| | <i>CDH1</i> | cadherin 1 |
| | <i>CDK4</i> | cyclin dependent kinase 4 |
| | <i>CDKN1B</i> | cyclin dependent kinase inhibitor 1B |
| | <i>CDKN2A</i> | cyclin-dependent_kinase_inhibitor_2A |
| | <i>CHEK2</i> | checkpoint kinase 2 |
| | <i>DDB2</i> | damage specific DNA binding protein 2 |
| | <i>DICER1</i> | Dicer 1, ribonuclease III |
| | <i>DIS3L2</i> | |
| | <i>DKC1</i> | Dyskerin pseudouridine synthase 1 |
| | <i>ELANE</i> | elastase, neutrophil expressed |
| | <i>EPAS1</i> | Endothelial PAS domain protein 1 |
| | <i>EPCAM</i> | Epithelial cell adhesion molecule |
| | <i>ERCC1</i> | ERCC excision repair 1, endonuclease non-catalytic subunit |
| | <i>ERCC2</i> | ERCC excision repair 2, endonuclease non-catalytic subunit |

| | |
|----------------|---|
| <i>ERCC3</i> | ERCC excision repair 3, endonuclease non-catalytic subunit |
| <i>ERCC4</i> | ERCC excision repair 4, endonuclease non-catalytic subunit |
| <i>ERCC5</i> | ERCC excision repair 5, endonuclease non-catalytic subunit |
| <i>ERCC6</i> | ERCC excision repair 6, endonuclease non-catalytic subunit |
| <i>FANCA</i> | Fanconi anemia complementation group A |
| <i>FANCB</i> | Fanconi anemia complementation group B |
| <i>FANCC</i> | Fanconi anemia complementation group C |
| <i>FANCD2</i> | Fanconi anemia complementation group D2 |
| <i>FANCE</i> | Fanconi anemia complementation group E |
| <i>FANCF</i> | Fanconi anemia complementation group F |
| <i>FANCG</i> | Fanconi anemia complementation group G |
| <i>FANCI</i> | Fanconi anemia complementation group I |
| <i>FANCL</i> | Fanconi anemia complementation group L |
| <i>FANCM</i> | Fanconi anemia complementation group M |
| <i>FH</i> | Fumarate hydratase |
| <i>FLCN</i> | folliculin |
| <i>G6PC3</i> | glucose-6-phosphatase catalytic subunit 3 |
| <i>GFI1</i> | Growth factor independent 1 transcriptional repressor |
| <i>GREM1</i> | Gremlin 1. DAN family BMP antagonist |
| <i>HOXB13</i> | Homeobox B13 |
| <i>JAGN1</i> | Jagunal homolog 1 |
| <i>KIF1B</i> | Kinesin family member 1B |
| <i>KIT</i> | KIT proto-oncogene receptor tyrosine kinase |
| <i>MAX</i> | MYC associated factor X |
| <i>MDH2</i> | malate dehydrogenase 2 |
| <i>MEN1</i> | menin 1 |
| <i>MET</i> | MET proto-oncogene, receptor tyrosine kinase |
| <i>MITF</i> | melanogenesis associated transcription factor |
| <i>MLH1</i> | MutL homolog 1 |
| <i>MNX1</i> | Motor neuron and pancreas homeobox 1 |
| <i>MSH2</i> | MutS homolog 2 |
| <i>MSH6</i> | MutS homolog 6 |
| <i>MSR1</i> | Macrophage scavenger receptor 1 |
| <i>MUTYH</i> | MutY DNA glycosylase |
| <i>NBN</i> | nibrin |
| <i>NF2</i> | neurofibromin 2 |
| <i>NFIX</i> | Nuclear factor I X |
| <i>NHP2</i> | NHP2 ribonucleoprotein |
| <i>NOP10</i> | NOP10 ribonucleoprotein |
| <i>NSD1</i> | nuclear receptor binding SET domain protein 1 |
| <i>NTHL1</i> | Nth like DNA glycosylase 1 |
| <i>PALB2</i> | Partner and localizer of BRCA2 |
| <i>PARN</i> | Poly(A)-specific ribonuclease |
| <i>PDGFRA</i> | Platelet derived growth factor receptor alpha |
| <i>PMS1</i> | PMS1 homolog 1, mismatched repair system component |
| <i>POLD1</i> | DNA polymerase delta 1, catalytic subunit |
| <i>POLE</i> | DNA polymerase epsilon, catalytic subunit |
| <i>POLH</i> | DNA polymerase eta |
| <i>POT1</i> | Protection of telomeres 1 |
| <i>PRKAR1A</i> | Protein kinase cAMP-dependent type I regulatory subunit alpha |
| <i>PTCH1</i> | patched 1 |
| <i>PTEN</i> | phosphatase_and_tensin_homolog |
| <i>RAD50</i> | RAD50 double strand break repair protein |
| <i>RAD51</i> | RAD51 recombinase |
| <i>RAD51C</i> | RAD51 paralog C |
| <i>RAD51D</i> | RAD51 paralog D |
| <i>RB1</i> | RB_transcriptional_corepressor_1 |
| <i>RECQL</i> | RecQ like helicase |
| <i>RECOL4</i> | RecQLike helicase 4 |
| <i>RET</i> | Ret proto-oncogene |
| <i>RTEL1</i> | regulator of telomere elongation helicase 1 |
| <i>SCG5</i> | Secretogranin V |
| <i>SLX4</i> | SLX4 structure-specific endonuclease subunit |
| <i>SMAD4</i> | SMAD family member 4 |
| <i>SMARCA4</i> | SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily a, member 4 |
| <i>STK11</i> | serine/threonine kinase 11 |
| <i>SUFU</i> | SUFU negative regulator of hedgehog signaling |
| <i>TERC</i> | Telomerase RNA component |
| <i>TERT</i> | Telomerase reverse transcriptase |
| <i>TINF2</i> | TERF1 interacting nuclear factor 2 |
| <i>TMEM127</i> | Transmembrane protein 127 |
| <i>TP53</i> | tumor protein p53 |
| <i>TSC1</i> | TSC complex subunit 1 |
| <i>TSC2</i> | TSC complex subunit 2 |
| <i>UBE2T</i> | Ubiquitin conjugation enzyme E2 |
| <i>VHL</i> | Von Hippel-Lindau tumor suppressor |
| <i>VPS45</i> | Vacuolar protein sorting 45 homolog |
| <i>WAS</i> | Wiskott-Aldrich syndrome |
| <i>WRN</i> | Werner syndrome RecQLike helicase |
| <i>WT1</i> | Wilms tumor 1 |
| <i>XPA</i> | XPA, DNA damage recognition and repair factor |
| <i>XPC</i> | XPC complex subunit, DNA damage recognition and repair factor |
| <i>XRCC2</i> | X-ray repair cross complementing 2 |
| <i>SRP72</i> | Signal recognition particle 72 |
| <i>HAX1</i> | HCLS1 associated protein X-1 |
| <i>RBBP6</i> | Rbbinding protein 6, ubiquitin ligase |
| <i>PAX5</i> | paired box 5 |
| <i>HOXD4</i> | Homeobox D4 |
| <i>HOXB5</i> | Homeobox B5 |

| | | |
|-----------------------------|-----------------|--|
| | <i>HOXB7</i> | Homeobox B7 |
| | <i>HOXD9</i> | Homeobox B9 |
| | <i>HOXD10</i> | Homeobox B10 |
| | <i>HOXD12</i> | Homeobox B12 |
| | <i>FANCV</i> | Mitotic arrest deficient 2 like 2 |
| | <i>SAMD9</i> | Sterile alpha motif domain containing 9 |
| | <i>SAMD9L</i> | Sterile alpha motif domain containing 9 like |
| | <i>ATG2B</i> | Autophagy related 2B |
| | <i>GSKIP</i> | GSK3B interacting protein |
| | <i>CTC1</i> | CST telomere replication complex component 1 |
| | <i>WRAP53</i> | WD repeat containing antisense to TP53 |
| | <i>NAF1</i> | Nuclear assembly factor 1 ribonucleoprotein |
| | <i>STN1</i> | STN1, CST complex subunit |
| | <i>USP1</i> | U6 snRNA biogenesis phosphodiesterase 1 |
| Primary Immunodeficiency | <i>IL2RG</i> | interleukin_2_receptor_subunit_gamma |
| | <i>JAK3</i> | Janus kinase 3 |
| | <i>IL7R</i> | interleukin_7_receptor |
| | <i>PTPRC</i> | protein_tyrosine_phosphatase_receptor_type_C |
| | <i>CD3D</i> | CD3d_molecule |
| | <i>CORO1A</i> | coronin 1A |
| | <i>CD3E</i> | CD3e_molecule |
| | <i>CD3G</i> | CD3g_molecule |
| | <i>RAG1</i> | recombination activating 1 |
| | <i>RAG2</i> | recombination activating 2 |
| | <i>DCLRE1C</i> | DNA cross-link repair 1C |
| | <i>PRKDC</i> | protein kinase, DNA-activated, catalytic polypeptide |
| | <i>AK2</i> | Adenylate kinase 2 |
| | <i>ADA</i> | Adenosin deaminase |
| | <i>LIG4</i> | DNA ligase 4 |
| | <i>NHEJ1</i> | Non-homologous end joining factor 1 |
| | <i>PNP</i> | Purine nucleoside phosphorylase |
| | <i>CD8A</i> | CD8a_molecule |
| | <i>ZAP70</i> | zeta_chain_of_T_cell_receptor_associated_protein_kinase_70kDa |
| | <i>TAP2</i> | Transporter 2, ATP binding cassette subfamily B member |
| | <i>ORAI1</i> | ORAI calcium release-activated calcium modulator 1 |
| | <i>STIM1</i> | Stromal interaction molecule 1 |
| | <i>TAP1</i> | transporter_1_ATP-binding_cassette_sub-family_B_MDR_TAP |
| | <i>RFX5</i> | Regulatory factor X5 |
| | <i>FOXN1</i> | Forkhead box N1 |
| | <i>TBX1</i> | T-box 1 |
| | <i>RFXAP</i> | Regulatory factor X associated protein |
| | <i>TAPBP</i> | TAP binding protein |
| | <i>CITA</i> | class_II_major_histocompatibility_complex_transactivator |
| | <i>RFXANK</i> | Regulatory factor X associated ankyrin containing protein |
| | <i>RMRP</i> | RNA component of mitochondrial RNA processing endoribonuclease |
| | <i>IKZF1</i> | IKAROS_family_zinc_finger_1 |
| | <i>STAT5B</i> | signal transducer and activator of transcription 5B |
| | <i>ITK</i> | IL2_inducible_T-cell_kinase |
| | <i>MAGT1</i> | Magnesium transporter 1 |
| | <i>DOCK8</i> | Dedicator of cytokinesis 8 |
| | <i>WAS</i> | Wiskott-Aldrich syndrome |
| | <i>ATM</i> | ATM serine/threonine kinase |
| | <i>MRE11A</i> | MRE11A homolog A, double strand break repair nuclease. |
| | <i>NBN</i> | nibrin |
| | <i>RECQL3</i> | Bloom syndrome RecQ like helicase |
| | <i>DNMT3B</i> | DNA methyltransferase 3 beta |
| | <i>PMS2</i> | PMS1 homolog 1, mismatch repair system component |
| | <i>RNF168</i> | Ring finger protein 168 |
| | <i>SMARCAL1</i> | SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily a like 1 |
| | <i>SPINK5</i> | Serine peptidase inhibitor, Kazal type 5 |
| | <i>TYK2</i> | tyrosine kinase 2 |
| | <i>SP110</i> | SP110 nuclear body protein |
| | <i>DKC1</i> | U2 small nuclear RNA auxiliary factor 2 |
| | <i>NOLA3</i> | NOP10 ribonucleoprotein |
| | <i>TERC</i> | Telomerase RNA component |
| | <i>BTK</i> | Bruton tyrosine kinase |
| | <i>IGHM</i> | Immunoglobulin heavy constant mu |
| | <i>IGLL1</i> | Immunoglobulin lambda like polypeptide 1 |
| | <i>CD79A</i> | CD79a molecule |
| | <i>CD79B</i> | CD79b molecule |
| | <i>EOMES</i> | Eomesodermin |
| | <i>ICOS</i> | inducible_T-cell_costimulator |
| | <i>CD19</i> | CD19_molecule |
| | <i>CD81</i> | CD81_molecule |
| | <i>CD20</i> | CD20_molecule |
| | <i>TNFRSF3B</i> | Tumor necrosis factor receptor superfamily, member 3B |
| | <i>TNFRSF3C</i> | Tumor necrosis factor receptor superfamily, member 3C |
| | <i>CD40LG</i> | CD40_ligand |
| | <i>CD40</i> | CD40_molecule |
| | <i>AICDA</i> | Activation induced cytidine deaminase |
| | <i>UNG</i> | Uracil DNA glycosylase |
| | <i>IGKC</i> | Immunoglobulin kappa constant |
| | <i>LYST</i> | Lysosomal trafficking regulator |
| | <i>RAB27A</i> | RAB27A, member RAS oncogene family |
| | <i>AP3B1</i> | Adaptor related protein complex 3 subunit beta 1 |
| | <i>PRF1</i> | perforin_1 |
| | <i>UNC13D</i> | unc-13 homolog D |
| | <i>STX11</i> | Syntaxin 11 |
| | <i>STXBP2</i> | Syntaxin binding protein |

| | | |
|-----------------|-----------------|---|
| | <i>SH2D1A</i> | SH2 domain containing 1A |
| | <i>XIAP</i> | X-linked inhibitor of apoptosis |
| | <i>FAS</i> | Fas_cell_surface_death_receptor |
| | <i>FASLG</i> | Fas_ligand |
| | <i>CASP10</i> | caspase 10 |
| | <i>CASP8</i> | caspase 18 |
| | <i>FADD</i> | Fas associated via death domain |
| | <i>AIRE</i> | Autoimmune regulator |
| | <i>FOXP3</i> | forkhead_box_P3 |
| | <i>IL2RA</i> | interleukin_2_receptor_subunit_alpha |
| | <i>ITCH</i> | Itchy E3 ubiquitin protein ligase |
| | <i>ELANE</i> | elastase, neutrophil expressed |
| | <i>GF11</i> | Growth factor independent 1 transcriptional repressor |
| | <i>HAX1</i> | HCLS1 associated protein X-1 |
| | <i>G6PC3</i> | glucose-6-phosphatase catalytic subunit 3 |
| | <i>SLC37A4</i> | Solute carrier family 37 member 4 |
| | <i>WAS</i> | Wiskott-Aldrich syndrome |
| | <i>LAMTOR2</i> | late endosomal/lysosomal adaptor, MAPK and MTOR activator 2 |
| | <i>TAZ</i> | Tafazzin |
| | <i>VPS13B</i> | Vacuolar protein sorting 13 homolog B |
| | <i>USB1</i> | U6 snRNA biogenesis phosphodiesterase 1 |
| | <i>ITGB2</i> | integrin_subunit_beta_2 |
| | <i>SLC35C1</i> | Solute carrier family 35 member C1 |
| | <i>KIND3</i> | Fermitin family member 3 |
| | <i>RAC2</i> | Rac family small GTPase 2 |
| | <i>ACTB</i> | actin beta |
| | <i>FPR1</i> | Formyl peptide receptor 1 |
| | <i>CTSC</i> | cathepsin C |
| | <i>CEBPE</i> | CCAAT/enhancer binding protein epsilon |
| | <i>SBDS</i> | SBDS, ribosome maturation factor |
| | <i>CYBB</i> | Cytochrome b-245 beta chain |
| | <i>CYBA</i> | Cytochrome b-245 alpha chain |
| | <i>IL12RB1</i> | interleukin 12 receptor subunit beta 1 |
| | <i>IL12B</i> | interleukin_12B |
| | <i>IFNGR1</i> | interferon gamma receptor 1 |
| | <i>IFNGR2</i> | interferon gamma receptor 2 |
| | <i>STAT1</i> | signal transducer and activator of transcription 1 |
| | <i>IRF8</i> | Interferon regulatory factor 8 |
| | <i>NCF1</i> | neutrophil_cytosolic_factor_1 |
| | <i>NCF2</i> | neutrophil_cytosolic_factor_2 |
| | <i>NCF4</i> | neutrophil_cytosolic_factor_4 |
| | <i>GATA2</i> | GATA2 binding protein |
| | <i>CSF2RA</i> | colony stimulating factor 2 receptor alpha subunit |
| | <i>IKBKG</i> | inhibitor of nuclear factor kappa B kinase subunit gamma |
| | <i>NFKBIA</i> | NFKB_inhibitor_alpha |
| | <i>IRAK4</i> | Interleukin 1 receptor associated kinase 4 |
| | <i>MYD88</i> | Myeloid differentiation primary response 88 |
| | <i>CXCR4</i> | C-X-C motif chemokine receptor 4 |
| | <i>TLR3</i> | toll_like_receptor_3 |
| | <i>UNC93B1</i> | Unc-93 homolog B1, TLR signaling regulator |
| | <i>CARD9</i> | Caspase recruitment domain family member 9 |
| | <i>IL17RA</i> | interleukin 17 receptor A |
| | <i>IL17F</i> | interleukin_17F |
| | <i>APOL1</i> | Apolipoprotein L1 |
| Immune response | <i>ADGRE5</i> | Adhesion G protein-coupled receptor E5 |
| | <i>ADORA2A</i> | adenosine_A2a_receptor |
| | <i>AI1</i> | allograft_inflammatory_factor_1 |
| | <i>AKT1</i> | AKT_serine_threonine_kinase_1 |
| | <i>ALOX15B</i> | arachidonate_15-lipoxygenase_type_B |
| | <i>ARG1</i> | arginase_1 |
| | <i>AXL</i> | AXL_receptor_tyrosine_kinase |
| | <i>B3GAT1</i> | beta-13-glucuronidyltransferase_1 |
| | <i>BAGE</i> | B_melanoma_antigen |
| | <i>BATF</i> | basic_leucine_zipper_ATF-like_transcription_factor |
| | <i>BCL2</i> | B-cell CLL_lymphoma_2 |
| | <i>BCL2L11</i> | BCL2_like_11 |
| | <i>BCL6</i> | B-cell CLL_lymphoma_6 |
| | <i>BRCA1</i> | BRCA1_DNA_repair_associated |
| | <i>BRCA2</i> | BRCA2_DNA_repair_associated |
| | <i>BST2</i> | bone_marrow_stromal_cell_antigen_2 |
| | <i>BTLA</i> | B_and_T_lymphocyte_associated |
| | <i>BUB1</i> | BUB1_mitotic_checkpoint_serine_threonine_kinase |
| | <i>C10orf54</i> | chromosome_10_open_reading_frame_54 |
| | <i>C1QA</i> | complement_component_1_q_subcomponent_A_chain |
| | <i>C1QB</i> | complement_component_1_q_subcomponent_B_chain |
| | <i>CA4</i> | carbonic_anhydrase_4 |
| | <i>CBLB</i> | Cbl_proto-oncogene_B |
| | <i>CCL17</i> | C-C_motif_chemokine_ligand_17 |
| | <i>CCL18</i> | C-C_motif_chemokine_ligand_18 |
| | <i>CCL2</i> | C-C_motif_chemokine_ligand_2 |
| | <i>CCL20</i> | C-C_motif_chemokine_ligand_20 |
| | <i>CCL21</i> | C-C_motif_chemokine_ligand_21 |
| | <i>CCL22</i> | C-C_motif_chemokine_ligand_22 |
| | <i>CCL3</i> | C-C_motif_chemokine_ligand_3 |
| | <i>CCL4</i> | C-C_motif_chemokine_ligand_4 |
| | <i>CCL5</i> | C-C_motif_chemokine_ligand_5 |
| | <i>CCNB2</i> | cyclin_B2 |
| | <i>CCR1</i> | C-C_motif_chemokine_receptor_1 |
| | <i>CCR2</i> | C-C_motif_chemokine_receptor_2 |

| | |
|----------------|---|
| <i>CCR4</i> | C-C motif chemokine receptor 4 |
| <i>CCR5</i> | C-C motif chemokine receptor 5 gene pseudogene |
| <i>CCR6</i> | C-C motif chemokine receptor 6 |
| <i>CCR7</i> | C-C motif chemokine receptor 7 |
| <i>CD14</i> | CD14 molecule |
| <i>CD160</i> | CD160 molecule |
| <i>CD163</i> | CD163 molecule |
| <i>CD19</i> | CD19 molecule |
| <i>CD1C</i> | CD1c molecule |
| <i>CD1D</i> | CD1d molecule |
| <i>CD2</i> | CD2 molecule |
| <i>CD209</i> | CD209 molecule |
| <i>CD22</i> | CD22 molecule |
| <i>CD226</i> | CD226 molecule |
| <i>CD244</i> | CD244 molecule |
| <i>CD247</i> | CD247 molecule |
| <i>CD27</i> | CD27 molecule |
| <i>CD274</i> | CD274 molecule |
| <i>CD276</i> | CD276 molecule |
| <i>CD28</i> | CD28 molecule |
| <i>CD33</i> | CD33 molecule |
| <i>CD37</i> | CD37 molecule |
| <i>CD38</i> | CD38 molecule |
| <i>CD3D</i> | CD3d molecule |
| <i>CD3E</i> | CD3e molecule |
| <i>CD3G</i> | CD3g molecule |
| <i>CD4</i> | CD4 molecule |
| <i>CD40</i> | CD40 molecule |
| <i>CD40LG</i> | CD40 ligand |
| <i>CD44</i> | CD44 molecule_Indian_blood_group |
| <i>CD47</i> | CD47 molecule |
| <i>CD48</i> | CD48 molecule |
| <i>CD52</i> | CD52 molecule |
| <i>CD53</i> | CD53 molecule |
| <i>CD6</i> | CD6 molecule |
| <i>CD63</i> | CD63 molecule |
| <i>CD68</i> | CD68 molecule |
| <i>CD69</i> | CD69 molecule |
| <i>CD70</i> | CD70 molecule |
| <i>CD74</i> | CD74 molecule |
| <i>CD79A</i> | CD79a molecule |
| <i>CD79B</i> | CD79b molecule |
| <i>CD80</i> | CD80 molecule |
| <i>CD83</i> | CD83 molecule |
| <i>CD86</i> | CD86 molecule |
| <i>CD8A</i> | CD8a molecule |
| <i>CD8B</i> | CD8b molecule |
| <i>CDK1</i> | cyclin-dependent kinase 1 |
| <i>CDKN2A</i> | cyclin-dependent_kinase_inhibitor_2A |
| <i>CDKN3</i> | cyclin-dependent_kinase_inhibitor_3 |
| <i>CEACAM1</i> | carcinoembryonic_antigen_related_cell_adhesion_molecule_1 |
| <i>CEACAM8</i> | carcinoembryonic_antigen_related_cell_adhesion_molecule_8 |
| <i>CITA</i> | class_II_major_histocompatibility_complex_transactivator |
| <i>CLEC4C</i> | C-type_lectin_domain_family_4_member_C |
| <i>CMKLRL1</i> | chemerin_chemokine-like_receptor_1 |
| <i>CORO1A</i> | coronin_1A |
| <i>CRTAM</i> | cytotoxic_and_regulatory_T-cell_molecule |
| <i>CSF1R</i> | colony_stimulating_factor_1_receptor |
| <i>CSF2RB</i> | colony_stimulating_factor_2_receptor_beta_common_subunit |
| <i>CTAG1B</i> | cancer_testis_antigen_1B |
| <i>CTAG2</i> | cancer_testis_antigen_2 |
| <i>CTLA4</i> | cytotoxic_T-lymphocyte_associated_protein_4 |
| <i>CTSS</i> | cathepsin_S |
| <i>CX3CL1</i> | C-X3-C_motif_chemokine_ligand_1 |
| <i>CX3CR1</i> | C-X3-C_motif_chemokine_receptor_1 |
| <i>CXCL1</i> | C-X-C_motif_chemokine_ligand_1 |
| <i>CXCL10</i> | C-X-C_motif_chemokine_ligand_10 |
| <i>CXCL11</i> | C-X-C_motif_chemokine_ligand_11 |
| <i>CXCL13</i> | C-X-C_motif_chemokine_ligand_13 |
| <i>CXCL8</i> | C-X-C_motif_chemokine_ligand_8 |
| <i>CXCL9</i> | C-X-C_motif_chemokine_ligand_9 |
| <i>CXCR2</i> | C-X-C_motif_chemokine_receptor_2 |
| <i>CXCR3</i> | C-X-C_motif_chemokine_receptor_3 |
| <i>CXCR4</i> | C-X-C_motif_chemokine_receptor_4 |
| <i>CXCR5</i> | C-X-C_motif_chemokine_receptor_5 |
| <i>CXCR6</i> | C-X-C_motif_chemokine_receptor_6 |
| <i>CYBB</i> | cytochrome_b-245_beta_chain |
| <i>DDX58</i> | DEXD_H-box_helicase_58 |
| <i>DGAT2</i> | diacylglycerol_O-acyltransferase_2 |
| <i>DMBT1</i> | deleted_in_malignant_brain_tumors_1 |
| <i>EBI3</i> | Epstein-Barr_virus_induced_3 |
| <i>EFNA4</i> | ephrin_A4 |
| <i>EGFR</i> | epidermal_growth_factor_receptor |
| <i>EGR2</i> | early_growth_response_2 |
| <i>EGR3</i> | early_growth_response_3 |
| <i>EIF2AK2</i> | eukaryotic_translation_initiation_factor_2_alpha_kinase_2 |

| | |
|------------------------------|--|
| <i>ENTPD1</i> | ectonucleoside_triphosphate_diphosphohydrolase_1 |
| <i>EOMES</i> | eomesodermin |
| <i>FAS</i> | Fas_cell_surface_death_receptor |
| <i>FASLG</i> | Fas_ligand |
| <i>FCER1G</i> | Fc_fragment_of_IgE_receptor_Ig |
| <i>FCGR1A</i> | Fc_fragment_of_IgG_receptor_Ia |
| <i>FCGR2B</i> | Fc_fragment_of_IgG_receptor_IIB |
| <i>FCGR3A</i> | Fc_fragment_of_IgG_receptor_IIIA |
| <i>FCGR3B</i> | Fc_fragment_of_IgG_receptor_IIIB |
| <i>FCRLA</i> | Fc_receptor_like_A |
| <i>FOXM1</i> | forkhead_box_M1 |
| <i>FOXO1</i> | forkhead_box_O1 |
| <i>FOXP3</i> | forkhead_box_P3 |
| <i>FUT4</i> | fucosyltransferase_4 |
| <i>FYB</i> | FYN_binding_protein |
| <i>GADD45GIP1</i> | GADD45G_interacting_protein_1 |
| <i>GAGE1,GAGE12I,GAGE12F</i> | G_antigen_1 |
| <i>GAGE10</i> | G_antigen_10 |
| <i>GAGE12J</i> | G_antigen_12J |
| <i>GAGE13</i> | G_antigen_13 |
| <i>GAGE2C,GAGE2A,GAGE2E</i> | G_antigen_2C |
| <i>GATA3</i> | GATA_binding_protein_3 |
| <i>GBP1</i> | guanylate_binding_protein_1 |
| <i>GNLY</i> | granulysin |
| <i>GPR18</i> | G_protein-coupled_receptor_18 |
| <i>GRAP2</i> | GRB2-related_adaptor_protein_2 |
| <i>GZMA</i> | granzyme_A |
| <i>GZMB</i> | granzyme_B |
| <i>GZMH</i> | granzyme_H |
| <i>GZMK</i> | granzyme_K |
| <i>HAVCR2</i> | hepatitis_A_virus_cellular_receptor_2 |
| <i>HERC6</i> | HECT_and_RLD_domain-containing_E3 ubiquitin_protein_ligase_family_member_6 |
| <i>HGF</i> | hepatocyte_growth_factor |
| <i>HIF1A</i> | hypoxia_inducible_factor_1_alpha_subunit |
| <i>HLA-A</i> | major_histocompatibility_complex_class_I_A |
| <i>HLA-B</i> | major_histocompatibility_complex_class_I_B |
| <i>HLA-C</i> | major_histocompatibility_complex_class_I_C |
| <i>HLA-DMA</i> | major_histocompatibility_complex_class_II_DM_alpha |
| <i>HLA-DMB</i> | major_histocompatibility_complex_class_II_DM_beta |
| <i>HLA-DQA</i> | major_histocompatibility_complex_class_II_DQ_alpha |
| <i>HLA-DOB</i> | major_histocompatibility_complex_class_II_DO_beta |
| <i>HLA-DPA1</i> | major_histocompatibility_complex_class_II_DP_alpha_1 |
| <i>HLA-DPB1</i> | major_histocompatibility_complex_class_II_DP_beta_1 |
| <i>HLA-DQA1</i> | major_histocompatibility_complex_class_II_DQ_alpha_1 |
| <i>HLA-DQA2</i> | major_histocompatibility_complex_class_II_DQ_alpha_2 |
| <i>HLA-DQB2</i> | major_histocompatibility_complex_class_II_DQ_beta_2 |
| <i>HLA-DRA</i> | major_histocompatibility_complex_class_II_DR_alpha |
| <i>HLA-DRB1</i> | major_histocompatibility_complex_class_II_DR_beta_1 |
| <i>HLA-E</i> | major_histocompatibility_complex_class_I_E |
| <i>HLA-F</i> | major_histocompatibility_complex_class_I_F |
| <i>HLA-F-AS1</i> | HLA-F_antisense_RNA_1 |
| <i>HLA-G</i> | major_histocompatibility_complex_class_I_G |
| <i>ICAM1</i> | intercellular_adhesion_molecule_1 |
| <i>ICOS</i> | inducible_T-cell_costimulator |
| <i>ICOSLG</i> | inducible_T-cell_costimulator_ligand |
| <i>ID2</i> | inhibitor_of_DNA_binding_2_HLH_protein |
| <i>ID3</i> | inhibitor_of_DNA_binding_3_HLH_protein |
| <i>IDO1</i> | indoleamine_23-dioxygenase_1 |
| <i>IDO2</i> | indoleamine_23-dioxygenase_2 |
| <i>IFI27</i> | interferon_alpha_inducible_protein_27 |
| <i>IFI35</i> | interferon_induced_protein_35 |
| <i>IFI44L</i> | interferon_induced_protein_44_like |
| <i>IFI6</i> | interferon_alpha_inducible_protein_6 |
| <i>IFIH1</i> | interferon_induced_with_helicase_C_domain_1 |
| <i>IFIT1</i> | interferon_induced_protein_with_tetratricopeptide_repeats_1 |
| <i>IFIT2</i> | interferon_induced_protein_with_tetratricopeptide_repeats_2 |
| <i>IFIT3</i> | interferon_induced_protein_with_tetratricopeptide_repeats_3 |
| <i>IFITM1</i> | interferon_induced_transmembrane_protein_1 |
| <i>IFITM2</i> | interferon_induced_transmembrane_protein_2 |
| <i>IFNA17</i> | interferon_alpha_17 |
| <i>IFNB1</i> | interferon_beta_1 |
| <i>IFNG</i> | interferon_gamma |
| <i>IGF1R</i> | insulin_like_growth_factor_1_receptor |
| <i>IGSF6</i> | immunoglobulin_superfamily_member_6 |
| <i>IKZF1</i> | IKAROS_family_zinc_finger_1 |
| <i>IKZF2</i> | IKAROS_family_zinc_finger_2 |
| <i>IKZF3</i> | IKAROS_family_zinc_finger_3 |
| <i>IKZF4</i> | IKAROS_family_zinc_finger_4 |
| <i>IL10</i> | interleukin_10 |
| <i>IL10RA</i> | interleukin_10_receptor_subunit_alpha |
| <i>IL12A</i> | interleukin_12A |
| <i>IL12B</i> | interleukin_12B |
| <i>IL13</i> | interleukin_13 |
| <i>IL15</i> | interleukin_15 |
| <i>IL17A</i> | interleukin_17A |
| <i>IL17F</i> | interleukin_17F |
| <i>IL18</i> | interleukin_18 |
| <i>IL1A</i> | interleukin_1_alpha |
| <i>IL1B</i> | interleukin_1_beta |

| | |
|-----------------|---|
| <i>IL2</i> | interleukin_2 |
| <i>IL21</i> | interleukin_21 |
| <i>IL22</i> | interleukin_22 |
| <i>IL23A</i> | interleukin_23_subunit_alpha |
| <i>IL2RA</i> | interleukin_2_receptor_subunit_alpha |
| <i>IL2RB</i> | interleukin_2_receptor_subunit_beta |
| <i>IL2RG</i> | interleukin_2_receptor_subunit_gamma |
| <i>IL3RA</i> | interleukin_3_receptor_subunit_alpha |
| <i>IL4</i> | interleukin_4 |
| <i>IL6</i> | interleukin_6 |
| <i>IL7</i> | interleukin_7 |
| <i>IL7R</i> | interleukin_7_receptor |
| <i>IRF1</i> | interferon_regulatory_factor_1 |
| <i>IRF4</i> | interferon_regulatory_factor_4 |
| <i>IRF9</i> | interferon_regulatory_factor_9 |
| <i>IRS1</i> | insulin_receptor_substrate_1 |
| <i>ISG15</i> | ISG15_ubiquitin-like_modifier |
| <i>ISG20</i> | interferon_stimulated_exonuclease_gene_20 |
| <i>ITGA1</i> | integrin_subunit_alpha_1 |
| <i>ITGAE</i> | integrin_subunit_alpha_E |
| <i>ITGAL</i> | integrin_subunit_alpha_L |
| <i>ITGAM</i> | integrin_subunit_alpha_M |
| <i>ITGAX</i> | integrin_subunit_alpha_X |
| <i>ITGB1</i> | integrin_subunit_beta_1 |
| <i>ITGB2</i> | integrin_subunit_beta_2 |
| <i>ITGB7</i> | integrin_subunit_beta_7 |
| <i>ITK</i> | IL2_inducible_T-cell_kinase |
| <i>JAML</i> | junction_adhesion_molecule_like |
| <i>JCHAIN</i> | joining_chain_of_multimeric_IgA_and_IgM |
| <i>KIAA0101</i> | KIAA0101 |
| <i>KIR2DL1</i> | killer_cell_immunoglobulin_like_receptor_two Ig_domains_and_long_cytoplasmic_tail_1 |
| <i>KIR2DL2</i> | killer_cell_immunoglobulin_like_receptor_two Ig_domains_and_long_cytoplasmic_tail_2 |
| <i>KIR2DL3</i> | killer_cell_immunoglobulin_like_receptor_two Ig_domains_and_long_cytoplasmic_tail_3 |
| <i>KLF2</i> | Kruppel_like_factor_2 |
| <i>KLRB1</i> | killer_cell_lectin_like_receptor_B1 |
| <i>KLRD1</i> | killer_cell_lectin_like_receptor_D1 |
| <i>KLRF1</i> | killer_cell_lectin_like_receptor_F1 |
| <i>KLRG1</i> | killer_cell_lectin_like_receptor_G1 |
| <i>KLRK1</i> | killer_cell_lectin_like_receptor_K1 |
| <i>KREMEN1</i> | kringle-containing_transmembrane_protein_1 |
| <i>KRT5</i> | keratin_5 |
| <i>KRT7</i> | keratin_7 |
| <i>LAG3</i> | lymphocyte_activating_3 |
| <i>LAMP1</i> | lysosomal_associated_membrane_protein_1 |
| <i>LAMP3</i> | lysosomal_associated_membrane_protein_3 |
| <i>LAFTM5</i> | lysosomal_protein_transmembrane_5 |
| <i>LCK</i> | LCK_proto-oncogene_Src_family_tyrosine_kinase |
| <i>LCN2</i> | lipocalin_2 |
| <i>LEXM</i> | lymphocyte_expansion_molecule |
| <i>LILRB1</i> | leukocyte_immunoglobulin_like_receptor_B1 |
| <i>LILRB2</i> | leukocyte_immunoglobulin_like_receptor_B2 |
| <i>LRG1</i> | leucine_alpha-2-glycoprotein_1 |
| <i>LST1</i> | leukocyte_specific_transcript_1 |
| <i>LY9</i> | lymphocyte_antigen_9 |
| <i>LYZ</i> | lysozyme |
| <i>M6PR</i> | mannose-6-phosphate_receptor_cation_dependent |
| <i>MAD2L1</i> | MAD2_mitotic_arrest_deficient-like_1_yeast |
| <i>MADCAM1</i> | mucosal_vascular_addressin_cell_adhesion_molecule_1 |
| <i>MAGEA1</i> | MAGE_family_member_A1 |
| <i>MAGEA10</i> | MAGE_family_member_A10 |
| <i>MAGEA12</i> | MAGE_family_member_A12 |
| <i>MAGEA3</i> | MAGE_family_member_A3 |
| <i>MAGEA4</i> | MAGE_family_member_A4 |
| <i>MAGEC2</i> | MAGE_family_member_C2 |
| <i>MAPK1</i> | mitogen-activated_protein_kinase_1 |
| <i>MAPK14</i> | mitogen-activated_protein_kinase_14 |
| <i>MELK</i> | maternal_embryonic_leucine_zipper_kinase |
| <i>MIF</i> | macrophage_migration_inhibitory_factor_glycosylation-inhibiting_factor |
| <i>MKI67</i> | marker_of_proliferation_Ki-67 |
| <i>MLANA</i> | melan-A |
| <i>MMP2</i> | matrix_metallopeptidase_2 |
| <i>MMP9</i> | matrix_metallopeptidase_9 |
| <i>MPO</i> | myeloperoxidase |
| <i>MRC1</i> | mannose_receptor_C_type_1 |
| <i>MS4A1</i> | membrane_spanning_4-domains_A1 |
| <i>MTOR</i> | mechanistic_target_of_rapamycin |
| <i>MX1</i> | Mx_dynamin_like_GTPase_1 |
| <i>MYC</i> | v-myc_avian_myelocytomatisis_viral_oncogene_homolog |
| <i>NCAM1</i> | neural_cell_adhesion_molecule_1 |
| <i>NCF1</i> | neutrophil_cytosolic_factor_1 |
| <i>NCR1</i> | natural_cytotoxicity_triggering_receptor_1 |
| <i>NCR3</i> | natural_cytotoxicity_triggering_receptor_3 |
| <i>NECTIN2</i> | nectin_cell_adhesion_molecule_2 |
| <i>NFATC1</i> | nuclear_factor_of_Activated_T-cells_1 |
| <i>NFKBIA</i> | NFKB_inhibitor_alpha |
| <i>NKG7</i> | natural_killer_cell_granule_protein_7 |
| <i>NOS2</i> | nitric_oxide_synthase_2 |
| <i>NOTCH3</i> | notch_3 |
| <i>NRP1</i> | neuropilin_1 |

| | |
|-----------------|---|
| <i>NTSE</i> | 5-nucleotidase_ecto |
| <i>NTN3</i> | netrin_3 |
| <i>OAS1</i> | 2-5-oligoadenylate synthetase_1 |
| <i>OAS2</i> | 2-5-oligoadenylate synthetase_2 |
| <i>OAS3</i> | 2-5-oligoadenylate synthetase_3 |
| <i>PDCD1</i> | programmed_cell_death_1 |
| <i>PDCD1LG2</i> | programmed_cell_death_1_ligand_2 |
| <i>PECAM1</i> | platelet_and_endothelial_cell_adhesion_molecule_1 |
| <i>PGF</i> | placental growth factor |
| <i>PIK3CA</i> | phosphatidylinositol-45-bisphosphate_3-kinase_catalytic_subunit_alpha |
| <i>PIK3CD</i> | phosphatidylinositol-45-bisphosphate_3-kinase_catalytic_subunit_delta |
| <i>PML</i> | premelanosome_protein |
| <i>POU2AF1</i> | POU_class_2_associating_factor_1 |
| <i>PRDM1</i> | PR_domain_1 |
| <i>PRF1</i> | perforin_1 |
| <i>PSMB9</i> | proteasome_subunit_beta_9 |
| <i>PTEN</i> | phosphatase_and_tensin_homolog |
| <i>PTGS2</i> | prostaglandin-endoperoxide_synthase_2 |
| <i>PTK7</i> | protein_tyrosine_kinase_7_inactive |
| <i>PTPN11</i> | protein_tyrosine_phosphatase_non-receptor_type_11 |
| <i>PTPN6</i> | protein_tyrosine_phosphatase_non-receptor_type_6 |
| <i>PTPN7</i> | protein_tyrosine_phosphatase_non-receptor_type_7 |
| <i>PTPRC</i> | protein_tyrosine_phosphatase_receptor_type_C |
| <i>PTPRCAP</i> | protein_tyrosine_phosphatase_receptor_type_C_associated_protein |
| <i>PVR</i> | poliovirus_receptor |
| <i>PYGL</i> | phosphorylase_glycogen_liver |
| <i>RB1</i> | RB_transcriptional_corepressor_1 |
| <i>RORC</i> | RAR_related_orphan_receptor_C |
| <i>RPS6</i> | ribosomal_protein_S6 |
| <i>S100A8</i> | S100_calciun_binding_protein_A8 |
| <i>S100A9</i> | S100_calciun_binding_protein_A9 |
| <i>SAMHD1</i> | SAM_and_HD_domain-containing_deoxyribose_triphosphate_triphosphohydrolase_1 |
| <i>SELL</i> | selectin_L |
| <i>SH2D1A</i> | SH2_domain-containing_1A |
| <i>SH2D1B</i> | SH2_domain-containing_1B |
| <i>SIT1</i> | signaling_threshold_regulating_transmembrane_adaptor_1 |
| <i>SKAP2</i> | src_kinase_associated_phosphoprotein_2 |
| <i>SLAMF7</i> | SLAM_family_member_7 |
| <i>SLAMF8</i> | SLAM_family_member_8 |
| <i>SNAI1</i> | snail_family_transcriptional_repressor_1 |
| <i>SNAI2</i> | snail_family_transcriptional_repressor_2 |
| <i>SRGN</i> | serglycin |
| <i>SSX2</i> | SSX_family_member_2 |
| <i>STAT1</i> | signal_transducer_and_activator_of_transcription_1 |
| <i>STAT3</i> | signal_transducer_and_activator_of_transcription_3 |
| <i>STAT4</i> | signal_transducer_and_activator_of_transcription_4 |
| <i>STAT5A</i> | signal_transducer_and_activator_of_transcription_5A |
| <i>STAT6</i> | signal_transducer_and_activator_of_transcription_6 |
| <i>TAGAP</i> | T-cell_activation_RhoGTPase_activating_protein |
| <i>TAP1</i> | transporter_1_ATP-binding_cassette_sub-family_B_MDR_TAP |
| <i>TARP</i> | TCR_gamma_alternate_reading_frame_protein |
| <i>TBX21</i> | T-box_21 |
| <i>TCF7</i> | transcription_factor_7_T-cell_specific_HMG-box |
| <i>TDO2</i> | tryptophan_23-dioxygenase |
| <i>TGFB1</i> | transforming_growth_factor_beta_1 |
| <i>TIGIT</i> | T-cell_immunoreceptor_with_Ig_and_ITIM_domains |
| <i>TLR3</i> | toll_like_receptor_3 |
| <i>TLR7</i> | toll_like_receptor_7 |
| <i>TLR8</i> | toll_like_receptor_8 |
| <i>TLR9</i> | toll_like_receptor_9 |
| <i>TNF</i> | tumor_necrosis_factor |
| <i>TNFAIP8</i> | TNF_alpha_induced_protein_8 |
| <i>TNFRSF14</i> | tumor_necrosis_factor_receptor_superfamily_member_14 |
| <i>TNFRSF17</i> | tumor_necrosis_factor_receptor_superfamily_member_17 |
| <i>TNFRSF18</i> | tumor_necrosis_factor_receptor_superfamily_member_18 |
| <i>TNFRSF4</i> | tumor_necrosis_factor_receptor_superfamily_member_4 |
| <i>TNFRSF9</i> | tumor_necrosis_factor_receptor_superfamily_member_9 |
| <i>TNFSF10</i> | tumor_necrosis_factor_superfamily_member_10 |
| <i>TNFSF13B</i> | tumor_necrosis_factor_superfamily_member_13b |
| <i>TNFSF14</i> | tumor_necrosis_factor_superfamily_member_14 |
| <i>TNFSF18</i> | tumor_necrosis_factor_superfamily_member_18 |
| <i>TNFSF4</i> | tumor_necrosis_factor_superfamily_member_4 |
| <i>TNFSF9</i> | tumor_necrosis_factor_superfamily_member_9 |
| <i>TOP2A</i> | topoisomerase_DNA_II_alpha |
| <i>TP63</i> | tumor_protein_p63 |
| <i>TRIM29</i> | tripartite_motif-containing_29 |
| <i>TWIST1</i> | twist_family_bHLH_transcription_factor_1 |
| <i>TYROBP</i> | TYRO_protein_tyrosine_kinase_binding_protein |
| <i>VCAM1</i> | vascular_cell_adhesion_molecule_1 |
| <i>VEGFA</i> | vascular_endothelial_growth_factor_A |
| <i>VTCN1</i> | V-set_domain-containing_T_cell_activation_inhibitor_1 |
| <i>XAGE1B</i> | X_antigen_family_member_1B |
| <i>ZAP70</i> | zeta_chain_of_T_cell_receptor_associated_protein_kinase_70kDa |
| <i>ZBTB46</i> | zinc_finger_and_BTB_domain-containing_46 |
| <i>ZEB1</i> | zinc_finger_E-box_binding_homeobox_1 |

Table S2. Cancer associated genes analyzed in the donors.

| Donor | Gene | Nt. Change | Protein Change | Cancer association | VAF | EXAC P. frequency | RefSeq |
|-------|---------------|---------------------|--------------------|------------------------------|------|----------------------|--------------|
| 1 | Monosity 7 | - | - | Hematological neoplasm | - | - | - |
| 2 | <i>KLLN</i> | c.445T>A | p.Trp149Arg | Breast cancer | 0.48 | 0.009 | NM_001126049 |
| 3 | <i>HOXD4</i> | c.242A>T | p.Glu81Val | Acute lymphoblastic leukemia | 0.48 | 0.0008 | NM_014621 |
| 4 | <i>MSR1</i> | c.877C>T | p.Arg293X | Prostate cancer | 0.44 | 0.007 | NM_138715 |
| 5 | <i>HOXD12</i> | c.213T>C | p.Leu77Pro | Acute lymphoblastic leukemia | 0.48 | 0.001 | NM_021193 |
| | <i>MOS</i> | c.426_432dupTGGCAAC | p.Val145TrpfsTer17 | - | 0.4 | - | NM_005372 |
| 6 | <i>SETBP1</i> | c.3962G>A | p.Arg1321His | Hematological neoplasm | 0.42 | 0.0004 | NM_015559 |
| 7 | <i>MAD1L1</i> | c.851A>G | p.Glu284Gly | Lymphoma and prostate cancer | 0.44 | 0.000008 | NM_003550 |

Table S3. Genetic risk variants in donors.

Figures

Figure S1. BM samples selected from patients at different time points from allo-HSCT to DCMN diagnosis and follow-up




Figure S2. Chimerism analysis.




Figure S3. CNV acquisition across the post-allo-HSCT samples in patient #1.




Figure S4. CNV acquisition across the post-allo-HSCT samples in patient #2.




Figure S5. CNV acquisition across the post-allo-HSCT samples in patient #3.




Figure S6. CNV acquisition across the post-allo-HSCT samples in patient #4.




Figure S7. CNV acquisition across the post-allo-HSCT samples in patient #5.




Figure S8. CNV acquisition across the post-allo-HSCT samples in patient #6.





Figure S9. CNV acquisition across the post-allo-HSCT samples in patient #7.



References

- 1 Li H, Durbin R. Fast and accurate short read alignment with Burrows-Wheeler transform. *Bioinformatics* 2009; **25**: 1754–1760.
- 2 Li H, Handsaker B, Wysoker A, Fennell T, Ruan J, Homer N *et al.* The Sequence Alignment/Map format and SAMtools. *Bioinformatics* 2009; **25**: 2078–2079.
- 3 Koboldt DC, Chen K, Wylie T, Larson DE, McLellan MD, Mardis ER *et al.* VarScan: variant detection in massively parallel sequencing of individual and pooled samples. *Bioinformatics* 2009; **25**: 2283–2285.
- 4 McKenna A, Hanna M, Banks E, Sivachenko A, Cibulskis K, Kernytsky A *et al.* The Genome Analysis Toolkit: A MapReduce framework for analyzing next-generation DNA sequencing data. *Genome Res* 2010; **20**: 1297–1303.
- 5 Talevich E, Shain AH, Botton T, Bastian BC. CNVkit: Genome-Wide Copy Number Detection and Visualization from Targeted DNA Sequencing. *PLOS Comput Biol* 2016; **12**: e1004873.
- 6 Flliceck P, Amode MR, Barrell D, Beal K, Brent S, Carvalho-Silva D *et al.* Ensembl 2012. *Nucleic Acids Res* 2012; **40**: D84–D90.
- 7 Kitts A, Phan L, Ward M, Holmes JB. The database of short genetic variation (dbSNP). 2014.
- 8 McVean GA, Altshuler (Co-Chair) DM, Durbin (Co-Chair) RM, Abecasis GR, Bentley DR, Chakravarti A *et al.* An integrated map of genetic variation from 1,092 human genomes. *Nature* 2012; **491**: 56–65.
- 9 Forbes SA, Beare D, Boutselakis H, Bamford S, Bindal N, Tate J *et al.*

- COSMIC: somatic cancer genetics at high-resolution. *Nucleic Acids Res* 2017; **45**: D777–D783.
- 10 Ng PC. SIFT: predicting amino acid changes that affect protein function. *Nucleic Acids Res* 2003; **31**: 3812–3814.
- 11 Adzhubei IA, Schmidt S, Peshkin L, Ramensky VE, Gerasimova A, Bork P *et al.* A method and server for predicting damaging missense mutations. *Nat Methods* 2010; **7**: 248–249.
- 12 Stenson PD, Mort M, Ball EV, Evans K, Hayden M, Heywood S *et al.* The Human Gene Mutation Database: towards a comprehensive repository of inherited mutation data for medical research, genetic diagnosis and next-generation sequencing studies. *Hum Genet* 2017; **136**: 665–677.
- 13 Miller CA, McMichael J, Dang HX, Maher CA, Ding L, Ley TJ *et al.* Visualizing tumor evolution with the fishplot package for R. *BMC Genomics* 2016; **17**: doi:10.1186/s12864-016-3195-z.
- 14 Ribera J-M, Oriol A, Morgades M, Montesinos P, Sarrà J, González-Campos J *et al.* Treatment of High-Risk Philadelphia Chromosome–Negative Acute Lymphoblastic Leukemia in Adolescents and Adults According to Early Cytologic Response and Minimal Residual Disease After Consolidation Assessed by Flow Cytometry: Final Results of the PETHEMA ALL-AR-03 Trial. *J Clin Oncol* 2014; **32**: 1595–1604.
- 15 Ribera J-M, García O, Montesinos P, Brunet S, Abella E, Barrios M *et al.* Treatment of young patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia using increased dose of imatinib and deintensified chemotherapy before allogeneic stem cell transplantation. *Br J Haematol* 2012; **159**: 78–81.